<DOCUMENT>
<TYPE>EX-2.1
<SEQUENCE>2
<FILENAME>b865206kexv2w1.htm
<DESCRIPTION>EX-2.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv2w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit
2.1</b>
</DIV>


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B><I>EXECUTION VERSION</I></B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>BUSINESS COMBINATION AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>BY AND AMONG</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ELAN CORPORATION, PLC,</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ANTLER SCIENCE TWO LIMITED,</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ELAN SCIENCE FOUR LIMITED,</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>EDT PHARMA HOLDINGS LIMITED,</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>EDT US HOLDCO INC.,</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ANTLER ACQUISITION CORP.,</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>AND</B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>ALKERMES, INC.</B>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>DATED AS OF MAY 9, 2011</B>
</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Article&nbsp;I</B><BR></TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Certain Definitions</B><BR></TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;1.1. Definitions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;1.2. Usage</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">18</TD>
    <TD>&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Article&nbsp;II</B><BR></TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>The Merger; Closing of Transactions</B><BR></TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.1. Time and Place of Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.2. Elan Proceeds</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">20</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.3. Alkermes Payments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.4. The Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.5. Effective Time</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.6. Effects of the Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.7. Governing Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.8. Officers and Directors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">21</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.9. Effect on Capital Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">22</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.10. Exchange of Shares and Certificates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">23</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.11. Alkermes Stock Based Awards</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">25</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.12. Additional Assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.13. Deliveries by Elan and the Continuing Affiliates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">26</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.14. Deliveries by Alkermes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">28</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;2.15. Closing Payments Adjustment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">29</TD>
    <TD>&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Article&nbsp;III</B><BR></TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Representations and Warranties of Elan</B><BR></TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.1. Incorporation; Authorization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">31</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.2. Capitalization; Structure</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">32</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.3. No Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.4. Financial Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">34</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.5. No Undisclosed Liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.6. Properties; Sufficiency</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">35</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.7. Absence of Certain Changes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.8. Litigation; Orders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">36</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-i-&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B><br>
(continued)
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.9. Intellectual Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.10. Licenses; Authorizations; Reports</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">37</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.11. Labor Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.12. Compliance with Laws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">38</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.13. Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">40</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.14. Material Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">41</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.15. Brokers, Finders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.16. Opinion of Elan Financial Advisor</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.17. Board Approval</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.18. No Shareholder Vote</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.19. Environmental Health and Safety Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">42</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.20. Employee Benefit Plans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">43</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.21. Acquisition of Shares for Investment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.22. Operations of Certain Entities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;3.23. Products; Recalls</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">46</TD>
    <TD>&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Article&nbsp;IV</B><BR></TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Representations and Warranties of Alkermes</B><BR></TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.1. Incorporation; Authorization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">47</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.2. Capitalization; Structure</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">48</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.3. Litigation; Orders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.4. Authorizations; Consents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.5. Compliance with Laws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.6. SEC Reports; Financial Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">49</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.7. No Undisclosed Liabilities</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.8. Absence of Certain Changes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.9. Brokers, Finders</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.10. Opinions of Alkermes Financial Advisor</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.11. Board Approval</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.12. Required Shareholder Vote</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.13. Antitakeover Statute</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-ii-&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B><br>
(continued)
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;4.14. Financing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">51</TD>
    <TD>&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Article&nbsp;V</B><BR></TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Covenants of the Parties</B><BR></TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.1. Access to Information; Retention of Records; Confidentiality</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">52</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.2. Filings; Other Actions; Notification</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">54</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.3. Further Assurances</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.4. Conduct of Business</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">59</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.5. Public Announcements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.6. Guarantees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">63</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.7. Affiliate Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.8. No Solicitation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">64</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.9. Non-Compete; Employment Non-Solicitation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">65</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.10. Notices of Certain Events</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.11. Preparation of SEC Documents</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">66</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.12. Shareholder Meetings; Board Recommendations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">67</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.13. Stock Exchange Listing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.14. Insurance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.15. Indebtedness</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.16. Alkermes Common Stock</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">68</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.17. Resignations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.18. Designated Assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.19. Directors and Officers Indemnification</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.20. Additional Financial Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.21. Financing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">69</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.22. Re-registration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.23. Change of Name of Antler Science One Public Limited Company</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.24. Reduction of Share Capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.25. Acquisition of Ordinary Shares of New Alkermes Denominated in Euro</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">74</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.26. Purchase of Own Shares and Re-issue of Treasury Shares</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.27. Transfer and Assumption of Alkermes Equity Incentive Plans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-iii-&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B><br>
(continued)
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;5.28. Transfer Out of Irish Dormant Companies</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75</TD>
    <TD>&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Article&nbsp;VI</B><BR></TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Employee Benefits Matters</B><BR></TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.1. Employee Plans</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">75</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.2. U.S. Employees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">76</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.3. Ireland Employees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">77</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;6.4. Miscellaneous</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">78</TD>
    <TD>&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Article&nbsp;VII</B><BR></TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Tax Matters</B><BR></TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.1. Tax Representations of Elan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">78</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.2. Tax Indemnification</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">81</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.3. Allocation of Certain Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">82</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.4. Carryovers, Refunds and Related Matters</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.5. Preparation and Filing of Tax Returns</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">83</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.6. Tax Contests</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">84</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.7. Cooperation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">86</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.8. Termination of Tax Sharing Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">86</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.9. Tax Election</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">86</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.10. Certain Disputes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">87</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.11. Definitions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">87</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.12. Survival</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.13. Treatment for U.S. Federal Income Tax Purposes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;7.14. Adjustments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">88</TD>
    <TD>&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Article&nbsp;VIII</B><BR></TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Conditions Precedent</B><BR></TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.1. Conditions to Each Party&#146;s Obligation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">89</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.2. Additional Conditions to Alkermes&#146; Obligations</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">90</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;8.3. Additional Conditions to Obligations of the Elan Parties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">91</TD>
    <TD>&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Article&nbsp;IX</B><BR></TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Survival; Indemnification</B><BR></TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.1. Survival</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">92</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->-iv-&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>TABLE OF CONTENTS</B><br>
(continued)
</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="88%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right" colspan="2"><B>Page</B></TD>
    <TD>&nbsp;</TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.2. Indemnification by Elan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">92</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.3. Indemnification by Alkermes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">93</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.4. Indemnification Procedures</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">94</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.5. Limitations; Additional Procedures</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">96</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;9.6. Exclusive Tax Indemnification</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">97</TD>
    <TD>&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Article&nbsp;X</B><BR></TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Termination</B><BR></TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;10.1. Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">97</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;10.2. Procedure and Effect of Termination</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;10.3. Termination Payments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">98</TD>
    <TD>&nbsp;</TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Article&nbsp;XI</B><BR></TD>
</TR>
<TR valign="bottom">
    <TD colspan="5" align="center"><B>Miscellaneous</B><BR></TD>
</TR>
<tr><td>&nbsp;</td></tr>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.1. Counterparts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.2. Governing Law; Jurisdiction and Forum; Waiver of Jury Trial</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">100</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.3. Entire Agreement; Third Party Beneficiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">101</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.4. Expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">101</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.5. Notices</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">102</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.6. Successors and Assigns</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">103</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.7. Headings; Definitions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">103</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.8. Amendments and Waivers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">103</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.9. Severability</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">103</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Section&nbsp;11.10. Specific Performance</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">104</TD>
    <TD>&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><U><B>Exhibits</B></U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Exhibit&nbsp;A &#151; Form of New Alkermes Shareholder&#146;s Agreement

</DIV>






<P align="center" style="font-size: 10pt"><!-- Folio -->-v-&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>BUSINESS COMBINATION AGREEMENT AND PLAN OF MERGER</B>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;THIS BUSINESS COMBINATION AGREEMENT AND PLAN OF MERGER (the &#147;<U>Agreement</U>&#148;), dated as of
May&nbsp;9, 2011, is by and among Elan Corporation, plc, a public limited company incorporated in
Ireland (registered number 30356) whose registered address is Treasury Building, Lower Grand Canal
Street, Dublin 2, Ireland (&#147;<U>Elan</U>&#148;), Antler Science Two Limited, a private limited company
incorporated in Ireland (registered number 498284) whose registered address is 25/28 North Wall
Quay, Dublin 1, Ireland and which, immediately prior to the Closing, shall be a wholly owned
indirect subsidiary of Elan (&#147;<U>New Alkermes</U>&#148;), Elan Science Four Limited, a private limited
company incorporated in Ireland (registered number 476691) whose registered address is Monksland,
Athlone Co., Westmeath, Ireland, and which, immediately prior to the Closing, shall be a wholly
owned direct subsidiary of New Alkermes (&#147;<U>Holdco</U>&#148;), EDT Pharma Holdings Limited, a private
limited company incorporated in Ireland (registered number 448848) whose registered address is
25/28 North Wall Quay, Dublin 1, Ireland and which, immediately prior to the Closing, shall be a
wholly owned direct subsidiary of Holdco (&#147;<U>Interco</U>&#148;), EDT US Holdco Inc., a Delaware
corporation which, immediately prior to the Closing, shall be a wholly owned direct subsidiary of
Interco (&#147;<U>U.S. Holdco</U>&#148;), Antler Acquisition Corp., a Pennsylvania corporation and direct
wholly owned subsidiary of U.S. Holdco (&#147;<U>Merger Sub</U>&#148;), and Alkermes, Inc., a Pennsylvania
corporation (&#147;<U>Alkermes</U>&#148;). Elan, New Alkermes, Holdco, Interco, U.S. Holdco and Merger Sub,
collectively, may be referred to herein as the &#147;<U>Elan Parties</U>&#148; and each of them,
individually, as an &#147;<U>Elan Party</U>&#148; and, together with Alkermes, the &#147;<U>Parties</U>&#148; and
each and any of them individually a &#147;<U>Party</U>&#148;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, as of the date hereof, (a)&nbsp;Elan, certain of its Subsidiaries (as defined below)
listed on <U>Schedule&nbsp;A</U> hereto and Elan Science Three Limited (such Subsidiaries, the
&#147;<U>Transferring Subsidiaries</U>&#148;) and (b)&nbsp;EHI, conduct the Business (as defined below).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, Alkermes and Elan desire to combine the businesses of Alkermes with the Business,
upon the terms and subject to the conditions set forth in this Agreement, through (a)&nbsp;effectuation
by Elan prior to the Closing (as defined below) of the reorganization described in Steps 1 through
11 of <U>Schedule&nbsp;1</U> (such Steps, as modified in accordance with <U>Sections&nbsp;5.3(a)</U> and
<U>5.18</U>, the &#147;<U>Reorganization</U>&#148;), including the transfer by Elan and a Transferring
Subsidiary to U.S. Holdco of 100% of all equity interests in Eagle Holdings as set forth on
<U>Schedule&nbsp;1</U> and thereby the indirect transfer to U.S. Holdco of 100% of all equity interests
in EHI (the equity interests in Eagle Holdings and EHI, collectively, the &#147;<U>Purchased
Interests</U>&#148;) as set forth on <U>Schedule&nbsp;1</U> and the transfer by Elan and the Transferring
Subsidiaries to New Alkermes and one or more of the New Alkermes Group Entities (as specified on
<U>Schedule&nbsp;1</U>) of all of their respective right, title and interest in and to the assets and
properties currently primarily used or held for use in the Business, other than the Excluded Assets
(as defined below) (collectively, with the Purchased Interests, the &#147;<U>Business Assets</U>&#148;), but
including the Additional Assets (as defined below), in each case upon the terms and subject to the
conditions set forth in the agreements relating to such transfers to be entered in Agreed Form in
connection with the Reorganization (collectively, the &#147;<U>Reorganization Transfers</U>&#148; and such
agreements in form and substance reasonably acceptable to Alkermes, collectively, the
&#147;<U>Reorganization Transfer Agreements</U>&#148;); (b)&nbsp;the merger (the &#147;<U>Merger</U>&#148;) of Merger Sub
(which at such time shall be a wholly owned indirect subsidiary of New Alkermes) with and into
Alkermes, with Alkermes as the surviving corporation in the Merger as a wholly owned indirect
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">subsidiary of New Alkermes; and (c)&nbsp;the consummation of the transactions contemplated by the
IP Transfer Agreement and the IP Transfer Loan Note (the steps outlined in clauses (a)&nbsp;through (c),
including the Reorganization and the Merger being collectively referred to as the
&#147;<U>Transactions</U>&#148;);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, as a result of the Merger, the Alkermes Common Stock will be canceled and, at
Closing, and in consideration of and in connection therewith, New Alkermes will issue New Alkermes
Ordinary Shares to the holders of the shares of Alkermes Common Stock (or their nominees) as more
fully described in this Agreement in further consideration of the payment of US$500&nbsp;million by
Merger Sub to New Alkermes and the issue of shares between certain of the New Alkermes Group
Entities in the manner set out in Step 12B/C of <U>Schedule&nbsp;1</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, (a)&nbsp;the respective boards of directors of Alkermes and Merger Sub have each
determined that the Transactions and this Agreement are advisable, fair to and in the best
interests of their respective shareholders and have approved and adopted this Agreement and the
Plan of Merger contained herein (the &#147;<U>Plan of Merger</U>&#148;), (b)&nbsp;U.S. Holdco, as sole
shareholder of Merger Sub, has approved and adopted this Agreement and the Plan of Merger and (c)
the board of directors of Elan has determined that the Transactions (including the Reorganization)
are in the best interest of Elan and has approved and adopted this Agreement and the transactions
contemplated herein (including the Reorganization); and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;WHEREAS, in connection with the closing of the transactions contemplated by this Agreement,
Elan, a Subsidiary of Elan (the &#147;<U>Elan Shareholder</U>&#148;), and New Alkermes will enter into a
Shareholder&#146;s Agreement in the Agreed Form set forth as <U>Exhibit&nbsp;A</U> to this Agreement (the
&#147;<U>Shareholder&#146;s Agreement</U>&#148; and, collectively, with the IP Transfer Agreement, the IP
Transfer Loan Note, the Transition Services Agreement and the ELN005 Agreement, the &#147;<U>Ancillary
Agreements</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;NOW, THEREFORE, in consideration of the foregoing and the mutual covenants and agreements
contained in this Agreement, and intending to be legally bound hereby, the parties hereto agree as
follows:
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE I</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Certain Definitions</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.1. <U>Definitions</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;As used in this Agreement the following terms and derivations thereof shall have the
meanings specified in this <U>Section&nbsp;1.1</U>:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Action</U>&#148; shall mean any action, suit, arbitration, hearing, proceeding, investigation
or formal inquiry (in each case, whether civil, criminal, administrative, judicial or
investigative, whether public or private) commenced, brought, conducted or heard before any
Governmental Authority.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->2<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Additional Assets</U>&#148; shall mean Building 17 of the Monksland Campus, located at
Athlone, County Westmeath, Ireland.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Affiliate</U>&#148; shall mean, with respect to any Person, any other Person that directly, or
indirectly through one or more intermediaries, Controls, or is Controlled by, or is under Common
Control with, such first Person, it being understood that (a)&nbsp;Elan and the Continuing Affiliates
shall not be considered to be Affiliates of New Alkermes and its Subsidiaries (including the
Surviving Corporation) and vice versa after the Effective Time for purposes of Articles <U>VII</U>
and <U>IX</U> and Sections <U>5.3</U>, <U>5.5</U> and <U>5.9</U> and (b)&nbsp;New Alkermes and the
New Alkermes Group Entities shall be considered to be Affiliates of Elan at all times prior to the
Effective Time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Agreed Adjustments</U>&#148; shall mean certain adjustments to the financial statements of the
Business set forth on <U>Schedule&nbsp;2</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Agreed Form</U>&#148; shall mean an agreement or other document in the form attached to this
Agreement or, if no form is attached, in such form as is reasonably satisfactory to the Parties,
unless otherwise provided in this Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Alkermes Acquisition Proposal</U>&#148; shall mean any direct or indirect inquiry, proposal,
request or offer (or any improvement, restatement, amendment, renewal or reiteration thereof)
relating to any Alkermes Alternative Transaction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Alkermes Alternative Transaction</U>&#148; shall mean any direct or indirect acquisition or
purchase by, or other transfer to, any Person (other than New Alkermes or any of its Subsidiaries)
of 50% or more of the Alkermes Common Stock or of Alkermes or the assets of Alkermes, including by
way of any merger, business combination, joint venture, reorganization, consolidation,
recapitalization, liquidation, dissolution or other extraordinary transaction (other than the
Merger).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Alkermes Common Stock</U>&#148; shall mean the common stock, par value $0.01 per share, of
Alkermes and the non-voting common stock, par value $0.01 per share, of Alkermes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Alkermes Financial Advisor</U>&#148; shall mean Morgan Stanley &#038; Co. Incorporated.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Alkermes Material Adverse Effect</U>&#148; means any event, change, occurrence or development
that, individually or when taken together with all other events, changes, occurrences or
developments, has a material adverse effect on (a)&nbsp;the business, assets, liabilities, operations or
condition (financial or otherwise) of Alkermes and its Subsidiaries, taken as a whole, or (b)&nbsp;the
ability of Alkermes and its Subsidiaries to perform their material obligations under this Agreement
and any Ancillary Agreement or to consummate the transactions contemplated hereby and thereby;
<U>provided</U>, that any such effect shall, to the extent resulting from the following, be
disregarded, in the case of clause <U>(a)</U> only, in determining whether an &#147;Alkermes Material
Adverse Effect&#148; has occurred or would reasonably be expected to occur: (i)&nbsp;any change in the market
price or trading volume of Alkermes Common Stock in and of itself (it being understood that, except
as provided in clauses <U>(ii)</U> through <U>(vi)</U>, an event, change, occurrence or
development causing or contributing to such change may be considered for purposes of determining
the occurrence of an &#147;Alkermes Material Adverse Effect&#148;); (ii)&nbsp;any
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->3<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">changes in Law (or official interpretations thereof) applicable to Alkermes and its
Subsidiaries; (iii)&nbsp;changes in general economic, monetary, market or financial conditions, whether
in the United States, Ireland or any other country or international market; (iv)&nbsp;acts of God,
calamities, national or international political or social conditions, including the engagement in
or escalation by any country or any non-state actor in hostilities, whether commenced before or
after the date hereof, and whether or not pursuant to a formal declaration of emergency or war, or
the occurrence of any military or terrorist attack; (v)&nbsp;changes in U.S. GAAP, IFRS or other
accounting principles applicable to Alkermes and its Subsidiaries; or (vi)&nbsp;any delays in, or
rejection of, approval for commercial sale by the FDA, the European Medicines Board or any other
applicable Governmental Authority of BYDUREON<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>; except, in the case of each of the foregoing
clauses <U>(ii)</U> through <U>(v)</U> to the extent the same has had or would reasonably be
expected to have a disproportionate effect on Alkermes and its Subsidiaries relative to the effect
generally on other companies in industries or markets similar to Alkermes and its Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Alkermes Rights Agreement</U>&#148; shall mean the rights agreement, dated as of February&nbsp;7,
2003, as amended, between Alkermes and EquiServe Trust Company, N.A., as Rights Agent.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Alkermes SEC Reports</U>&#148; shall mean all forms, reports and documents (including all
exhibits, schedules and annexes thereto) filed by Alkermes with the SEC since January&nbsp;1, 2008.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Alkermes Shareholder Approval</U>&#148; shall mean the approval of the Merger by the
shareholders of Alkermes by the Required Alkermes Vote.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Alkermes Termination Fee</U>&#148; shall mean an amount equal to $25,000,000.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Audited Financial Statements</U>&#148; shall mean the audited combined financial statements of
the Business containing balance sheets as of December&nbsp;31, 2010, 2009 and 2008, and statements of
operations and of cash flows of the Business for each of the fiscal years in the three-year period
ended December&nbsp;31, 2010, in each case prepared in accordance with U.S. GAAP applied on a consistent
basis throughout the periods involved and audited in accordance with the standards of the Public
Company Accounting Oversight Board (U.S.).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Beneficially Own</U>&#148; shall mean, with respect to any securities, (i)&nbsp;having &#147;beneficial
ownership&#148; of such securities for purposes of Rule&nbsp;13d-3 or 13d-5 under the Exchange Act (or any
successor statute or regulation), (ii)&nbsp;having the right to become the &#147;beneficial owner&#148; of such
securities (whether such right is exercisable immediately or only after the passage of time or the
occurrence of conditions) pursuant to any agreement, arrangement or understanding, or upon the
exercise of conversion rights, exchange rights, rights, warrants or options, or otherwise, or (iii)
having an exercise or conversion privilege or a settlement payment or mechanism with respect to any
option, warrant, convertible security, stock appreciation, swap agreement or other security,
contract right or derivative position, whether or not currently exercisable, at a price related to
the value of the securities for which &#147;beneficial ownership&#148; is being determined or a value
determined in whole or part with reference to, or derived in whole or in part from, the value of
the securities for which &#147;beneficial ownership&#148; is being determined that increases in value as the
value of the securities for which &#147;beneficial ownership&#148; is being
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->4<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">determined increases or that provides to the holder an opportunity, directly or indirectly, to
profit or share in any profit derived from any increase in the value of the securities for which
&#147;beneficial ownership&#148; is being determined (excluding any interests, rights, options or other
securities set forth in Rule&nbsp;16a-1(c)(1)-(5) or (7)&nbsp;promulgated pursuant to the Exchange Act). The
terms &#147;<U>Beneficial Owner</U>&#148; and &#147;<U>Beneficial Ownership</U>&#148; shall have a correlative
meaning.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Books and Records</U>&#148; shall mean all of the books, records, information and data of a
Person, including (i)&nbsp;corporate minute books, (ii)&nbsp;books and records relating to employees, the
purchase of materials, supplies and services, research and development, manufacture and sale of
products and services, advertising, packaging, promotional materials and dealings with customers,
(iii)&nbsp;books of account, ledgers, general, financial, accounting and personnel records, files,
invoices, customer and counterparty lists, documents, agreements, sales data and information,
billing records, manuals, material client, counterparty and supplier correspondence, (iv)
historical and archival data (in all cases, in any form or medium, including computerized media)
and (v)&nbsp;all other registers or books, including registers of members, required to be maintained
under applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Business</U>&#148; shall mean the entire global drug delivery technologies business of Elan
and its Affiliates, consisting of researching, developing, licensing, manufacturing, marketing and
selling drug delivery technologies or pharmaceutical products incorporating drug delivery
technologies and the contract manufacturing of pharmaceutical products.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Business Day</U>&#148; shall mean any day that is not a Saturday, Sunday or other day on which
the commercial banks in New York City, New York, United States, or Dublin, Ireland, are authorized
or required by Law to remain closed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Business Intellectual Property Rights</U>&#148; means all Intellectual Property Rights owned
or licensed and used or held for use in the Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Business Material Adverse Effect</U>&#148; means any event, change, occurrence or development
that, individually or when taken together with all other events, changes, occurrences or
developments, has a material adverse effect on (a)&nbsp;the business, assets, liabilities, operations or
condition (financial or otherwise) of the Business, taken as a whole, or (b)&nbsp;the ability of the
Elan Entities to perform their material obligations under this Agreement, the Reorganization
Transfer Agreements and any Ancillary Agreement or to consummate the transactions contemplated
hereby and thereby; <U>provided</U>, that any such effect shall, to the extent resulting from the
following, be disregarded, in the case of clause <U>(a)</U> only, in determining whether a
&#147;Business Material Adverse Effect&#148; has occurred or would reasonably be expected to occur: (i)&nbsp;any
changes in Law (or official interpretations thereof) applicable to the Business; (ii)&nbsp;changes in
general economic, monetary, market or financial conditions, whether in the United States, Ireland
or any other country or international market; (iii)&nbsp;acts of God, calamities, national or
international political or social conditions, including the engagement in or escalation by any
country or any non-state actor in hostilities, whether commenced before or after the date hereof,
and whether or not pursuant to a formal declaration of emergency or war, or the occurrence of any
military or terrorist attack; or (iv)&nbsp;changes in U.S. GAAP, IFRS or other accounting principles
applicable to the Business; except, in the case of each of the foregoing clauses <U>(i)</U>
through <U>(iv)</U> to the extent the same has had or would reasonably be expected to have a
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->5<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">disproportionate effect on the Business relative to the effect generally on other companies in
industries or markets similar to the Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Certificate of Analysis and Conformity</U>&#148; means the certificate for each batch of
Product delivered with such Product and listing the tests performed, the specifications for the
manufacture of such Product, and the test results and certifying that such batch of Product was
manufactured in accordance with applicable Law, including cGMPs, and production standard operating
procedures.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>cGMPs</U>&#148; means current good manufacturing practices as defined in the U.S. Code of
Federal Regulations, 21 CFR Part&nbsp;210 <U>et seq.</U>, the European Union Guidelines to Good
Manufacturing Practices for Medicinal Products for Human and Veterinary Use (Vol. IV Rules
Governing Medicinal Products in the European Union 2004), and any successor regulatory schemes, as
well as any corresponding requirements in other regulatory jurisdictions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Closing Adjustment Amount</U>&#148; shall mean the amount, which may be positive or negative,
equal to (a) (i)&nbsp;the Modified Working Capital as of the Effective Time, minus (ii)&nbsp;the Target
Working Capital, plus (iii)&nbsp;the Net Cash Amount.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Code</U>&#148; shall mean the Internal Revenue Code of 1986, or any Similar Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Companies Acts</U>&#148; shall mean the Irish Companies Acts 1963 to 2009.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Competing Business</U>&#148; shall mean any drug delivery technologies business, consisting of
researching, developing, licensing, manufacturing, marketing and selling of drug delivery
technologies or pharmaceutical products incorporating drug delivery technologies (which are
comparable to oral controlled release technologies and bioavailability enhancement platforms,
including nanocrystal technology).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Continuing Affiliate</U>&#148; shall mean any Affiliate of Elan that will continue to be an
Affiliate of Elan after the Effective Time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Control</U>&#148; (including, with correlative meanings, &#147;<U>Controlled by</U>&#148; and
&#147;<U>under Common Control with</U>&#148;) shall mean the possession, direct or indirect, of the power to
direct or cause the direction of management or policies of a Person, whether through ownership of
securities, by contract or otherwise.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Controlled Group Liability</U>&#148; means any and all liabilities of Elan or any entity that
is treated as a single employer with Elan for purposes of Title IV of ERISA (i)&nbsp;under Title IV of
ERISA, (ii)&nbsp;under Section&nbsp;302 of ERISA, (iii)&nbsp;under Sections&nbsp;412 and 4971 of the Code, (iv)&nbsp;as a
result of a failure to comply with the continuation coverage requirements of Section&nbsp;601 et seq. of
ERISA and Section&nbsp;4980B of the Code and (v)&nbsp;under any Similar Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Corporate Integrity Agreement</U>&#148; shall mean the Corporate Integrity Agreement between
OIG and Elan, dated as of December&nbsp;15, 2010, as it may be amended.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Covered Losses</U>&#148; shall mean any and all losses, liabilities, claims, fines,
deficiencies, damages, obligations, payments (including those arising out of any settlement,
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->6<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">judgment or compromise relating to any Action), reasonable costs and expenses (including
interest and penalties due and payable with respect thereto and reasonable attorneys&#146; and
accountants&#146; fees and any other reasonable out-of-pocket expenses incurred in investigating,
preparing, defending, avoiding or settling any Action), including any of the foregoing arising
under, out of or in connection with any Action, order or consent decree of any Governmental
Authority or award of any arbitrator of any kind, or any law, rule, regulation, contract,
commitment or undertaking.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>De Minimis Damages</U>&#148; shall mean any single claim (or series of claims arising from the
same or similar facts, events or circumstances) for Covered Losses in an amount that is less than
$100,000.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Eagle Holdings</U>&#148; shall mean Eagle Holdings USA, Inc.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>EDDI</U>&#148; shall mean Elan Drug Delivery, Inc., a Delaware corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>EDDI Contracts</U>&#148; shall mean those contracts set forth on <U>Schedule&nbsp;4</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>EDT Acquisition Proposal</U>&#148; shall mean any direct or indirect inquiry, proposal or
offer (or any improvement, restatement, amendment, renewal or reiteration thereof) relating to any
EDT Alternative Transaction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>EDT Alternative Transaction</U>&#148; shall mean any direct or indirect acquisition or
purchase by, or other transfer to, any Person (other than pursuant to this Agreement) of all or any
substantial part of the Business, including by way of any merger, business combination, joint
venture, reorganization, consolidation, recapitalization, liquidation, dissolution or other
extraordinary transaction involving any of New Alkermes or any New Alkermes Group Entity or any
assets or equity of New Alkermes or any New Alkermes Group Entity or any interests constituting
part of the Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>EDT Pharma Pension Schemes</U>&#148; shall mean the EDT Pharma Executive Pension Scheme, the
EDT Pharma Employee Benefit Plan and the EDT Pharma AVC Scheme, each established by trust Deeds and
Rules dated 1 October&nbsp;2008.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>EHI</U>&#148; shall mean Elan Holdings, Inc., a Massachusetts corporation, or any successor
thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Employee Plan</U>&#148; means any employment, severance or similar contract, plan, policy,
fund or arrangement (whether or not written) providing for compensation, bonus, profit-sharing,
stock option, or other stock-related rights or other forms of incentive or deferred compensation,
perquisites, vacation benefits, insurance coverage (including any self-insured arrangements),
health or medical benefits, disability benefits, worker&#146;s compensation, supplemental unemployment
benefits, severance benefits and post-employment or retirement benefits (including compensation,
pension, health, medical or life insurance or other benefits) under which any employee or former
employee of the Business, or any beneficiary of such person, may be extended benefits or with
respect to which New Alkermes or any New Alkermes Group Entity may have any Liability by operation
of Law or otherwise.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->7<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Environment</U>&#148; shall mean any ambient, workplace or indoor air, surface water, drinking
water, groundwater, land surface, subsurface strata, sediment, plant or animal life, natural
resources, workplace, and real property and the physical buildings, structures, improvements and
fixtures thereon, including sewer, septic and waste treatment, storage or disposal systems.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Environmental Laws</U>&#148; shall mean any Law related to: (a)&nbsp;the Environment, including
pollution, contamination, cleanup, preservation, protection, Remediation or reclamation of the
Environment; (b)&nbsp;human health or safety or the exposure of employees and other persons to any
Hazardous Substance; (c)&nbsp;any Release or threatened Release, including investigation, study,
assessment, testing, monitoring, containment, removal, Remediation, cleanup or abatement of such
Release or threatened Release; (d)&nbsp;the management, manufacture, generation, formulation,
processing, labeling, distribution, introduction into commerce, registration, use, treatment,
handling, storage, disposal, transportation, re-use, recycling or reclamation of any Hazardous
Substance; or (e)&nbsp;the physical structure or condition of a building, facility, fixture or other
structure as related to environmental or health and safety impacts.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Environmental License</U>&#148; shall mean any permit, license, consent, approval,
certificate, qualification, specification, registration or other authorization by a Governmental
Authority required by applicable Environmental Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>EPIL</U>&#148; shall mean Elan Pharma International Ltd.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>ERISA</U>&#148; shall mean the Employee Retirement Income Security Act of 1974, or any Similar
Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>ES5</U>&#148; shall mean Elan Science Five Limited, a private limited company incorporated in
Ireland.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Elan Entity</U>&#148; means the Elan Parties and each Affiliate of Elan that is or is intended
to be a party to this Agreement or any Ancillary Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Elan Financial Advisors</U>&#148; means Citibank, N.A. and Ondra Partners.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Elan Reorganization Indebtedness</U>&#148; shall mean Indebtedness of $500&nbsp;million that,
following the Reorganization, shall be owing from New Alkermes and certain New Alkermes Group
Entities to certain Subsidiaries of Elan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Elan Termination Fee</U>&#148; shall mean an amount equal to $25,000,000.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Exchange Act</U>&#148; shall mean the Securities Exchange Act of 1934.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Excluded Assets</U>&#148; shall mean those items set forth on <U>Schedule&nbsp;3</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>FCPA</U>&#148; shall mean the Foreign Corrupt Practices Act of 1977.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Governing Documents</U>&#148; means with respect to any Person, (a)&nbsp;if a corporation
(including any Irish public or private limited liability company), the memorandum and articles of
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->8<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">association, articles or certificate of incorporation and the bylaws or similar documents; (b)
if a general partnership or limited liability partnership, the partnership agreement and any
statement of partnership; (c)&nbsp;if a limited partnership, the limited partnership agreement and the
certificate of limited partnership; (d)&nbsp;if a limited liability company, the certificate of
formation and limited liability company agreement; (e)&nbsp;if another type of Person, any charter or
similar document adopted or filed in connection with the creation, formation or organization of the
Person; (f)&nbsp;all equityholders&#146; agreements, voting agreements, voting trust agreements or other
similar agreements or documents relating to the organization, management or operation of such
entity; and (g)&nbsp;any amendment or supplement to any of the foregoing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Government Official</U>&#148; shall mean any officer, employee, official advisor or agent of
(a)&nbsp;a Governmental Authority; (b)&nbsp;a public international organization (e.g., The World Bank); (c)&nbsp;a
political party or official thereof; or (d)&nbsp;a candidate for any political office.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Governmental Authority</U>&#148; shall mean any international, supranational, federal, state,
local, municipal, foreign or other governmental or quasi-governmental authority or self-regulatory
organization of any nature of competent authority (including any agency, branch, department, board,
commission, court, tribunal, arbitral body or other entity exercising governmental or
quasi-governmental powers) or exercising, or entitled or purporting to exercise, any
administrative, executive, judicial, legislative, enforcement, regulatory or taxing authority or
power.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Hazardous Substance</U>&#148; shall mean any pollutant, contaminant, chemical, petroleum or
any fraction thereof, asbestos or asbestos-containing material, polychlorinated biphenyls, or
industrial, solid, toxic, radioactive, infectious, disease-causing or hazardous substance,
material, waste or agent, including all substances, materials, wastes or agents which are
identified, regulated, the subject of liability or requirements for Remediation under, or otherwise
subject to, any Environmental Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Holdco Ordinary Shares</U>&#148; shall mean the ordinary shares of EUR 1.00 per share of
Holdco.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>HSR Act</U>&#148; means the Hart-Scott-Rodino Antitrust Improvements Act of 1976.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>IFRS</U>&#148; shall mean International Financial Reporting Standards promulgated by the
International Accounting Standards Board (which includes standards and interpretations approved by
the International Accounting Standards Board and International Accounting Standards issued under
previous constitutions), together with its pronouncements thereon from time to time, as adopted by
the European Union, and applied on a basis consistent with Elan&#146;s historic accounting principles
and practices.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Indebtedness</U>&#148; shall mean with respect to any Person, any obligations of such Person
(a)&nbsp;for borrowed money, (b)&nbsp;evidenced by notes, bonds, debentures or similar instruments, (c)&nbsp;for
the deferred purchase price of goods or services (other than payables or accruals incurred in the
Ordinary Course of Business), (d)&nbsp;under capital leases, or (e)&nbsp;in the nature of guarantees of the
obligations described in clauses <U>(a)</U> through <U>(d)</U> above of any other Person.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->9<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Intellectual Property Right</U>&#148; means any trademark, service mark, trade name, mask
work, invention, discoveries, patent, patent application, trade secret, copyright, know-how, data,
proprietary information, processes, procedure, protocol, techniques, designs, formulae, products,
compound, composition, material, technologies, apparatus, Internet domain names, trade dress and
general intangibles of like nature (together with goodwill), customer lists, confidential
information, licenses, software, databases and compilations including any and all collections of
data and all documentation thereof (including any registrations or applications for registration of
any of the foregoing) or any other similar type of proprietary intellectual property right.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Interco Ordinary Shares</U>&#148; shall mean the ordinary shares of EUR 1.00 per share of
Interco.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>IP Transfer Agreement</U>&#148; shall mean the agreement for the transfer of certain
Intellectual Property Rights by Alkermes to Interco in the Agreed Form set forth in <U>Schedule
B</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>IP Transfer Loan Note</U>&#148; shall mean the note issued by Interco to Alkermes under the IP
Transfer Agreement in the Agreed Form set forth in <U>Schedule&nbsp;C</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Ireland</U>&#148; shall mean the island of Ireland, excluding the counties of Antrim, Armagh,
Derry, Down, Fermanagh and Tyrone.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Ireland DB Plans</U>&#148; shall mean the Elan Corporation, plc Defined Benefit Plan (pension
and risk benefits) &#151; Executives and the Elan Corporation, plc Defined Benefit Plan (pension and
risk benefits) &#151; Staff referred to in <U>Section&nbsp;3.20(a)</U> of the Elan Disclosure Schedule.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Ireland Employees</U>&#148; shall mean the employees whose names are set out in <U>Section
3.20(g)(i)</U> of the Elan Disclosure Schedule and who are employees of New Alkermes or its
Subsidiaries immediately after the Effective Time. The term &#147;<U>Ireland Employees</U>&#148; shall not
include any employees or former employees of Elan or its Subsidiaries who prior to the Effective
Time have retired or have otherwise ceased employment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>ISE</U>&#148; shall mean the Irish Stock Exchange Limited.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Knowledge</U>&#148; of any Person shall mean the actual knowledge of such Person&#146;s executive
officers after reasonable inquiry of the employees of such Person and its Subsidiaries and others
responsible for the facts or matters specified.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Law</U>&#148; shall mean any United States federal, state or local, or any non-U.S., order,
ruling, writ, injunction, judgment, award, decree, statute, law, ordinance, rule or regulation or
other requirement issued by a Governmental Authority.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Liability</U>&#148; shall mean with respect to any Person, any Indebtedness, liability or
obligation of such Person of any kind, character or description, whether known or unknown, absolute
or contingent, accrued or unaccrued, disputed or undisputed, liquidated or unliquidated, secured or
unsecured, joint or several, due or to become due, vested or unvested, executory, determined,
determinable or otherwise, and whether or not the same is required by IFRS or U.S. GAAP to be
accrued on the financial statements of such Person.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->10<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Lien</U>&#148; shall mean any imperfection of title, easement, encroachment, security
interest, pledge, mortgage, lien (including environmental and tax liens), charge, encumbrance,
proxy, right of first option, right of first refusal, conditional sale contract, voting trust or
voting agreement or similar restriction or contract to grant any of the foregoing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Marketing Period</U>&#148; shall mean the first period of twenty-five (25)&nbsp;consecutive
Business Days after the date hereof throughout which: (i)&nbsp;Alkermes shall have the Required
Financial Information that Elan is required to provide to Alkermes pursuant to <U>Section
5.21</U>; <U>provided</U>, that if Elan shall in good faith reasonably believe it has delivered
the Required Financial Information, it may deliver to Alkermes a written notice to that effect
(stating when it believes it completed such delivery), in which case the Marketing Period shall be
deemed to have commenced on the date of such notice unless Alkermes in good faith reasonably
believes Elan has not completed delivery of the Required Financial Information, and, within four
(4)&nbsp;Business Days after the delivery of such notice by Elan, delivers a written notice to Elan to
that effect (stating to the extent reasonably possible which Required Financial Information Elan
has not delivered), and (ii)&nbsp;the conditions set forth in <U>Section&nbsp;8.1</U> and <U>Section
8.2</U> shall be satisfied (other than those conditions that by their nature can only be satisfied
at the Closing) and nothing has occurred and no condition exists that would cause any of the
conditions set forth in <U>Section&nbsp;8.1</U> and <U>Section&nbsp;8.2</U> to fail to be satisfied
assuming the Closing were scheduled for any time during such 25-consecutive-Business-Day period;
<U>provided</U>, that such period shall not include any period that includes the period from and
including August&nbsp;19, 2011 through and including September&nbsp;5, 2011; <U>provided</U>,
<U>further</U>, that the Marketing Period shall not be deemed to have commenced if, prior to the
completion of such 25-consecutive-Business-Day period, (A)&nbsp;KPMG LLP shall have withdrawn its audit
opinion with respect to any of the financial statements contained in the Required Financial
Information, or (B)&nbsp;Elan shall have publicly announced any intention to restate any material
financial information included in the Required Financial Information or that any such restatement
is under consideration, in which case the Marketing Period shall be deemed not to commence at the
earliest unless and until such restatement has been completed and the affected Required Financial
Information has been amended or Elan has publicly announced that no restatement will be required.
For the avoidance of doubt, after the Marketing Period has commenced, furnishing Alkermes and/or
the Financing Parties with updates to the Required Information (including updates to the financial
statements and projections) as required by the Commitment Letter shall not be deemed to restart the
25-consecutive-Business-Day period then in effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Memorandum and Articles of Association</U>&#148; shall mean the memorandum and articles of
association of New Alkermes in effect as of the Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Merger Sub Common Stock</U>&#148; shall mean the Common Stock, no par value, of Merger Sub.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Modified Working Capital</U>&#148; shall mean, as of any date, the cumulative amount, stated
in U.S. Dollars, as of such date, of the asset and liability accounts of the Business specified on
<U>Schedule&nbsp;D</U> (with such adjustments as specified on <U>Schedule&nbsp;D</U>) and determined in
accordance with U.S. GAAP (applied on a consistent basis with <U>Schedule&nbsp;D</U>, to the extent
<U>Schedule&nbsp;D</U> is in accordance with U.S. GAAP) and consistent with the illustrative pro forma
calculations of what the Modified Working Capital would have been as of March&nbsp;31, 2011 as set
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->11<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">forth on <U>Schedule&nbsp;D</U> for information purposes (the &#147;<U>Modified Working Capital
Statement</U>&#148;). For the avoidance of doubt, to the extent inclusion of any asset or liability in
Modified Working Capital would result in double counting of any item included in the calculation of
Net Cash Amount, such asset and/or liability shall be excluded from the calculation of Modified
Working Capital.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Multiemployer Plan</U>&#148; means a multiemployer plan, as defined in Section&nbsp;3(37) of ERISA.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>NASDAQ</U>&#148; shall mean the Nasdaq Global Select Stock Market.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Net Cash Amount</U>&#148; shall mean, as of the Effective Time, (a)&nbsp;the aggregate amount, as
of such time, of all unrestricted cash and cash equivalents (as determined in accordance with U.S.
GAAP applied on a consistent basis with the Audited Financial Statements) of New Alkermes and the
New Alkermes Group Entities, minus (b)&nbsp;the aggregate amount, as of such time, of all Indebtedness
of New Alkermes and the New Alkermes Group Entities (other than the Elan Reorganization
Indebtedness and the Indebtedness represented by the IP Transfer Loan Note), stated in U.S.
Dollars.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>New Alkermes Employee</U>&#148; shall mean any (i)&nbsp;Transferred Employee or (ii)&nbsp;any employee
of Alkermes or any of its Subsidiaries who is so employed on the date of this Agreement or as of
the Closing.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>New Alkermes Group Entities</U>&#148; shall mean, collectively, Holdco, Interco, U.S. Holdco,
Merger Sub (prior to the Effective Time) and the U.S. Acquired Entities, and, each of them,
individually, a &#147;<U>New Alkermes Group Entity</U>&#148;.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>New Alkermes Ordinary Shares</U>&#148; shall mean the ordinary shares, with a nominal value of
$0.01, of New Alkermes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>OIG</U>&#148; shall mean the Office of the Inspector General of the Department of Health and
Human Services or any successor thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Ordinary Course of Business</U>&#148; shall mean the ordinary course of business of a Person;
<U>provided</U>, that an action taken by a Person will be deemed to have been taken in the
ordinary course of business if that action is substantially consistent with the past practices of
such Person; <U>provided</U>, <U>further</U>, that the ordinary course of business of the
Business shall refer to the ordinary course of business of (i)&nbsp;New Alkermes and the New Alkermes
Group Entities and (ii)&nbsp;prior to the Reorganization Transfers, Elan and its Subsidiaries (other
than New Alkermes and the New Alkermes Group Entities, but including EHI) in respect of the
Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>PBCL</U>&#148; means the Pennsylvania Business Corporation Law of 1988.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>PBGC</U>&#148; means the Pension Benefit Guaranty Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Permitted Liens</U>&#148; shall mean all Liens (i)&nbsp;which are reflected or reserved against in
the Business Balance Sheet (up to the amounts so reflected or reserved against); (ii)&nbsp;which arise
out of Taxes or general or special assessments not in default and payable without penalty or
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->12<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">interest or the validity of which is being contested in good faith by appropriate proceedings
and for which adequate reserves have been established in accordance with IFRS and reflected on the
Business Balance Sheet; (iii)&nbsp;of carriers, warehousemen, mechanics, materialmen and other similar
persons or otherwise imposed by law incurred in the Ordinary Course of Business for sums not yet
delinquent or being contested in good faith; (iv)&nbsp;which relate to deposits made in the Ordinary
Course of Business in connection with workers&#146; compensation, unemployment insurance and other types
of social security; (v)&nbsp;which do not materially impair the use of the asset subject thereof for the
purposes for which currently used; and (vi)&nbsp;in the case of the Business Real Property, (A)
easements, quasi-easements, licenses, covenants, rights-of-way, rights of re-entry or other similar
restrictions that would be shown by a current title report or other similar report or listing, (B)
any conditions that may be shown by a current survey or physical inspection and (C)&nbsp;zoning,
building, subdivision or other similar requirements or restrictions, in the case of each of the
agreements, conditions, restrictions or other matters referenced in this clause <U>(vi)</U> which
do not materially impair the use, utility, marketability or value of the applicable property
affected or encumbered thereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Person</U>&#148; shall mean any individual, private or public company, corporation (including
not-for-profit), general or limited partnership, unlimited or limited liability company, joint
venture, estate, trust, association, organization or other entity of any kind or nature, including
a government or political subdivision or an agency or instrumentality thereof.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Post-Closing Employee Plan</U>&#148; shall mean any employment, severance or similar contract,
plan, policy, fund or arrangement (whether or not written) providing for compensation, bonus,
profit-sharing, stock option, or other stock-related rights or other forms of incentive or deferred
compensation, perquisites, vacation benefits, insurance coverage (including any self-insured
arrangements), health or medical benefits, disability benefits, worker&#146;s compensation, supplemental
unemployment benefits, severance benefits and post-employment or retirement benefits (including
compensation, pension, health, medical or life insurance or other benefits) maintained for the
benefit of Transferred Employees in respect of service after the Closing Date by New Alkermes or
any New Alkermes Group Entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Pre-Closing Environmental Matters</U>&#148; shall mean (a)&nbsp;any and all non-compliance with
Environmental Laws or Environmental Licenses by or in respect of the Business, New Alkermes, the
New Alkermes Group Entities or the Additional Assets, to the extent attributable to events, acts,
failures to act or conditions which occurred or existed prior to or at the Effective Time,
including any fines or penalties and any reasonable costs or expenses necessary to correct such
non-compliance; (b)&nbsp;any Action pursuant to Environmental Law for personal injury, property damage,
damage to the Environment, relating to the Business or the Additional Assets or against New
Alkermes or the New Alkermes Group Entities, to the extent attributable to events, acts, failures
to act or conditions which occurred or existed prior to or at the Effective Time; (c)&nbsp;any Liability
of New Alkermes or any New Alkermes Group Entity resulting from a threatened or actual Release or
presence of or exposure to any Hazardous Substance, to the extent attributable to events, acts,
failures to act or conditions which occurred or existed prior to or at the Effective Time; (d)&nbsp;any
Remediation required by Environmental Law, relating to the Business, the Additional Assets, New
Alkermes or the New Alkermes Group Entities, to the extent attributable to events, acts, failures
to act or conditions which occurred, existed or originated prior to or at the Effective Time; and
(e)&nbsp;any Liability of New Alkermes or any New
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->13<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Alkermes Group Entity resulting from any waste materials or other Hazardous Substances
generated by the Business, the Additional Assets, New Alkermes or the New Alkermes Group Entities
prior to or at the Effective Time, and recycled, treated, stored, transported, or disposed of
on-site or off-site, including pursuant to the U.S. Comprehensive Environmental Response,
Compensation and Liability Act, or any Similar Laws or similar U.S. state Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Products</U>&#148; shall mean any product currently or historically developed, manufactured,
marketed, processed, distributed, sold or introduced into commerce by the Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Registration Statement</U>&#148; means the registration statement of New Alkermes on Form S-4,
registering under the Securities Act the New Alkermes Ordinary Shares to be issued to holders of
Alkermes Common Stock in the Merger.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Release</U>&#148; shall mean any spilling, leaking, pumping, pouring, emitting, emptying,
discharging, injecting, escaping, leaching, dumping or disposing of any Hazardous Substance, in,
on, into or onto the Environment, including the abandonment or discard of barrels, containers,
tanks or other receptacles containing any Hazardous Substance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Remediation</U>&#148; shall mean any investigation, study, assessment, testing, monitoring,
containment, removal, remediation, response, cleanup or abatement of any threatened or actual
Release or presence of or exposure to any Hazardous Substance, whether on-site or off-site.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Representatives</U>&#148; shall mean a Person&#146;s officers, directors, consultants, advisors,
employees, stockholders, agents or other advisors or representatives.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>SEC</U>&#148; shall mean the United States Securities and Exchange Commission.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Securities Act</U>&#148; shall mean the Securities Act of 1933.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Similar Law</U>&#148; shall mean any law of a jurisdiction outside the United States that is
similar to the applicable U.S. federal, state or local Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Specified Matters</U>&#148; shall mean (i)&nbsp;the Excluded Assets, (ii)&nbsp;the Reorganization,
including as a result of any failure to seek or obtain a ruling or other relief from any
Governmental Authority (including Irish Revenue) in respect of the Reorganization and (iii)&nbsp;Actions
or claims by Transferred Employees relating to or arising from the Elan Stock Option Plans.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Subsidiary</U>&#148; shall mean, with respect to any Person, any other entity (i)&nbsp;whose
securities or other ownership interests, having by their terms the power to elect a majority of the
board of directors or other Persons performing similar functions, are Beneficially Owned or
Controlled, directly or indirectly, by such Person, (ii)&nbsp;whose business and policies such Person
has the power, directly or indirectly, to direct, or (iii)&nbsp;of which 50% or more of the securities,
partnership or other ownership interests are owned, directly or indirectly, by such Person; it
being understood that, unless otherwise specified, New Alkermes and the New Alkermes Group Entities
shall be considered Subsidiaries of Elan at all times prior to the Effective Time.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->14<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Target Working Capital</U>&#148; shall mean $65,800,000.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Termination Fee</U>&#148; means the Alkermes Termination Fee or the Elan Termination Fee, as
applicable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Title IV Plan</U>&#148; means a plan subject to Title IV of ERISA other than any Multiemployer
Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Transfer Regulations</U>&#148; shall mean the European Communities (Protection of Employees on
Transfer of Undertakings) Transfer Regulations, 2003.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Transferred Books and Records</U>&#148; shall mean all Books and Records held for or on behalf
of New Alkermes or any New Alkermes Group Entity and all Books and Records held for or on behalf of
Elan or any Continuing Affiliates relating primarily to the operations of the Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Transferred Employees</U>&#148; means the Ireland Employees and the U.S. Employees
collectively.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Transferred IP</U>&#148; shall mean any Intellectual Property Right owned by or licensed to
Elan or any of its Subsidiaries and used in the Business, but, for the avoidance of doubt, shall
not include any Intellectual Property Right transferred by Alkermes to a New Alkermes Group Entity
pursuant to the IP Transfer Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>Transition Services Agreement</U>&#148; shall mean the transition services agreement between
New Alkermes, on the one hand, and Elan and any relevant Continuing Affiliates, on the other hand,
to be in a form mutually acceptable to the Parties and executed on or prior to the Closing Date, by
which Elan and any relevant Continuing Affiliates agree to provide services to New Alkermes and its
Subsidiaries (and vice versa) from and after the Closing Date, including services and other terms
and conditions are specified on <U>Schedule&nbsp;E</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>TUPE Transfer</U>&#148; shall mean a transfer of a business within the meaning of the Transfer
Regulations.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>TUPE Transfer Date</U>&#148; shall mean the date with effect from which a TUPE Transfer
occurs.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>U.S. Acquired Entities</U>&#148; shall mean Eagle Holdings and EHI.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>U.S. Employees</U>&#148; shall mean the employees whose names are set out in <U>Section
3.20(g)(ii)</U> of the Elan Disclosure Schedule and who are employees of New Alkermes or its
Subsidiaries immediately after the Effective Time. The term &#147;<U>U.S. Employees</U>&#148; shall not
include any employees or former employees of Elan or its Subsidiaries who prior to the Effective
Time have retired or have otherwise terminated employment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>U.S. GAAP</U>&#148; shall mean United States generally accepted accounting principles.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->15<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#147;<U>U.S. Holdco Common Stock</U>&#148; shall mean the Common Stock, par value $0.01 per share, of
U.S. Holdco.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each of the following terms is defined in the Section set forth opposite such term:
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="85%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Section</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Accrued Bonus Expense</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.1(b)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Acquired Confidential Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.1(c)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Adjustment Payment Date</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(f)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Affiliate Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.14&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes Balance Sheet</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.7&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes Balance Sheet Date</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.7&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes Certificates</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.10(b)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes Change in Recommendation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.1(e)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes Disclosure Schedule</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Article IV</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes Financial Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.6(b)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes Indemnified Parties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.2(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes Options</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.2(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes Proxy Statement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.11(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes SEC Reports</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.6&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes Shareholders Meeting</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.12&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes Stock Awards</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.2(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Alkermes Tax Indemnitees</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Ancillary Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Anti-Bribery Laws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.12(d)(i)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Articles of Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.5&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Balance Sheet Date</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.4(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Business Assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Business Balance Sheet</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.4(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Business Material Contracts</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.14&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Business Real Property</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.6(b)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Cash Payment</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.2&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Closing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.1&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Closing Date</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.1&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Closing Modified Working Capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(b)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Closing Net Cash Amount</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(b)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Closing Payment Certificate</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Closing Payments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.2&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">COBRA coverage</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.2(b)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Commitment Letter</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.14(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Confidentiality Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.1(c)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Deeds of Transfer</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.3(i)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Definitive Financing Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.21(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Designated Assets</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.18&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->16<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="85%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Section</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Effective Time</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.5&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Elan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Elan Disclosure Schedule</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Article III</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Elan Indemnified Parties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.3(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Elan Parties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Elan Shareholder</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Elan Tax Indemnitors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(b)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">ELN005 Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.7(b)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Estimated Closing Adjustment Amount</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Estimated Modified Working Capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Estimated Net Cash Amount</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exchange Agent</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.10(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exchange Fund</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.10(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Exchange Ratio</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.9(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">FDA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.10&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">FDCA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.10&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Final Closing Adjustment Amount</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(d)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Final Modified Working Capital</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(d)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Final Net Cash Amount</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(d)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Financing</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.14(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Financing Parties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.21(b)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Governmental Antitrust Authority</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.2(c)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Historical Financial Statements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.4(a)&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Holdco</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">IMB</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.10&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Import/Export Control Laws</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.12(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Indemnity Recipient</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.14&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Interco</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Irish Revenue</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.6(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Licenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.10&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Merger Consideration</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.9(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Merger Sub</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Neutral Auditors</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(d)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">New Alkermes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">New Alkermes 401(k) Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.2(c)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">New Alkermes Transition Bonus Plan</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">6.1(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Notice of Claim</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.4(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Parties</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">PHSA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">3.10&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Plan of Merger</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Post-Closing Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(c)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Post-Closing Straddle Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(h)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pre-Closing Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(d)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Pre-Closing Straddle Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(e)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Proposed Final Closing Adjustment Amount</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(b)</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->17<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="85%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="10%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Term</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="left" style="border-bottom: 1px solid #000000"><B>Section</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Purchased Interests</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Receiving Party</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.1(c)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Reorganization</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Relevant Indemnity Payments</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.14&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Reorganization Transfer Agreements</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Reorganization Transfers</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Required Alkermes Vote</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.12&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Required Financial Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.21(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Resolution Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.15(c)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Retained Confidential Information</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">5.1(c)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Returns</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(f)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Rights</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">4.2(a)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">SDCA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.6(d)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Shareholder&#146;s Agreement</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Straddle Period</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(g)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Straddle Period Return</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.5(c)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Surviving Corporation</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">2.4&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tax</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(i)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Taxes</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(i)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tax Accounting Referee</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(j)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tax Benefits</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.14(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tax Claim</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(k)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tax Proceeding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.6(e)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Tax Returns</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(f)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Taxing Authority</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(l)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">TCA</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.1(f)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Termination Date</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">10.1(b)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Threshold</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">9.5&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Transactions</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Transfer Tax</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">7.11(m)</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">Transferring Subsidiaries</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Recitals</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:15px; text-indent:-15px">U.S. Holdco</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Preamble</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;1.2. <U>Usage</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Interpretation</U>. In this Agreement, unless a clear contrary intention appears:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the singular number includes the plural number and vice versa;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) reference to any Person includes such Person&#146;s legal representatives,
successors and assigns but, if applicable, only if such successors and assigns are
not prohibited by this Agreement, and reference to a Person in a particular capacity
excludes such Person in any other capacity or individually;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) reference to either gender includes the other gender;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->18<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) reference to any agreement, document or instrument means such agreement,
document or instrument as amended or modified and in effect in accordance with the
terms thereof;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) reference to any Law means such Law as amended, modified, codified,
replaced or reenacted, in whole or in part, and in effect from time to time,
including rules and regulations promulgated thereunder, and reference to any section
or other provision of any Law means that provision of such Law from time to time in
effect and constituting the substantive amendment, modification, codification,
replacement or reenactment of such section or other provision;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) &#147;hereunder,&#148; &#147;hereof,&#148; &#147;hereto,&#148; and words of similar import shall be
deemed references to this Agreement as a whole and not to any particular Article,
Section or other provision hereof;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) &#147;including&#148; (and with correlative meaning &#147;include&#148;) means including
without limiting the generality of any description preceding such term;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) with respect to the determination of any period of time, &#147;from&#148; means
&#147;from and including&#148; and &#147;to&#148; means &#147;to but excluding&#148;;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) &#147;provided to Alkermes&#148; means made available to Alkermes in the electronic
dataroom at https://datasite.merrillcorp.com/bidder/index&#95;frame.do?projectId=87114,
or other permanent physical or electronic media, in each case, prior to the date
hereof;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) references to &#147;USD&#148; &#147;$&#148; or &#147;dollars&#148; shall be to U.S. Dollars;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) any reference herein to &#147;EUR&#148;, &#147;&#128;&#148; or &#147;euros&#148; are to euros, the lawful
currency of Ireland;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) any references herein to a specific Section, Schedule, Annex or Exhibit
shall refer, respectively, to Sections, Schedules, Annexes or Exhibits of this
Agreement;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) words and phrases the definitions of which are contained or referred to
in the Companies Acts shall be construed as having the meanings thereby attributed
to them;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv) any reference to an Irish legal term for any action, remedy, method of
judicial proceeding, legal document, legal status, court, official or any legal
concept or thing shall, in respect of any jurisdiction other than Ireland, be deemed
to include a reference to what most nearly approximates in that jurisdiction to the
Irish legal term;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xv) any reference to a U.S. federal, state or local Law shall, whether or not
accompanied by reference to Similar Laws, be construed where appropriate to
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->19<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">include references to the nearest equivalent applicable Laws in any other
jurisdiction;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvi) any reference to any statute or statutory provision shall be deemed to
include any statute or statutory provision that amends, extends, consolidates,
re-enacts or replaces same, or which has been amended, extended, consolidated,
re-enacted or replaced (whether before or after the date of this Agreement) by same
and shall include any orders, regulations, instruments or other subordinate
legislation made under the relevant statute; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvii) references to documents, instruments or agreements shall be deemed to
refer as well to all addenda, exhibits (other than exhibits constituting agreements,
which shall only become legally binding upon execution and delivery by the parties
thereto), schedules or amendments thereto from time to time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Accounting Terms and Determinations</U>. Unless otherwise specified herein, all
accounting terms used herein shall be interpreted and all accounting determinations hereunder shall
be made in accordance with U.S. GAAP.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Legal Representation of the Parties</U>. This Agreement was negotiated by the Parties
with the benefit of legal representation, and any rule of construction or interpretation otherwise
requiring this Agreement to be construed or interpreted against any Party shall not apply to any
construction or interpretation hereof.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE II</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>The Merger; Closing of Transactions</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.1. <U>Time and Place of Closing</U>. The closing of the Transactions (the
&#147;<U>Closing</U>&#148;) shall take place (a)&nbsp;at 9:00 a.m., New York City time, at the offices of Cleary
Gottlieb Steen &#038; Hamilton LLP, One Liberty Plaza, New York, New York 10006, on the later of (i)&nbsp;the
fifth (5<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>) Business Day following the date on which the last to be satisfied or waived
of the conditions set forth in <U>Article&nbsp;VIII</U> (other than those conditions that by their
nature cannot be satisfied until the Closing, but subject to the satisfaction or, where permitted,
waiver of those conditions) shall be satisfied or waived in accordance with this Agreement and (ii)
the earlier of (A)&nbsp;a date during the Marketing Period to be specified by Alkermes on at least three
(3)&nbsp;Business Days&#146; notice to Elan and (B)&nbsp;the final day of the Marketing Period, or (b)&nbsp;at such
other place, time and/or date as Alkermes and Elan shall agree (the date of the Closing, the
&#147;<U>Closing Date</U>&#148;). The Closing shall be deemed to occur at 12:01&nbsp;a.m., New York City time,
on the Closing Date.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.2. <U>Elan Proceeds</U>. The aggregate payments received by Elan (or one or more
of its Continuing Affiliates) pursuant to this Agreement in connection with the Transactions and
other transactions contemplated hereby shall consist of (a)&nbsp;31,900,000 New Alkermes Ordinary Shares
that the Elan Shareholder shall continue to hold as of the Effective Time, plus (b)&nbsp;a payment by
wire transfer from or on behalf of Alkermes, New Alkermes or their respective Subsidiaries, as
applicable, of immediately available funds in an amount equal to
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->20<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">$500,000,000 in full and final satisfaction of the Elan Reorganization Indebtedness (the
&#147;<U>Cash Payment</U>&#148;) (collectively, the &#147;<U>Closing Payments</U>&#148;), subject to any adjustment
to the Cash Payment pursuant to <U>Section&nbsp;2.15</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.3. <U>Alkermes Payments</U>. In addition to other good and valuable consideration,
including the cancellation of the Alkermes Common Stock pursuant to the Merger, Merger Sub shall
make a payment of $500&nbsp;million by way of paying up the nominal value and any premium of the New
Alkermes Ordinary Shares to be issued at the Effective Time to New Alkermes in consideration for
the undertaking by New Alkermes to issue New Alkermes Ordinary Shares valued at $500&nbsp;million to
holders of Alkermes Common Stock as of immediately prior to the Effective Time in accordance with
<U>Section&nbsp;2.9(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.4. <U>The Merger</U>. Upon the terms and subject to the conditions set forth in
this Agreement, and in accordance with Section&nbsp;1921 et seq. of the PBCL, Merger Sub shall be merged
with and into Alkermes at the Effective Time. Following the Merger, the separate corporate
existence of Merger Sub shall cease and Alkermes shall continue as the surviving corporation (the
&#147;<U>Surviving Corporation</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.5. <U>Effective Time</U>. Upon the Closing, Merger Sub and Alkermes shall (a)&nbsp;file
articles of merger with the Department of State of the Commonwealth of Pennsylvania (the
&#147;<U>Articles of Merger</U>&#148;) in such form as is required by and executed in accordance with the
relevant provisions of the PBCL and (b)&nbsp;make all other filings or recordings required under the
PBCL. The Merger shall become effective at such time as the Articles of Merger are duly filed with
the Department of State of the Commonwealth of Pennsylvania, or at such subsequent time as Alkermes
and Elan shall agree and as shall be specified in the Articles of Merger (the date and time the
Merger becomes effective being the &#147;<U>Effective Time</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.6. <U>Effects of the Merger</U>. At and after the Effective Time, the Merger will
have the effects set forth in the PBCL. Without limiting the generality of the foregoing, and
subject thereto, at the Effective Time, the separate corporate existence of Merger Sub shall cease
and all the property, rights, privileges, powers and franchises of Alkermes and Merger Sub shall be
vested in the Surviving Corporation, and all debts, liabilities and duties of Alkermes and Merger
Sub shall become the debts, liabilities and duties of the Surviving Corporation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.7. <U>Governing Documents</U>. (a)&nbsp;The articles of incorporation of the Surviving
Corporation shall be amended as of the Effective Time to read in the Agreed Form as set forth on
<U>Schedule&nbsp;F</U>. The by-laws of Alkermes, as in effect immediately prior to the Effective Time,
shall be the by-laws of the Surviving Corporation until thereafter changed or amended as provided
therein or by applicable Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Elan and New Alkermes shall take, or cause to be taken, such actions as are necessary so
that, effective as of the Effective Time, the Memorandum and Articles of Association of New
Alkermes read in the Agreed Form as set forth on <U>Schedule&nbsp;G</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.8. <U>Officers and Directors</U>. (a)&nbsp;The officers of Alkermes as of immediately
prior to the Effective Time shall be the initial officers of the Surviving Corporation, until the
earlier of their resignation or removal or otherwise ceasing to be an officer or until their
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->21<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">respective successors are duly elected and qualified, as the case may be. The directors of
Alkermes as of immediately prior to the Effective Time shall be the initial directors of the
Surviving Corporation, which individuals will serve as directors of the Surviving Corporation until
the earlier of their resignation or removal or otherwise ceasing to be a director or until their
respective successors are duly elected and qualified.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Elan, New Alkermes, Holdco, Interco and U.S. Holdco shall take, or cause to be taken, such
actions as are necessary so that, effective as of the Effective Time, the officers and directors of
New Alkermes, Holdco, Interco and U.S Holdco shall be the individuals specified by Alkermes to Elan
in writing at least three (3)&nbsp;Business Days prior to Closing, which individuals will serve in such
capacities until the earlier of their resignation or removal or otherwise ceasing to be an officer
or director, as the case may be, or until their respective successors are duly elected and
qualified, as the case may be.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.9. <U>Effect on Capital Stock</U>. At the Effective Time, by virtue of the Merger
and without any action on the part of the Parties or any of their respective shareholders:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Conversion of Alkermes Common Stock</U>. Each share of Alkermes Common Stock issued
and outstanding immediately prior to the Effective Time, and all rights in respect thereof,
including the associated Series&nbsp;A Junior Participating Preferred Stock Purchase Rights issuable
pursuant to the Alkermes Rights Agreement, shall be canceled and automatically converted into and
become the right to receive one New Alkermes Ordinary Share (the &#147;<U>Exchange Ratio</U>&#148;). As a
result of the Merger, at the Effective Time, each holder of an Alkermes Certificate shall cease to
have any rights with respect thereto, except the right to receive the consideration payable in
respect of the shares of Alkermes Common Stock represented by such Alkermes Certificate immediately
prior to the Effective Time and any dividends or other distributions payable pursuant to
<U>Section&nbsp;2.10(c)</U>, all to be issued or paid, without interest, in consideration therefor upon
surrender of such Alkermes Certificate in accordance with <U>Section&nbsp;2.10(b)</U> (or, in the case
of a lost, stolen or destroyed Alkermes Certificate, <U>Section&nbsp;2.10(i)</U>), collectively,
referred to as the &#147;<U>Merger Consideration</U>&#148;. Each share of Alkermes Common Stock held in
treasury immediately prior to the Effective Time shall be canceled and extinguished without any
conversion thereof and no distribution shall be made with respect thereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Merger Sub Capital Stock</U>. At the Effective Time, by virtue of the Merger and
without any action on the part of the Parties or any of their respective shareholders, each share
of Merger Sub Common Stock issued and outstanding immediately prior to the Effective Time, and all
rights in respect thereof, shall forthwith be canceled and cease to exist and be converted into one
fully paid and nonassessable share of common stock of the Surviving Corporation, which shall
constitute the only outstanding shares of capital stock of the Surviving Corporation and which
shall be held by U.S. Holdco.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Additional Issuances</U>. At the Effective Time, by virtue of the Merger and in
consideration of the undertaking of each parent entity to effect the Transactions as described in
this Agreement, without any further action on the part of the Parties or any of their respective
shareholders: (i)&nbsp;U.S. Holdco shall issue to Interco the number of shares of U.S. Holdco Common
Stock equal to three times (3X) the number of shares of U.S. Holdco Common Stock which Interco
holds immediately prior to the Effective Time; (ii)&nbsp;Interco shall issue to Holdco
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->22<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the number of Interco Ordinary Shares equal to three times (3X) the number of Interco Ordinary
Shares which Holdco holds immediately prior to the Effective Time; and (iii)&nbsp;Holdco shall issue to
New Alkermes the number of Holdco Ordinary Shares equal to three times (3X) the number of Holdco
Ordinary Shares which New Alkermes holds immediately prior to the Effective Time.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.10. <U>Exchange of Shares and Certificates</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) <U>Exchange Agent</U>. Prior to the Effective Time, New Alkermes shall engage
Computershare or another institution satisfactory to Alkermes (acting in its sole discretion) to
act as exchange agent in connection with the Merger (the &#147;<U>Exchange Agent</U>&#148;). At or prior to
the Effective Time, New Alkermes shall issue to the Exchange Agent, in trust for the benefit of the
holders of shares of Alkermes Common Stock immediately prior to the Effective Time, certificates
representing the New Alkermes Ordinary Shares issued pursuant to <U>Section&nbsp;2.9(a)</U> (or
appropriate alternative arrangements satisfactory to Alkermes (acting in its sole discretion) shall
be made by New Alkermes if uncertificated New Alkermes Ordinary Shares will be issued). In
addition, New Alkermes shall make available by depositing with the Exchange Agent, as necessary
from time to time after the Effective Time, cash in an amount sufficient to make the payments in
respect of any dividends or distributions to which holders of shares of New Alkermes Ordinary
Shares may be entitled pursuant to <U>Section&nbsp;2.10(c)</U>. All cash and certificates representing
New Alkermes Ordinary Shares deposited with the Exchange Agent shall hereinafter be referred to as
the &#147;<U>Exchange Fund</U>.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Exchange Procedures</U>. As soon as reasonably practicable after the Effective Time,
and in any event within ten (10)&nbsp;Business Days after the Effective Time, New Alkermes shall cause
the Exchange Agent to mail to each holder of record of a certificate or certificates which
immediately prior to the Effective Time represented outstanding shares of Alkermes Common Stock
(the &#147;<U>Alkermes Certificates</U>&#148;), which at the Effective Time were converted into the right to
receive the Merger Consideration pursuant to <U>Section&nbsp;2.9</U>, (i)&nbsp;a letter of transmittal
(which shall specify that delivery shall be effected, and that risk of loss and title to the
Alkermes Certificates shall pass, only upon delivery of the Alkermes Certificates to the Exchange
Agent and which shall be in form and substance reasonably satisfactory to New Alkermes and
Alkermes) and (ii)&nbsp;instructions for use in effecting the surrender of the Alkermes Certificates in
exchange for New Alkermes Ordinary Shares and any dividends or other distributions payable pursuant
to <U>Section&nbsp;2.10(c)</U>. Upon surrender of Alkermes Certificates for cancellation to the
Exchange Agent, together with such letter of transmittal, duly completed and validly executed in
accordance with the instructions thereto, and such other documents as may reasonably be required by
the Exchange Agent, the holder of such Alkermes Certificates shall be entitled to receive in
exchange therefor that number of New Alkermes Ordinary Shares (after taking into account all
Alkermes Certificates surrendered by such holder) to which such holder is entitled pursuant to
<U>Section&nbsp;2.9</U> (which shall be in uncertificated form) and any dividends or distributions
payable pursuant to <U>Section&nbsp;2.10(c)</U>, and the Alkermes Certificates so surrendered shall
forthwith be canceled. In the event of a transfer of ownership of shares of Alkermes Common Stock
which is not registered in the transfer records of Alkermes, the proper number of New Alkermes
Ordinary Shares in form may be transferred to a Person other than the Person in whose name the
Alkermes Certificate so surrendered is registered, if such Alkermes Certificate shall be properly
endorsed or otherwise be in proper form for transfer and the Person requesting such transfer shall
pay any transfer or other Taxes required by reason of the issuance of New
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->23<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Alkermes Ordinary Shares to a Person other than the registered holder of such Alkermes
Certificate or establish to the reasonable satisfaction of New Alkermes that such Tax has been paid
or is not applicable. Until surrendered as contemplated by this <U>Section&nbsp;2.10(a)</U>, each
Alkermes Certificate shall be deemed at any time after the Effective Time to represent only the
right to receive the Merger Consideration upon such surrender. No interest shall be paid or shall
accrue on any amount payable pursuant to <U>Section&nbsp;2.10(c)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) <U>Distributions with Respect to Unexchanged Shares</U>. No dividends or other
distributions with respect to New Alkermes Ordinary Shares with a record date after the Effective
Time shall be paid to the holder of any unsurrendered Alkermes Certificate with respect to the New
Alkermes Ordinary Shares represented thereby until such Alkermes Certificate has been surrendered
in accordance with this <U>Section&nbsp;2.10</U>. Subject to applicable Law and the provisions of this
<U>Section&nbsp;2.10</U>, following surrender of any such Alkermes Certificate, there shall be
transferred or paid to the recordholder thereof by the Exchange Agent, without interest, (i)
promptly after such surrender, the number of New Alkermes Ordinary Shares transferrable in exchange
therefor pursuant to this <U>Section&nbsp;2.10</U> and the amount of dividends or other distributions
with a record date after the Effective Time theretofore paid with respect to such whole New
Alkermes Ordinary Shares and (ii)&nbsp;at the appropriate payment date, the amount of dividends or other
distributions with a record date after the Effective Time and a payment date subsequent to such
surrender payable with respect to such New Alkermes Ordinary Shares.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) <U>No Further Ownership Rights in Alkermes Common Stock</U>. All New Alkermes Ordinary
Shares transferred upon the surrender for exchange of Alkermes Certificates in accordance with the
terms of this <U>Article&nbsp;II</U> and any cash paid pursuant to <U>Section&nbsp;2.10(c)</U> shall be
deemed to have been transferred (or paid) in full satisfaction of all rights pertaining to the
shares of Alkermes Common Stock previously represented by such Alkermes Certificates. After the
Effective Time, the stock transfer books of Alkermes shall be closed, and there shall be no further
registration of transfers on the stock transfer books of the Surviving Corporation of the shares of
Alkermes Common Stock which were outstanding immediately prior to the Effective Time. If, after
the Effective Time, Alkermes Certificates are presented to the Surviving Corporation or the
Exchange Agent for any reason, they shall be canceled and exchanged as provided in this <U>Article
II</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Termination of Exchange Fund</U>. Any portion of the Exchange Fund which has not been
transferred to the holders of Alkermes Certificates as of the one year anniversary of the Effective
Time shall be delivered to New Alkermes or its designee, upon demand, and the New Alkermes Ordinary
Shares included therein shall be sold at the best price reasonably obtainable at that time. Any
holder of Alkermes Certificates who has not complied with this <U>Article&nbsp;II</U> prior to the one
year anniversary of the Effective Time shall thereafter look only to New Alkermes for payment of
such holder&#146;s claim for the Merger Consideration (subject to abandoned property, escheat or other
similar applicable Laws) but only as a general creditor thereof for payment of such holder&#146;s claim
for such holder&#146;s portion of the cash proceeds of the sale of the New Alkermes Ordinary Shares (and
any related cash).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f) <U>No Liability</U>. None of New Alkermes, any New Alkermes Group Entity, Merger Sub,
Alkermes, any Elan Entity or the Exchange Agent or any of their respective directors, officers,
employees and agents shall be liable to any Person in respect of any New
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->24<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Alkermes Ordinary Shares (or dividends or distributions with respect thereto) or cash from the
Exchange Fund delivered to a public official pursuant to any applicable abandoned property, escheat
or similar Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Investment of Exchange Fund</U>. The Exchange Agent shall invest any cash included in
the Exchange Fund as directed by New Alkermes on a daily basis; <U>provided</U>, that no such
investment or loss thereon shall affect the amounts payable to former stockholders of Alkermes
after the Effective Time pursuant to this <U>Article&nbsp;II</U>. Any interest and other income
resulting from such investment shall become a part of the Exchange Fund, and any amounts in excess
of the amounts payable pursuant to this <U>Article&nbsp;II</U> shall promptly be paid to New Alkermes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h) <U>Withholding Rights</U>. New Alkermes and the Exchange Agent shall be entitled to
deduct and withhold from any amount payable pursuant to this Agreement to any Person who was a
holder of Alkermes Common Stock immediately prior to the Effective Time such amounts as New
Alkermes or the Exchange Agent may be required to deduct and withhold with respect to the making of
such payment under the Code or any other provision of federal, state, local or non-U.S. Tax law.
To the extent that amounts are so withheld by New Alkermes or the Exchange Agent, such withheld
amounts shall be treated for all purposes of this Agreement as having been paid to the Person to
whom such consideration would otherwise have been paid.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) <U>Lost, Stolen or Destroyed Certificates</U>. In the event any Alkermes Certificates
shall have been lost, stolen or destroyed, the Exchange Agent shall issue in exchange for such
lost, stolen or destroyed Alkermes Certificates, upon the making of an affidavit of that fact by
the holder thereof, such New Alkermes Ordinary Shares as may be required pursuant to <U>Section
2.9(a)</U> and any dividends or distributions payable pursuant to <U>Section&nbsp;2.10(c)</U>;
<U>provided</U>, that New Alkermes may, in its discretion and as a condition precedent to the
issuance thereof, require the owner of such lost, stolen or destroyed Alkermes Certificates to
deliver an agreement of indemnification in a form reasonably satisfactory to New Alkermes, or a
bond in such sum as New Alkermes may reasonably direct as indemnity, against any claim that may be
made against New Alkermes or the Exchange Agent in respect of the Alkermes Certificates alleged to
have been lost, stolen or destroyed.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.11. <U>Alkermes Stock Based Awards</U>. (a)&nbsp;Each Alkermes Option that is
outstanding immediately prior to the Effective Time shall be converted at the Effective Time into
an option to acquire, on substantially the same terms and conditions as were applicable under such
Alkermes Option, the number of New Alkermes Ordinary Shares, determined by multiplying the number
of shares of Alkermes Common Stock subject to such Alkermes Option immediately prior to the
Effective Time by the Exchange Ratio, at an exercise price per New Alkermes Ordinary Share equal to
(A)&nbsp;the exercise price per share of Alkermes Common Stock otherwise purchasable pursuant to such
Alkermes Option divided by (B)&nbsp;the Exchange Ratio; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Alkermes Stock Award that is outstanding immediately prior to the Effective Time
shall be converted at the Effective Time into a right to receive, on substantially the same terms
and conditions as were applicable under such Alkermes Stock Award, the
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->25<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">number of New Alkermes Ordinary Shares, determined by multiplying the number of shares of
Alkermes Common Stock subject to such Alkermes Stock Award immediately prior to the Effective Time
by the Exchange Ratio.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The adjustments provided in <U>Section&nbsp;2.11</U> with respect to any Alkermes Options that
are &#147;incentive stock options&#148; (as defined in Section&nbsp;422 of the Code) are intended to be effected
in a manner that is consistent with Section 424(a) of the Code. For the avoidance of doubt, the
exercise price of, and the number of shares subject to, each Adjusted Option and Adjusted Post
Signing Option shall be determined in a manner necessary to comply with Section&nbsp;409A of the Code
and the Treasury Regulations thereunder.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;As soon as reasonably practicable following the date of this Agreement, and in any event
prior to the Effective Time, the board of directors of Alkermes (or, if appropriate, any committee
administering Alkermes&#146; stock-based incentive plans) and New Alkermes shall adopt such resolutions
and take such other actions as may be reasonably required to effectuate the foregoing provisions of
this <U>Section&nbsp;2.11</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.12. <U>Additional Assets</U>. Elan shall, and shall cause its Subsidiaries to,
convey to New Alkermes or a New Alkermes Group Entity designated by Alkermes prior to the Closing,
all right, title and interest in and to the Additional Assets, such that from and after the
Closing, New Alkermes or one of its Subsidiaries shall hold all right, title and interest in and to
the Additional Assets.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.13. <U>Deliveries by Elan and the Continuing Affiliates</U>. At the Closing, Elan
shall, or shall cause one or more of the Continuing Affiliates to, as the case may be, deliver the
following to New Alkermes and Alkermes or the applicable Affiliate thereof:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) certificates or notarial assignment deeds for, or such other instruments
evidencing ownership by New Alkermes (directly or indirectly) under applicable Law
of, the Purchased Interests and all other outstanding equity of the New Alkermes
Group Entities, which constitute and will constitute as of the Closing, 100% of the
issued and outstanding shares of capital stock or other equity interests of the New
Alkermes Group Entities, in each case with appropriate stock powers or other
instruments of transfer and requisite tax stamps (including Irish e-stamping
certificates) attached and properly signed (and, in the event that the
Reorganization includes the transfer of assets and/or assumption of liabilities by
New Alkermes or any of the New Alkermes Group Entities, such other documentation as
may be reasonably requested by Alkermes to reflect the transfer of such assets and
liabilities to New Alkermes or the applicable New Alkermes Group Entities) and, in
the case of any Irish incorporated company, share registers showing the correct
legal ownership of shares in such company;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) a bill of sale or other appropriate document of transfer, in form and
substance reasonably acceptable to Alkermes, transferring the Designated Assets;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) all Transferred Books and Records, if any, in the possession of Elan or
any Continuing Affiliate to the extent not then in the custody of New
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->26<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Alkermes or any New Alkermes Group Entity or located on the premises of New
Alkermes or any New Alkermes Group Entity, other than Transferred Books and Records
that are not reasonably practicable to deliver at the Closing;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) the certificate required to be delivered by Elan pursuant to <U>Section
8.2(f)</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) a counterpart of the Shareholder&#146;s Agreement duly executed by Elan and the
Elan Shareholder;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) counterparts to the IP Transfer Agreement and IP Transfer Loan Note,
effective as of immediately prior to the Closing, duly executed by Interco, unless
Alkermes shall have determined, in its sole discretion, that there has been a change
in Law that would materially increase the risk of having an adverse impact on
Alkermes or the benefits intended to be achieved by such agreements;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) counterparts to any other Ancillary Agreement to be entered into at the
Effective Time;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) documentation reasonably satisfactory to Alkermes evidencing the payment
in full of the Elan Reorganization Indebtedness;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) certificates of the Secretary of Elan and any Transferring Subsidiary that
is expected to be a party to any Ancillary Agreement, dated the Closing Date, (i)&nbsp;as
to the incumbency and signatures of the officers or Representatives of Elan, New
Alkermes any New Alkermes Group Entity and any Continuing Affiliate executing this
Agreement or any Ancillary Agreement or certificate or other agreement to be
delivered pursuant to this Agreement or any Ancillary Agreement, together with
evidence of incumbency of such Secretary, and (ii)&nbsp;certifying attached resolutions
of the respective board of directors of Elan, New Alkermes, Holdco, Interco, U.S.
Holdco and Merger Sub and any Transferring Subsidiary that authorize the execution,
delivery and performance of this Agreement and the Ancillary Agreements, as the case
may be, which resolutions shall be in full force and effect at the Effective Time;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) resignations in Agreed Form, effective as of the Effective Time, of those
directors and officers of New Alkermes and the New Alkermes Group Entities as
Alkermes may request;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) a receipt acknowledging payment of the Cash Payment in full satisfaction
of Alkermes&#146; obligations under <U>Section&nbsp;2.2</U> (but subject to any further
obligations contained in this Agreement);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) a general release and discharge from Elan, on behalf of itself and the
Continuing Affiliates, executed and delivered to Alkermes, in form and substance
reasonably acceptable to Alkermes, releasing and discharging each of New Alkermes
and the New Alkermes Group Entities from any and all Liabilities to Elan or any
Continuing Affiliates in connection with or arising out of any act or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->27<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">omission of any of New Alkermes or any New Alkermes Group Entity or any of
their respective officers, directors, employees or agents, in such capacity, at or
prior to the Closing, except to the extent such Liabilities are expressly
contemplated to be retained by New Alkermes or any New Alkermes Group Entity
pursuant to this Agreement (including <U>Article&nbsp;IX</U>), including to the extent
such Liabilities are contemplated to be retained by or have been assumed by any of
New Alkermes or any New Alkermes Group Entity pursuant to any Reorganization
Transfer Agreement, or arise out of this Agreement or any of the Ancillary
Agreements;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) any written releases obtained by Elan pursuant to <U>Section&nbsp;5.6</U>;
and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv) such other documents, instruments and certificates as Alkermes may
reasonably request in connection with the transactions contemplated by this
Agreement or the Ancillary Agreements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.14. <U>Deliveries by Alkermes</U>. At the Closing, Alkermes shall deliver to Elan:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) the certificate required to be delivered by Alkermes pursuant to
<U>Section&nbsp;8.3(c)</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) the Cash Payment in U.S. dollars by wire transfer of immediately available
funds to an account designated in writing by Elan at least three (3)&nbsp;Business Days
prior to the Closing in accordance with <U>Schedule&nbsp;1</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) a duly executed counterpart of the Shareholder&#146;s Agreement executed by
Alkermes;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) counterparts to the IP Transfer Agreement and IP Transfer Loan Note,
effective as of immediately prior to the Closing, duly executed by Alkermes, unless
Alkermes shall have determined, in its sole discretion, that there has been a change
in Law that would materially increase the risk of having an adverse impact on
Alkermes or the benefits intended to be achieved by such agreements;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) counterparts to any other Ancillary Agreement to be entered into at the
Effective Time;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) certificates of the Secretary of Alkermes, dated the Closing Date, (i)&nbsp;as
to the incumbency and signatures of the officers or Representatives of Alkermes
executing this Agreement and any Ancillary Agreement, together with evidence of the
incumbency of such Secretary, and (ii)&nbsp;certifying attached resolutions of the board
of directors of Alkermes that authorize the execution, delivery and performance of
this Agreement and the Ancillary Agreements, which resolutions shall be in full
force and effect at the Effective Time;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->28<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) a general release and discharge from New Alkermes, on behalf of itself
and its Subsidiaries, executed and delivered to Elan, in form and substance
reasonably acceptable to Elan, releasing and discharging each of Elan and the
Continuing Affiliates from any and all Liabilities to New Alkermes or any of its
Subsidiaries in connection with or arising out of any act or omission of any of Elan
or any of its Subsidiaries or any of their respective officers, directors, employees
or agents, in such capacity, at or prior to the Closing, except to the extent such
Liabilities are expressly contemplated to be retained by Elan or any Continuing
Affiliate pursuant to this Agreement (including <U>Article&nbsp;IX</U>), and to the
extent such Liabilities are contemplated to be retained by or have been assumed by
any of Elan or any Continuing Affiliate pursuant to any Reorganization Transfer
Agreement, or arise out of this Agreement or any of the Ancillary Agreements; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) such other documents, instruments and certificates as Elan may
reasonably request in connection with the transactions contemplated by this
Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;2.15. <U>Closing Payments Adjustment</U>
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Not less than five (5)&nbsp;Business Days prior to the Closing Date, Elan shall deliver to
Alkermes a statement (the &#147;<U>Closing Payment Certificate</U>&#148;), certified as true and correct by
Elan&#146;s chief financial officer, setting forth in reasonable detail and accompanied by reasonably
detailed back-up documentation, as of the Effective Time, each of (i)&nbsp;the Modified Working Capital
(the &#147;<U>Estimated Modified Working Capital</U>&#148;), (ii)&nbsp;the Net Cash Amount (the &#147;<U>Estimated
Net Cash Amount</U>&#148;), and (iii)&nbsp;the calculation of the Closing Adjustment Amount (the
&#147;<U>Estimated Closing Adjustment Amount</U>&#148;). If the Estimated Closing Adjustment Amount is
positive, then the amount of the Cash Payment to be delivered at the Closing shall be increased by
the Estimated Closing Adjustment Amount. If the Estimated Closing Adjustment Amount is negative,
then the amount of the Cash Payment to be delivered at the Closing shall be reduced by the
Estimated Closing Adjustment Amount.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As soon as practicable, but in no event later than ninety (90)&nbsp;days following the Closing
Date, New Alkermes shall prepare a calculation, as of the Effective Time, of (i)&nbsp;the Modified
Working Capital (the &#147;<U>Closing Modified Working Capital</U>&#148;), (ii)&nbsp;the Net Cash Amount (the
&#147;<U>Closing Net Cash Amount</U>&#148;), and (iii)&nbsp;the calculation of the Closing Adjustment Amount (the
&#147;<U>Proposed Final Closing Adjustment Amount</U>&#148;). The Closing Modified Working Capital shall be
calculated in the same manner and based on the same items as the Modified Working Capital
Statement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;After receipt of the calculations of the Closing Modified Working Capital and Closing Net
Cash Amount, Elan shall have thirty (30)&nbsp;days to review such calculations together with the
workpapers used in the preparation thereof. Elan and its authorized Representatives shall have
access upon reasonable notice during normal business hours to all relevant books and records and
employees of New Alkermes and the New Alkermes Group Entities to the extent required to complete
their review of the calculations of Closing Modified Working Capital and Closing Net Cash Amount;
<U>provided</U>, that such access shall not
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->29<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">unreasonably disrupt the personnel and operations of New Alkermes or any of its Subsidiaries.
Unless Elan delivers written notice to New Alkermes on or prior to the thirtieth (30<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>)
day after Elan&#146;s receipt of the calculations of Closing Modified Working Capital and Closing Net
Cash Amount specifying in reasonable detail all disputed items and the basis therefor, Elan shall
be deemed to have accepted and agreed to such calculations. If Elan so notifies New Alkermes of
its objection to such calculations, New Alkermes and Elan shall, within thirty (30)&nbsp;days following
such notice (the &#147;<U>Resolution Period</U>&#148;), attempt to resolve their differences and any
resolution by them as to any disputed amounts shall be final, binding and conclusive.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;If, at the conclusion of the Resolution Period, amounts shall remain in dispute, then all
amounts remaining in dispute shall be submitted to Ernst &#038; Young LLP or another firm of
internationally recognized independent public accountants (the &#147;<U>Neutral Auditors</U>&#148;) selected
by Elan and New Alkermes within ten (10)&nbsp;days after the expiration of the Resolution Period. If
Elan and New Alkermes are unable to agree on the Neutral Auditors, then Elan and New Alkermes shall
each have the right to request the American Arbitration Association to appoint the Neutral Auditors
who shall not have had a material business relationship with Elan, New Alkermes or any of their
respective Affiliates within the past two (2)&nbsp;years. The Parties agree to execute, if requested by
the Neutral Auditors, a reasonable engagement letter. All fees and expenses relating to the work,
if any, to be performed by the Neutral Auditors shall be borne equally by Elan and New Alkermes.
The Neutral Auditors shall act as an arbitrator to determine only those issues still in dispute.
The Neutral Auditors&#146; determination shall be made within thirty (30)&nbsp;days of their selection, shall
be set forth in a written statement delivered to Elan and New Alkermes and shall be final, binding
and conclusive. The terms &#147;<U>Final Modified Working Capital</U>&#148;, &#147;<U>Final Net Cash
Amount</U>&#148; and &#147;<U>Final Closing Adjustment Amount</U>&#148; as used herein, shall mean the definitive
Modified Working Capital, Net Cash Amount and Closing Adjustment Amount, in each case, as of the
Effective Time, agreed or deemed to have been agreed to by Elan and New Alkermes in accordance with
<U>Section&nbsp;2.15(c)</U> or resulting from the determinations made by the Neutral Auditors in
accordance with this <U>Section&nbsp;2.15(d)</U> (in addition to those items theretofore agreed to by
Elan and New Alkermes).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;The Closing Payments shall be increased dollar for dollar by the amount, if any, by which
the Final Closing Adjustment Amount exceeds the Estimated Closing Adjustment Amount or reduced
dollar for dollar by the amount, if any, by which the Estimated Closing Adjustment Amount exceeds
the Final Closing Adjustment Amount. For the avoidance of doubt, in the event that the Final
Closing Adjustment Amount is not greater or less than the Estimated Closing Adjustment Amount, no
adjustment to the Closing Payments shall be made pursuant to this <U>Section&nbsp;2.15</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Any reduction in the Closing Payments made pursuant to <U>Section&nbsp;2.15(e)</U> shall be
paid by Elan, within five (5)&nbsp;Business Days after the Final Closing Adjustment Amount is agreed
upon or deemed to have been agreed upon by New Alkermes and Elan or the written statement of the
Neutral Auditors setting forth their determination regarding any remaining disputed items is
delivered to New Alkermes and Elan (such fifth (5<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>) Business Day, the &#147;<U>Adjustment
Payment Date</U>&#148;), by delivery to New Alkermes of the amount of such reduction (which shall bear
interest from (and including) the Closing Date through (and including) the date of payment at the
publicly announced prime interest rate of Citibank, N.A. in effect from time to
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->30<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">time for unsecured short-term commercial loans) in cash in U.S. dollars. The amount of any
such reduction shall be distributed or contributed to the New Alkermes Group Entities by New
Alkermes as necessary or appropriate to reflect the adjustments that resulted in such payment. Any
increase in the Closing Payments made pursuant to <U>Section&nbsp;2.15(e)</U> shall be paid by New
Alkermes by delivery to Elan on the Adjustment Payment Date of the amount of the increase (which
shall bear interest from (and including) the Closing Date through (and including) the date of
payment at the publicly announced prime interest rate of Citibank, N.A. in effect from time to time
for unsecured short-term commercial loans) in cash in U.S. dollars. The amount of any such
increase shall be allocated or charged to the New Alkermes Group Entities by New Alkermes as
necessary or appropriate to reflect the adjustments that resulted in such payment.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE III</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Representations and Warranties of Elan</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in the corresponding sections or subsections of the disclosure schedule
delivered to Alkermes by Elan on or prior to the date hereof (the &#147;<U>Elan Disclosure
Schedule</U>&#148;), Elan hereby makes to Alkermes, as of the date hereof and as of the Closing, each of
the representations and warranties contained in this <U>Article&nbsp;III</U>; it being understood that
disclosure of any item in any section or subsection of the Elan Disclosure Schedule shall also be
deemed disclosure with respect to any other section or subsection to which the relevance of such
item is readily apparent on its face.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.1. <U>Incorporation; Authorization</U>. (a)&nbsp;Each Elan Party and each New Alkermes
Group Entity is duly organized and validly existing and, to the extent applicable, in good standing
under the Laws of the jurisdiction of its organization. Each of New Alkermes and the New Alkermes
Group Entities (i)&nbsp;has the requisite corporate or similar power and authority to own its properties
and assets and to carry on its business as it is now being conducted and (ii)&nbsp;is duly qualified to
transact business in each jurisdiction in which the nature of property owned or leased by it or the
conduct of its business requires it to be so qualified, except where the failure to be so duly
qualified to transact business, or to have such power and authority, would not, individually or in
the aggregate, have or reasonably be expected to have a Business Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Elan Party has the requisite corporate or similar power to execute and deliver this
Agreement and the Ancillary Agreements to which it will be a party and to perform its obligations
hereunder and thereunder and to consummate the transactions contemplated hereby and thereby. The
execution and delivery by each Elan Party of this Agreement and the Ancillary Agreements to which
it will be a party, the performance by each Elan Party of its obligations hereunder and thereunder
and the consummation by each Elan Party of the transactions contemplated hereby and thereby
(including the issuance of shares as of the Effective Time as contemplated by <U>Section
2.9(c)</U>) have been duly and validly authorized by the respective boards of directors of each
Elan Party and, except for the filing of the Articles of Merger with the Department of State of the
Commonwealth of Pennsylvania, no other corporate proceedings on the part of the Elan Parties, their
respective boards of directors or shareholders are necessary therefor.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->31<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The execution, delivery and performance of this Agreement and the Ancillary Agreements
will not (i)&nbsp;violate any provision of any Governing Documents of any Elan Party or any New Alkermes
Group Entity, (ii)&nbsp;violate any provision of, or be an event that is (or with the passage of time
will result in) a violation of, or result in the acceleration of or entitle any party to accelerate
or exercise (whether after the giving of notice or lapse of time or both) any obligation or right
under, or result in the imposition of any Lien upon or the creation of a security interest in any
of the Purchased Interests, or any of New Alkermes&#146; or any New Alkermes Group Entity&#146;s assets or
properties pursuant to, any Lien, agreement, instrument, order, arbitration award, judgment or
decree to which any Elan Party or any New Alkermes Group Entity is a party or by which any of them
is bound, or (iii)&nbsp;violate or conflict with any Law or other restriction of any kind or character
to which any Elan Party, any Continuing Affiliate or any New Alkermes Group Entity is subject,
that, in the case of clauses <U>(ii)</U> or <U>(iii)</U> would, individually or in the aggregate,
have or reasonably be expected to have a Business Material Adverse Effect. This Agreement has been
duly executed and delivered by the Elan Parties, and, assuming the due execution hereof by
Alkermes, this Agreement constitutes the legal, valid and binding obligations of the Elan Parties,
enforceable against the Elan Parties in accordance with its terms, subject to the effect of
bankruptcy, insolvency, reorganization, liquidation, dissolution, moratorium or other similar Laws
relating to or affecting the rights of creditors generally and to the effect of the application of
general principles of equity (regardless of whether considered in proceedings at law or in equity).
At the Closing, each of the Ancillary Agreements to which any Elan Entity is or will be a party
will be duly executed and delivered by such Elan Entity and, assuming the due execution and
delivery thereof by the other parties thereto, at the Closing will constitute the legal, valid and
binding obligations of such Elan Entity, enforceable against the Elan Entities in accordance with
its terms, subject to the effect of bankruptcy, insolvency, reorganization, liquidation,
dissolution, moratorium or other similar Laws relating to or affecting the rights of creditors
generally and to the effect of the application of general principles of equity (regardless of
whether considered in proceedings at law or in equity). Elan has delivered to Alkermes a true and
correct copy of the Governing Documents in effect at the date hereof of each of New Alkermes and
each New Alkermes Group Entity.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Each Elan Entity that will be a party to any Reorganization Transfer Agreement will have
the requisite corporate or similar power to execute and deliver such Reorganization Transfer
Agreement and to perform its obligations thereunder and to consummate the transactions contemplated
thereby when such Reorganization Transfer Agreement is executed and delivered. No later than the
Closing, each of the Reorganization Transfer Agreements to which any Elan Entity will be a party
will be duly executed and delivered by such Elan Entity and, assuming the due execution and
delivery thereof by the other parties thereto, at the Closing will constitute the legal, valid and
binding obligations of such Elan Entity, enforceable against such Elan Entity in accordance with
its terms, subject to the effect of bankruptcy, insolvency, reorganization, liquidation,
dissolution, moratorium or other similar Laws relating to or affecting the rights of creditors
generally and to the effect of the application of general principles of equity (regardless of
whether considered in proceedings at law or in equity).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.2. <U>Capitalization; Structure</U>. (a) (i)&nbsp;The authorized capital stock of New
Alkermes consists of 450,000,000 New Alkermes Ordinary Shares and 50,000,000 preference shares, of
which 1 New Alkermes Ordinary Share is outstanding, is owned by
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->32<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Goodbody Subscriber One Limited and, as of the Closing, there will be 31,900,000 New Alkermes
Ordinary Shares outstanding, all of which will be owned by the Elan Shareholder free and clear of
all Liens except as provided in this Agreement. (ii)&nbsp;The authorized capital stock of Holdco
consists of 1,000,000 Holdco Ordinary Shares, of which 100 Holdco Ordinary Shares are outstanding,
all of which are owned by EPIL and, as of the Closing, all of which will be owned by New Alkermes
free and clear of all Liens except as provided in this Agreement. (iii)&nbsp;The authorized capital
stock of Interco consists of 200,000,000 Interco Ordinary Shares, of which 200 Interco Ordinary
Shares are outstanding, 100 of which are owned by Goodbody Subscriber One Limited and 100 of which
are owned by Goodbody Subscriber Two Limited and, as of Closing, all of which will be owned by
Holdco free and clear of all Liens except as provided in this Agreement. (iv)&nbsp;The authorized
capital stock of U.S. Holdco consists of 100 shares of U.S. Holdco Common Stock, of which 100
shares of U.S. Holdco Common Stock are outstanding, all of which are owned by Interco free and
clear of all Liens except as provided in this Agreement. (v)&nbsp;The authorized capital stock of
Merger Sub consists of 100 shares of Merger Sub Common Stock, of which 99 shares of Merger Sub
Common Stock are outstanding, all of which are owned by U.S. Holdco free and clear of all Liens
except as provided in this Agreement. (vi)&nbsp;All of the aforesaid New Alkermes Ordinary Shares, the
Holdco Ordinary Shares, the Interco Ordinary Shares, the shares of U.S. Holdco Common Stock and the
shares of Merger Sub Common Stock are or will be validly issued, fully paid and nonassessable, and
free of preemptive rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Section&nbsp;3.2(b)</U> of the Elan Disclosure Schedule sets forth a complete and accurate
list of the name of each New Alkermes Group Entity that is not an Elan Party, its jurisdiction of
incorporation or organization, the number of outstanding shares of its capital stock or other
equity interests of each class and the name and number of shares owned by each holder of any such
shares of capital stock or other equity interests. Except as set forth in <U>Section&nbsp;3.2(b)</U>
of the Elan Disclosure Schedule, all of the outstanding shares of capital stock or other equity
interests of such New Alkermes Group Entities have been validly issued, and are fully paid and
nonassessable, are free of preemptive rights, and are owned directly by Elan, the New Alkermes
Group Entities and the Transferring Subsidiaries as set forth on <U>Section&nbsp;3.2(b)</U> of the Elan
Disclosure Schedule, free and clear of all Liens. At the Closing, upon consummation of the
Transactions, Elan will deliver to Alkermes good and valid title to all of the Purchased Interests.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Except as expressly provided by this Agreement, there are no outstanding options, warrants
or other rights of any kind to acquire, or obligations to issue, shares of capital stock of any
class of, or other equity interests in, New Alkermes or any New Alkermes Group Entity. None of New
Alkermes or the New Alkermes Group Entities owns any equity interest, directly or indirectly, in
any Person other than New Alkermes or a New Alkermes Group Entity. There are no outstanding
obligations of any New Alkermes Group Entity (i)&nbsp;to repurchase, redeem or otherwise acquire any
shares of capital stock or other equity interests in any New Alkermes Group Entity or (ii)&nbsp;to grant
preemptive or anti-dilutive rights with respect to any such shares or interests.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;All of the New Alkermes Ordinary Shares, when issued in the Merger pursuant to this
Agreement and delivered pursuant hereto will, at such times, be duly authorized, validly issued,
fully paid and non-assessable and free of preemptive rights. All of the shares issued by the New
Alkermes Group Entities as of the Effective Time pursuant to <U>Section&nbsp;2.9(c)</U>,
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->33<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">when issued will be duly authorized, validly issued, fully paid and nonassessable, and free
and clear of preemptive rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;None of Elan, any of its Subsidiaries or, to the Knowledge of Elan, any of its Affiliates
Beneficially Owns any shares of Alkermes Common Stock.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.3. <U>No Consents</U>. <U>Section&nbsp;3.3</U> of the Elan Disclosure Schedule
contains a list of all registrations, filings, applications, notices, consents, approvals, orders,
qualifications and waivers required to be made, filed, given or obtained by any of Elan or its
Subsidiaries with, to or from any Persons or Governmental Authorities in connection with the
consummation of this Agreement (including the Merger), the Reorganization Transfer Agreements or
the Ancillary Agreements or the other transactions contemplated hereby or thereby, except for those
with respect to which the failure to make, file, give or obtain would not, individually or in the
aggregate, have or reasonably be expected to have a Business Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.4. <U>Financial Statements</U>. (a) <U>Section&nbsp;3.4(a)</U> of the Elan Disclosure
Schedule sets forth true and complete copies of the audited consolidated statements of income,
balance sheets and statements of cash flows of the Business as of and for the twelve months ended
December&nbsp;31, 2009, and December&nbsp;31, 2008, and the unaudited consolidated statement of income,
balance sheet and statement of cash flows of the Business as of and for the twelve months ended
December&nbsp;31, 2010, in each case including any notes thereto (collectively, the &#147;<U>Historical
Financial Statements</U>&#148;). The Historical Financial Statements, present fairly in all material
respects the consolidated financial position and results of operations and cash flows of the
Business for the respective periods or as of the respective dates set forth therein, in each case
in accordance with IFRS applied on a consistent basis throughout the periods involved (except, in
the case of unaudited statements, as otherwise indicated therein and except for changes resulting
from normal and recurring year-end adjustments that are not, in the aggregate, material in nature
or amount to the Business, taken as a whole), subject to the Agreed Adjustments. The Historical
Financial Statements have been prepared from and in all material respects in accordance with the
books and records of the Elan Parties, the Continuing Affiliates, the New Alkermes Group Entities
and the Business. The balance sheet as of December&nbsp;31, 2010 (the &#147;<U>Balance Sheet Date</U>&#148;)
included in the Historical Financial Statements is referred to herein as the &#147;<U>Business Balance
Sheet</U>.&#148;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Audited Financial Statements and any other financial statements (including, in each
case, any notes thereto), when delivered to Alkermes pursuant to <U>Section&nbsp;5.20</U> and
<U>Section&nbsp;5.21</U> as of the Closing Date, (i)&nbsp;will present fairly in all material respects the
combined financial position and results of operations and cash flows of the Business for the
respective periods or as of the respective dates set forth therein, in each case in accordance with
U.S. GAAP applied on a consistent basis throughout the periods involved (except, in the case of
interim periods, for changes resulting from normal and recurring year-end adjustments that are not,
in the aggregate, material in nature or amount to the Business, taken as a whole), subject only to
Agreed Adjustments, and (ii)&nbsp;will have been prepared from and in all material respects in
accordance with the books and records of the Elan Parties, the Continuing Affiliates, the New
Alkermes Group Entities and the Business.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->34<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Target Working Capital amount is equal to the arithmetic average of the Modified
Working Capital as of and for the month end reporting date of each month in the twelve-month period
ending on March&nbsp;31, 2011.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.5. <U>No Undisclosed Liabilities</U>. Except for Liabilities (i)&nbsp;which are
reflected or reserved against in the Business Balance Sheet, (ii)&nbsp;set forth in <U>Section&nbsp;3.5</U>
of the Elan Disclosure Schedule or (iii)&nbsp;incurred in the Ordinary Course of Business since the
Balance Sheet Date that, individually or in the aggregate, have not had and would not reasonably be
expected to have a Business Material Adverse Effect, (a)&nbsp;the Business has no Liabilities that would
be required to be reflected on a balance sheet prepared in accordance with IFRS or U.S. GAAP and
(b)&nbsp;to the Knowledge of Elan, the Business has no Liabilities whether or not required by IFRS or
U.S. GAAP to be reflected or reserved against on the Business Balance Sheet.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.6. <U>Properties; Sufficiency</U>. (a)&nbsp;With the exception of (i)&nbsp;properties
disposed of since the Balance Sheet Date in the Ordinary Course of Business and (ii)&nbsp;the Excluded
Assets, Elan and its Subsidiaries, taken together, has, and as of the Closing, New Alkermes and the
New Alkermes Group Entities, taken together, will have, good and marketable title to, or a valid
and existing lease or license, free and clear of all Liens other than Permitted Liens, each piece
of real and personal property capitalized on or included in the Business Balance Sheet (or for real
and personal property acquired by the Business since the date of the Business Balance Sheet, that
would have been, had it been acquired prior to such date, capitalized on or included in the
Business Balance Sheet) and each other piece of real and personal property used or held for use in
the Business, except where the failure to have such title or hold such lease or license would not,
individually or in the aggregate, have or reasonably be expected to have a Business Material
Adverse Effect. Each piece of real property used or held for use by the Business enjoys access and
egress over roads abutting such properties which have been taken in charge by the relevant
Governmental Authority. Elan has complied with its obligations in every such lease or license,
except where the failure to comply would not, individually or in the aggregate, have or reasonably
be expected to have a Business Material Adverse Effect. All documents necessary to prove such
title are in the possession or under the control of Elan (and, as of the Closing, will be in the
possession or under the control of New Alkermes or a New Alkermes Group Entity) or, where
appropriate, the Irish Land Registry, and are properly stamped.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Section&nbsp;3.6(b)(i)</U> of the Elan Disclosure Schedule sets forth a list of all the
real property owned or leased by Elan or any of its Subsidiaries in connection with the Business
(the &#147;<U>Business Real Property</U>&#148;). Elan has made available correct and complete copies of all
material leases and subleases (including all material amendments, modifications and side letters
thereto, and all notices of default and other material notices thereunder) relating to the Business
Real Property to which New Alkermes or any New Alkermes Group Entity is a party, all of which are
identified in <U>Section&nbsp;3.6(b)</U> of the Elan Disclosure Schedule and each of which is valid and
in full force and effect. There are no pending or, to the Knowledge of Elan, threatened
condemnation proceedings relating to any Business Real Property. Except as set forth on
<U>Section&nbsp;3.6(b)(ii)</U> of the Elan Disclosure Schedule, the construction, ownership, occupancy,
use and operation of the Business Real Property has complied and complies in all material respects
with all applicable planning, zoning or use Laws, including the Irish Planning Acts 2000-2010 or
comparable legislation, and there are no material defaults by Elan or any of its Subsidiaries in
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->35<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">respect of the Business Real Property in complying with the requirements of any notice
received from a Governmental Authority under any such Laws. Except as disclosed in <U>Section
3.6(b)(iii)</U> of the Elan Disclosure Schedule, none of the properties owned or leased by New
Alkermes or any New Alkermes Group Entity or otherwise used in the Business is shared by the
Business, on the one hand, and the other businesses, divisions or Subsidiaries of Elan or any
Continuing Affiliate, on the other hand.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The buildings, structures and improvements on each Business Real Property are in all
material respects in reasonable operating condition and repair, are structurally sound and free of
material defects, with no material alterations or repairs required under applicable Law and are
suitable in all material respects for their current use, operation and occupancy.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Following the Reorganization immediately prior to the Closing, the Business Assets will
constitute all of the assets (other than (i)&nbsp;the Excluded Assets and (ii)&nbsp;services to be provided
pursuant to the Transition Services Agreement) necessary to own and operate the Business in the
manner being conducted as of the date hereof. Elan and its Subsidiaries collectively own or lease,
or otherwise have good and valid rights to, and following the Reorganization and through the
Closing, New Alkermes and the New Alkermes Group Entities collectively will own or lease, or
otherwise have good and valid rights to, all Business Assets, except for the Excluded Assets and as
would not, individually or in the aggregate, have or reasonably be expected to have a Business
Material Adverse Effect. Following the Reorganization and immediately prior to the Effective Time,
New Alkermes and the New Alkermes Group Entities collectively shall not own or hold any Excluded
Assets, and shall not own or hold any assets, or be subject to any Liabilities, not related to the
Business, other than the Additional Assets and the Intellectual Property Rights transferred to a
New Alkermes Group Entity by Alkermes pursuant to the IP Transfer Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.7. <U>Absence of Certain Changes</U>. Since the Balance Sheet Date, there has been
no (a)&nbsp;change or development in or effect on the Business that has had, or would reasonably be
expected to have, a Business Material Adverse Effect, (b)&nbsp;other than in connection with the
Transactions, action or omission by any Elan Party, Continuing Affiliate or New Alkermes Group
Entity that was not in the Ordinary Course of Business or (c)&nbsp;action or omission that, if taken
from the date hereof through the Closing, would violate any of the provisions of <U>Section
5.4(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.8. <U>Litigation; Orders</U>. There are no Actions pending or, to the Knowledge of
Elan, threatened against the Business, New Alkermes or any New Alkermes Group Entity, or against
Elan or any Continuing Affiliate in respect of the Business that would, individually or in the
aggregate, have or reasonably be expected to have a Business Material Adverse Effect. There are no
judgments or outstanding orders, injunctions, decrees, stipulations or awards (whether rendered by
a court or administrative agency, or by arbitration) against or applicable to the Business, the
Business Assets, New Alkermes or any New Alkermes Group Entity or to Elan or any Continuing
Affiliate in respect of the Business, that would, individually or in the aggregate, have or
reasonably be expected to have a Business Material Adverse Effect.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->36<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.9. <U>Intellectual Property</U>. Elan and its Subsidiaries owns or has a valid
license to, and as of the Closing, New Alkermes or a New Alkermes Group Entity will own or have a
valid license to, or, in each case, has or will have the right to use, all Business Intellectual
Property Rights used in the conduct of the Business. No Business Intellectual Property Right is
subject to any outstanding judgment, injunction, order, decree or agreement restricting the use
thereof by Elan or its Subsidiaries, or will restrict the use thereof by New Alkermes, the New
Alkermes Group Entities, any other Subsidiary of New Alkermes or the Business following the
Closing, or restricts or would restrict following the Closing the licensing thereof by New
Alkermes, the New Alkermes Group Entities, any other Subsidiary of New Alkermes or the Business to
any Person. After the Closing, no Business Intellectual Property will be owned by EDDI. None of
Elan or its Subsidiaries, in respect of the Business, is infringing on any other Person&#146;s
Intellectual Property Rights and, to the Knowledge of Elan, no Person is infringing on any Business
Intellectual Property Rights, except, in either case, as would not, individually or in the
aggregate, have or reasonably be expected to have a Business Material Adverse Effect. Except for
such matters as would not have or reasonably be expected to have a Business Material Adverse
Effect: (i)&nbsp;none of Elan or any of its Subsidiaries is a defendant in any action, suit,
investigation or proceeding relating to, or otherwise has been notified of, any alleged claim of
infringement of any Intellectual Property Right in respect of the Business and (ii)&nbsp;none of Elan or
its Subsidiaries has any outstanding claim or suit for any continuing infringement by any other
Person of any Business Intellectual Property Rights. <U>Section&nbsp;3.9</U> of the Elan Disclosure
Schedule sets forth a list of all United States and non-U.S. patents and patent applications,
trademark registrations and applications therefor, registered copyrights and applications therefor
and trade names of Elan and its Subsidiaries that relate to the Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.10. <U>Licenses; Authorizations; Reports.</U> <U>Section&nbsp;3.10</U> of the Elan
Disclosure Schedule contains a complete and accurate list of all material governmental licenses,
consents, qualifications, registrations, clearances, permits, franchises, variances, exemptions and
other authorizations issued, granted, given or otherwise made available by or under the authority
of, or any required notification to, any Governmental Authority or pursuant to any Law
(&#147;<U>Licenses</U>&#148;) necessary for the conduct of the Business as conducted on the date hereof and
as of immediately following the Closing, including (i)&nbsp;all authorizations under the Federal Food,
Drug and Cosmetic Act of 1938 (the &#147;<U>FDCA</U>&#148;), the Public Health Service Act of 1944 (the
&#147;<U>PHSA</U>&#148;) and the regulations of the United States Food and Drug Administration (the
&#147;<U>FDA</U>&#148;) promulgated under any of the foregoing or any Similar Law or authorization of any
other Governmental Authority, (ii)&nbsp;all authorizations held under the Irish Medicinal Products
(Control of Manufacture) Regulations 2007 or the Irish Medicinal Products (Control of Placing on
the Market) Regulations 2007 and the regulations of the Irish Medicines Board (&#147;<U>IMB</U>&#148;),
(iii)&nbsp;all such authorizations by any other Governmental Authority that is concerned with the
quality, identity, strength, purity, safety, efficacy, marketing, developing or manufacturing of
the Products necessary for the lawful operating of the Business as conducted on the date hereof and
as of the Closing and (iv)&nbsp;all Environmental Licenses. Each such License (i)&nbsp;will be issued to or
be in the name of New Alkermes or a New Alkermes Group Entity as of the Closing and is, or will be
at the Closing, in full force and effect, except for those whose failure to be in full force and
effect would not, individually or in the aggregate, have or reasonably be expected to have a
Business Material Adverse Effect, and (ii)&nbsp;is not subject to any pending or, to the Knowledge of
Elan, threatened Action for the purposes of revoking, limiting or amending such License, except for
any revocation, amendment or limitation that would not, individually or in the aggregate,
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->37<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">have or reasonably be expected to have a Business Material Adverse Effect. As of the date
hereof, none of Elan or any of its Subsidiaries has received written notice or, to the Knowledge of
Elan, any other notice from any Governmental Authority that (A)&nbsp;any such existing License will be
revoked or (B)&nbsp;any pending application for any such new License or renewal of any existing License
will be denied, except as would not, individually or in the aggregate, have or reasonably be
expected to have a Business Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.11. <U>Labor Matters</U>. (a)&nbsp;With respect to employees of the Business in
Ireland, <U>Section&nbsp;3.11</U> of the Elan Disclosure Schedule sets forth a list of all agreements
with labor unions or associations representing, purporting to represent or attempting to represent
any employees of the Business. Except as set forth in <U>Section&nbsp;3.11</U> of the Elan Disclosure
Schedule, none of Elan or its Subsidiaries is involved in or, to the Knowledge of Elan, threatened
with any work stoppage or material labor dispute, arbitration, lawsuit or administrative proceeding
relating to labor matters involving the employees of the Business in Ireland.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;With respect to U.S. employees of the Business, Elan and their Subsidiaries are not bound
by any agreements with labor unions or associations representing employees, purporting to represent
or attempting to represent any U.S. employees of the Business. None of Elan or its Subsidiaries is
involved in or, to the Knowledge of Elan, threatened with any work stoppage or material labor
dispute, arbitration, lawsuit or administrative proceeding relating to labor matters involving the
U.S. employees of New Alkermes or the New Alkermes Group Entities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.12. <U>Compliance with Laws</U>. (a)&nbsp;Except as has not and would not reasonably
be expected to have, individually or in the aggregate, a Business Material Adverse Effect, since
January&nbsp;1, 2008, Elan and its Subsidiaries have operated the Business in compliance with all Laws
applicable thereto. Since January&nbsp;1, 2008, none of Elan or any of its Subsidiaries has received
any written or, to the Knowledge of Elan, any other communication from a Governmental Authority
that (i)&nbsp;alleges that the Business or such Person (in respect of the Business) is in material
violation of any applicable Law, including Import/Export Control Laws, (ii)&nbsp;any investigation or
review by any Governmental Authority with respect to the Business or such Person is pending or
contemplated and, to the Knowledge of Elan, no such investigation or review is threatened.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Since January&nbsp;1, 2008, all imports, exports, reexports/retransfers, &#147;deemed exports&#148; and
&#147;deemed reexports/retransfers&#148; of the Business have been made in all material respects in
accordance with all statutory and regulatory requirements under the Export Administration
Regulations and associated executive orders, and the Laws implemented by the Office of Foreign
Assets Controls, the United States Department of the Treasury and any other applicable import,
export control and sanctions Laws (collectively, and any successors or replacements thereof, the
&#147;<U>Import/Export Control Laws</U>&#148;).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Since January&nbsp;1, 2008, all applications, submissions, information and data utilized by
Elan or any of its Affiliates in respect of the Business as the basis for, or submitted by or, to
the Knowledge of Elan, on behalf of Elan or its Affiliates in connection with, any and all requests
for a License relating to the Business or any Products, when submitted to the FDA or other
Governmental Authority, were true and correct in all material respects as of the date of
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->38<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">submission, and any updates, changes, corrections or modification to such applications,
submissions, information and data required under applicable Laws have been submitted to the FDA or
other Governmental Authority.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Since January&nbsp;1, 2008:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) New Alkermes, the New Alkermes Group Entities and the Business and, solely
in respect of the Business, the Elan Parties and the Continuing Affiliates, have
been in compliance, in all material respects, with all legal requirements under (A)
the FCPA, (B)&nbsp;the Irish Prevention of Corruption Acts, 1889 to 2010 and the Irish
Ethics in Public Office Acts, 1995 to 2001, (C)&nbsp;the Organisation for Economic
Co-operation and Development Convention on Combating Bribery of Foreign Officials in
International Business Transactions and legislation implementing such convention,
and (D)&nbsp;all other international anti-bribery conventions and bribery Laws applicable
to the Business (collectively, the &#147;<U>Anti-Bribery Laws</U>&#148;);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) none of Elan or its Subsidiaries, or to the Knowledge of Elan, any of
their Representatives have, in relationship to the Business, taken any act in
furtherance of an offer, payment, promise to pay, authorization, or ratification of
the payment, directly or indirectly, of any gift, money or anything of value to a
Government Official to secure any improper advantage (e.g., to obtain a tax rate
lower than allowed by Law) or to obtain or retain business for any Person;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) none of Elan or its Subsidiaries, has received written or, to the
Knowledge of Elan, any other notice, and, to the Knowledge of Elan, none of their
Representatives has received any notice, of (A)&nbsp;any investigation of or request for
information from Elan, its Subsidiaries or any of their Representatives or relating
to the Business by law enforcement officials regarding the Anti-Bribery Laws, or (B)
any other allegation, investigation or inquiry regarding any of their or the
Business&#146; actual or possible violation of the Anti-Bribery Laws.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;None of the remedial measures required by the Corporate Integrity Agreement or any similar
agreement with any Governmental Authority affecting Elan or its Affiliates pertain to or create any
obligation for New Alkermes, the New Alkermes Group Entities or the Business, and the Corporate
Integrity Agreement shall not be applicable to New Alkermes or its Subsidiaries or to the Business
in any way following the Closing. None of the allegations set forth in the Corporate Integrity
Agreement relate to any activity of New Alkermes, the New Alkermes Group Entities or the Business.
There is no agreement or arrangement by Elan or any of its Affiliates with any Governmental
Authority, including any state entity or authority, similar to the Corporate Integrity Agreement
that is (or, following the Closing, will be) applicable to New Alkermes (or any of its
Subsidiaries), the New Alkermes Group Entities or the Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;The Elan Parties, the Continuing Affiliates and the New Alkermes Group Entities have
established and implemented reasonable internal controls and procedures, in respect of the
Business, intended to ensure compliance with the Anti-Bribery Laws in respect of
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->39<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Business, including anticorruption compliance policies that (i)&nbsp;require compliance with
the Anti-Bribery Laws and otherwise prohibits bribes or other unlawful payments to Government
Officials; (ii)&nbsp;restrict gifts, entertainment, and promotional and marketing expenses for
Government Officials; (iii)&nbsp;require diligence on, anticorruption contract language in agreements
with, and ongoing monitoring of third parties that may have relations with Government Officials on
behalf of New Alkermes, the New Alkermes Group Entities or the Business; (iv)&nbsp;restrict political
and charitable contributions; (v)&nbsp;mandate possible discipline for violations of the policy or
policies; (vi)&nbsp;require periodic certification by senior executives and relevant sales, financial
and accounting officials indicating awareness of and compliance with the policy or policies; (vii)
require distribution of the policy or policies to all employees; (viii)&nbsp;require periodic training
for relevant employees regarding the policy or policies; (ix)&nbsp;identify a senior executive or
executives responsible for implementation and monitoring of the policy or policies and (x)&nbsp;include
procedures for reporting and investigating possible violations of the policy or policies.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;The New Alkermes Group Entities and, in relation to the Business, the Elan Parties and the
Continuing Affiliates have maintained their books and records in a manner that, in reasonable
detail, accurately and fairly reflects the transactions and disposition of their assets, and
maintain a system of internal accounting controls sufficient to provide reasonable assurances that:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) transactions are executed and access to assets is given only in accordance
with management&#146;s authorization;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) transactions are recorded as necessary to permit preparation of periodic
financial statements and to maintain accountability of corporate assets; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) recorded assets are compared with existing assets at reasonable intervals
and appropriate action is taken with respect to any differences between recorded and
actual assets.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;No director or officer of any of the Elan Parties, the Continuing Affiliates or the New
Alkermes Group Entities has, directly or indirectly, made false or misleading statements in respect
of the Business to, or attempted to coerce or fraudulently influence, an accountant in connection
with any audit, review, or examination of the financial statements of the Business, New Alkermes or
any of the New Alkermes Group Entities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Neither Elan nor any of its Affiliates is in receipt of any payment, guarantee, financial
assistance or other aid from a Governmental Authority in respect of the Business that was not, but
should have been, notified to the European Commission under Article&nbsp;108 of the Treaty on the
Functioning of the European Union for decision declaring such aid to be compatible with the common
market, or which has been found to be incompatible with the common market.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.13. <U>Insurance</U>. Each of New Alkermes and the New Alkermes Group Entities is,
and all of the Business Assets are, covered by valid and currently effective insurance policies
issued for the benefit of New Alkermes and the New Alkermes Group Entities that are
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->40<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">customary for companies of similar size to the Business, taken as a whole, in the industry and
locale in which the Business operates.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.14. <U>Material Contracts</U>. <U>Section&nbsp;3.14</U> of the Elan Disclosure
Schedule sets forth all of the following contracts to which New Alkermes or any New Alkermes Group
Entity is a party or bound, in respect of which New Alkermes or any New Alkermes Group Entity may
have a Liability, or by which any of the assets or properties of any of them or of the Business is
bound (a)&nbsp;any employment or consulting agreement with an individual requiring payments of base
compensation in excess of $150,000 per year; (b)&nbsp;customer sale and purchase agreements with
indicated or estimated future payment obligations in excess of $500,000 in any 12-month period or
$2,000,000 in the aggregate; (c)&nbsp;drug delivery agreements or contract manufacturing agreements; (d)
any joint venture, partnership, technical assistance, research and development and other similar
collaborative agreements; (e)&nbsp;any contract which prohibits assignment by Elan or any of its
Subsidiaries or is terminable by the other party or parties thereto upon a change of control of New
Alkermes or any of the New Alkermes Group Entities, other than such contracts the inability to
assign or termination of which would not, individually or in the aggregate, have or reasonably be
expected to have a Business Material Adverse Effect; (f)&nbsp;any contract or agreement that materially
limits or purports to materially limit the ability of New Alkermes or any of the New Alkermes Group
Entities or any Affiliates of any of them to compete in any line of business or in any geographic
area following the Closing; (g)&nbsp;any contract or agreement between or among one or more of New
Alkermes or the New Alkermes Group Entities, on the one hand, and Elan or any Continuing Affiliate
or any officer or director of any of New Alkermes or the New Alkermes Group Entities, on the other
hand, each an &#147;<U>Affiliate Agreement</U>&#148;; (h)&nbsp;any contract, agreement or arrangement, entered
into other than in the Ordinary Course of Business, with indicated or estimated future payment
obligations in excess of $500,000 in any 12-month period or $2,000,000 in the aggregate; (i)&nbsp;any
service and supply agreements with indicated or estimated future payment obligations in excess of
$500,000 in any 12-month period or $2,000,000 in the aggregate; (j)&nbsp;any licensing agreements
(either as licensor or licensee); (k)&nbsp;any distributor, franchise, commission or agency and sales
representative agreements; (l)&nbsp;any derivative agreements; (m)&nbsp;any contracts of a loss-making
nature; (n)&nbsp;any contracts which cannot readily be fulfilled or performed on time without undue, or
unusual expenditure of money or effort by any of the Elan Parties, the Continuing Affiliates or the
New Alkermes Group Entities; (o)&nbsp;any agreements which are in the process of being negotiated or
modified (including term sheets in respect thereof) involving Business Intellectual Property Rights
or with indicated or estimated future payment obligations in excess of $500,000 in any 12-month
period or $2,000,000 in the aggregate and (p)&nbsp;any material amendments, modifications, extensions or
renewals of any of the foregoing or any exercise of any option in respect of any of the foregoing.
The contracts required to be so listed are referred to herein as &#147;<U>Business Material
Contracts</U>.&#148; With respect to all Business Material Contracts, (i)&nbsp;none of the Elan Parties, any
Continuing Affiliate or any New Alkermes Group Entity, nor, to the Knowledge of Elan, any other
party to any such Business Material Contract is in breach thereof or default thereunder, and (ii)
there does not exist under any provision thereof, any event that, with the giving of notice or the
lapse of time or both, would constitute such a breach or default, except for such breaches,
defaults and events which in the case of clauses <U>(i)</U> and <U>(ii)</U> would not,
individually or in the aggregate, have or reasonably be expected to have a Business Material
Adverse Effect. Elan has provided to Alkermes true, correct and complete copies of all Business
Material Contracts; <U>provided</U>, that, if, in the opinion of counsel to Elan, the provision of
a
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->41<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">contract pursuant to clause <U>(o)</U> would violate applicable antitrust Laws, then such
contract shall instead have been provided to (and solely for review by) outside counsel to
Alkermes. <U>Section&nbsp;3.14(2)</U> of the Elan Disclosure Schedule lists, as of the date hereof,
each note, mortgage, indenture and other obligation and agreement and other instrument for or
relating to any lending or borrowing (including assumed or guaranteed debt) effected by New
Alkermes or any New Alkermes Group Entity or to which any properties or assets of any of them or of
the Business are subject.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.15. <U>Brokers, Finders.</U> Except for the services of the Elan Financial
Advisors, neither Elan nor any of its Subsidiaries has employed, or is subject to any valid claim
of, any broker, finder, consultant or other intermediary in connection with the transactions
contemplated by this Agreement who might be entitled to a fee or commission in connection with such
transactions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.16. <U>Opinion of Elan Financial Advisor</U>. The board of directors of Elan has
received the opinion of Citibank, N.A., dated the date of this Agreement, to the effect that the
consideration to be received by Elan in connection with the Transactions is fair from a financial
point of view to Elan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.17. <U>Board Approval</U>. (a)&nbsp;The board of directors of Elan by resolutions duly
adopted at a meeting duly called and held and not subsequently rescinded or modified in any way,
has duly determined that the Transactions are fair and in the best interests of Elan, and approved
this Agreement and its execution for and on behalf of Elan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The board of directors of Merger Sub, by resolutions duly adopted at a meeting duly called
and held and not subsequently rescinded or modified in any way, has duly (i)&nbsp;determined that it is
advisable and in the best interests of Merger Sub to effect the Transactions, and (ii)&nbsp;approved and
adopted this Agreement and the Plan of Merger contained herein and its execution for and on behalf
of Merger Sub.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.18. <U>No Shareholder Vote</U>. No vote of the holders of any class of the issued
share capital of Elan is necessary to approve the disposal of the Business pursuant to this
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.19. <U>Environmental Health and Safety Matters</U>. (a)&nbsp;Except as set forth on
<U>Section&nbsp;3.19</U> of the Elan Disclosure Schedule, or as has not or would not reasonably be
expected to have, individually or in the aggregate, a Business Material Adverse Effect, since
January&nbsp;1, 2008, the Business, New Alkermes the New Alkermes Group Entities and their activities
and operations have been and are in compliance with all applicable Environmental Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Since January&nbsp;1, 2008, the Business, New Alkermes and the New Alkermes Group Entities
maintain and have been and are in compliance with all Environmental Licenses required for their
activities and operations. All such Environmental Licenses were validly issued and are in full
force and effect. All applications, notices and other documents have been filed as necessary to
effect the timely renewal or issuance of such Environmental
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->42<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Licenses. Such Environmental Licenses contain no terms or conditions that will require
material changes or limitations on the activities and operations of the Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Business, New Alkermes and the New Alkermes Group Entities are not parties to any
Action nor have they received any written notice, demand letter, complaint or information request
from a Governmental Authority or any other Person alleging a violation of, or any Liability of any
of them under, any Environmental Law or Environmental License, including any relating to the
Release or presence of, or exposure to, any Hazardous Substance, and, to the Knowledge of Elan, no
such Action is threatened.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;To the Knowledge of Elan, there are no conditions or occurrences, including the Release or
presence of, or exposure to, any Hazardous Substance, reasonably anticipated to result in material
Liabilities to, or requirements for Remediation by, the Business, New Alkermes or the New Alkermes
Group Entities, pursuant to any Environmental Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;No Liens arising under or pursuant to any Environmental Law or restrictions on use as a
result of the Release or presence of any Hazardous Substance have been or are imposed on the
properties associated with the Business, New Alkermes or any of the New Alkermes Group Entities,
and, to the Knowledge of Elan, no Action to impose such a Lien or restriction is pending or
threatened.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;To the Knowledge of Elan, all waste material generated by the Business, New Alkermes or
the New Alkermes Group Entities and sent off-site for storage, treatment, recycling or disposal has
been sent to facilities that operate in compliance with applicable Environmental Laws. The
Business, New Alkermes and the New Alkermes Group Entities have not been identified as potentially
responsible parties at any third party sites pursuant to any Environmental Law (including the
United States Comprehensive Environmental Response, Compensation and Liability Act of 1980).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;To the Knowledge of Elan, no asbestos-containing materials, polychlorinated biphenyls, or
underground storage tanks are present at, in, on or under the properties associated with the
Business, New Alkermes or the New Alkermes Group Entities.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;None of New Alkermes or the New Alkermes Group Entities has assumed by written or, to the
Knowledge of Elan, oral agreement any Liabilities pursuant to any Environmental Law.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Elan has provided to Alkermes copies of all written environmental, health or safety
assessments, audits, investigations, and sampling, monitoring, remediation reports and similar
documents relating to the Business or the properties associated with the Business, New Alkermes or
the New Alkermes Group Entities, including any documents relating to the Release or presence of, or
exposure to, any Hazardous Substance.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.20. <U>Employee Benefit Plans</U>. (a)&nbsp;Elan has made available to Alkermes copies
of each Employee Plan and all amendments subsequent thereto and any material communications related
thereto or notices thereunder, during the twelve (12)&nbsp;month period preceding the date hereof,
together with the most recent annual report, if required by Law, summary plan description and any
material modifications thereto, actuarial valuation report
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->43<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">prepared in connection with any such Employee Plan and all trust agreements, insurance
contracts and other funding vehicles relating thereto. <U>Section&nbsp;3.20(a)</U> of the Elan
Disclosure Schedule lists all Employee Plans.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each Employee Plan that is intended to be qualified under Section 401(a) of the Code and
each trust created under any such Employee Plan that is intended to be exempt from tax under
Section 501(a) of the Code or any Similar Law has received a favorable determination letter from
the IRS. Elan has provided to Alkermes the most recent determination letter of the Internal
Revenue Service relating to each such Employee Plan. Each Employee Plan has been maintained in
material compliance with its terms and with the requirements prescribed by any and all applicable
statutes, orders, rules and regulations, including ERISA and the Code and Similar Laws.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;There has been no amendment to, written interpretation of or announcement (whether or not
written) by Elan, New Alkermes or any New Alkermes Group Entity relating to, or change in employee
participation or coverage under, any Employee Plan that would increase materially the expense of
maintaining such Employee Plan above the level of expense incurred in respect thereof for the most
recent fiscal year ended prior to the date hereof, nor has any of New Alkermes or any New Alkermes
Group Entity undertaken to make any such amendments or to adopt or approve any new Employee Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Neither Elan nor any Subsidiary thereof maintains an Employee Plan that is subject to
Title IV of ERISA or any Similar Law. No Employee Plan is a Multiemployer Plan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e) <U>Section&nbsp;3.20(e)</U> of the Elan Disclosure Schedule sets forth: (i)&nbsp;each Employee
Plan under which the execution and delivery of this Agreement or the consummation of the
transactions contemplated hereby could (either alone or in conjunction with any other event such as
termination of employment) result in, cause the accelerated vesting, funding or delivery of, or
increase the amount or value of, any payment or benefit to any employee, officer or director of New
Alkermes or any New Alkermes Group Entity, or for which New Alkermes or any New Alkermes Group
Entity could be liable in an amount which would be material, or would limit the right of any of New
Alkermes or the New Alkermes Group Entities to amend, merge, terminate or receive a reversion of
assets from any Employee Plan or related trust; and (ii)&nbsp;estimates of the aggregate dollar amounts
payable by New Alkermes or the New Alkermes Group Entities pursuant to or with respect to bonuses
and other incentive compensation in connection with or as a result of the consummation of the
transactions contemplated hereby.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;There are no pending or, to the Knowledge of Elan, threatened claims (other than claims
for benefits in the ordinary course), investigations, lawsuits or arbitrations which have been
asserted or instituted against the Employee Plans, any fiduciaries thereof with respect to their
duties to such Employee Plans or the assets of any of the trusts under any of such Employee Plans
which would reasonably be expected to result in any Liability of New Alkermes or the New Alkermes
Group Entities to the PBGC, the Department of Treasury, the Department of Labor, or any other
Governmental Authority, or to any of such Employee Plan, any participant in any such Employee Plan,
or any other party. Without limiting the generality of the foregoing, none of New Alkermes or the
New Alkermes Group Entities has any actual or contingent Liability under any such Employee Plan or
under any applicable Law for pay or benefits incurred
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->44<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">as a result of corporate restructuring, downsizing, layoffs or similar events that has not
been fully satisfied or adequately reserved for in Historical Financial Statements or in the
Audited Financial Statements, when delivered.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g) <U>Section&nbsp;3.20(g)(i)</U> of the Elan Disclosure Schedule sets forth complete and
accurate details (including terms and conditions of employment) of all employees of Elan and its
Affiliates who are engaged in the Business and employed in Ireland as of the date hereof and whom
the Parties intend to become Ireland Employees, and <U>Section&nbsp;3.20(g)(i)</U> of the Elan
Disclosure Schedule sets forth complete and accurate details (including terms and conditions of
employment) of all employees of the U.S. Acquired Entities who are engaged in the Business and
employed in the United States as of the date hereof and whom the Parties intend to become U.S.
Employees. These details, or where appropriate copies of documents, include the following relating
to each Transferred Employee: date of birth; date of commencement of employment; remuneration
(including overtime pay, bonus, commission, profit sharing, share options, permanent health
insurance, medical expenses insurance, and cars and car allowances); notice periods; active or
inactive status, any arrangements or assurances, whether or not legally binding, for the payment of
compensation on termination of employment and copies of all currently in force consultancy
contracts in connection with the Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Since the Balance Sheet Date, there has been no material alteration in the terms of
employment of Transferred Employees. Elan and its Affiliates have not offered, promised or agreed
to any future variation in any contract of employment of any of Transferred Employee.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;There are no claims pending or threatened against Elan and its Subsidiaries in respect of
any accident, injury, disability or ill-health, termination of employment or in respect of terms
and conditions of employment, or under any Laws concerning fair employment, minimum wage,
discrimination, equality or similar Laws, involving Transferred Employees. To the Knowledge of
Elan, there are no circumstances which could give rise to such a claim by any of the Transferred
Employees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;Except as set forth in <U>Section&nbsp;3.20(j)</U> of the Elan Disclosure Schedule, Elan and
its Subsidiaries are not engaged or involved in any dispute, claim or Action (whether arising under
contract, common law, statute or in equity) with any of the Transferred Employees or any other
person currently or previously employed by or engaged in the Business or their dependents and, to
the Knowledge of Elan, there are no circumstances which could give rise to any such dispute, claim
or Action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;No Transferred Employee has given notice or is under notice of termination of employment.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;In respect of each of the Ireland Employees, Elan and its Subsidiaries have: (i)
performed all obligations and duties required to be performed by it, whether arising under
contract, statute, common law or in equity or otherwise; (ii)&nbsp;abided by the terms of any agreement
or arrangement with any employee representative or body of employees or their representatives
(whether binding or not) which may affect the Ireland Employees; (iii)&nbsp;fully complied with its
obligations under the Transfer Regulations in relation to any matter concerning
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->45<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or arising from this Agreement or affecting the Ireland Employees; (iv)&nbsp;maintained adequate,
suitable and up to date records relating to the Ireland Employees; and (v)&nbsp;operated the PAYE system
in accordance with all relevant rules, made all deductions required to be made in respect of income
tax, pay-related social insurance and levies and has paid to Irish Revenue and any other
appropriate authority all Taxes, including PAYE and other levies due in respect of the Ireland
Employees in connection with their employment by Elan and its Subsidiaries.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;The Ireland Employees are lawfully entitled to work for Elan and its Subsidiaries without
restriction or any visa, permit or consent being required. Elan and its Affiliates have complied
with the Employment Permits Acts 2003 and 2006 and all legislation and rules previously in force
relating to any of the matters covered by such legislation.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;Every employment contract between Elan and its Subsidiaries and the Ireland Employees can
be terminated by Elan and its Subsidiaries by 12&nbsp;weeks&#146; notice or less without giving rise to a
claim for damages or compensation (other than a statutory redundancy, unfair dismissal payment or
amounts required under an Elan written severance policy that are, in each case, consistent with the
severance payments made to Ireland Employees under the policy entitled &#147;Elan Employee Information
Booklet Ireland 2010&#148; in calendar year 2010).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;Elan and its Subsidiaries have complied in all respects with all conditions of service,
codes of practice and customs and practice which may affect the Ireland Employees.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(p)&nbsp;Elan and its Subsidiaries are not, nor have they been, a party to a dispute nor is there a
threat of a dispute, pursuant to the Industrial Relations Acts 1946 &#151; 2004, the Industrial
Relations Act 1990 (Enhanced Code of Practice on Voluntary Dispute Resolution) (Declaration) Order
2004 (S.I. 76 of 2004) or the Industrial Relations Act 1990 (Code of Practice on Voluntary Dispute
Resolution) (Declaration) Order 2000 (S.I. 145 of 2000).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.21. <U>Acquisition of Shares for Investment</U>. Elan agrees and acknowledges that
any New Alkermes Ordinary Shares it Beneficially Owns may not be sold, transferred, offered for
sale, pledged, hypothecated or otherwise disposed of without registration under the Securities Act,
except pursuant to an exemption from such registration available under the Securities Act.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.22. <U>Operations of Certain Entities</U>. Each of New Alkermes and each New
Alkermes Group Entity is, or will be as of the Closing, a direct or indirect wholly owned
subsidiary of Elan, and, other than in the case of EHI, (i)&nbsp;has been formed solely for the purpose
of engaging in a reorganization of the Business, (ii)&nbsp;since incorporation has engaged in no other
business activities other than those incident to its organization, a reorganization of the Business
and the Transactions, as contemplated by this Agreement, and (iii)&nbsp;has no Liabilities other than
those Liabilities expressly provided for herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;3.23. <U>Products; Recalls</U>. Since January&nbsp;1, 2008:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;except as would not, individually or in the aggregate, have or reasonably be expected to
have a Business Material Adverse Effect, all Products manufactured and supplied by Elan in respect
of the Business: (i)&nbsp;were manufactured in compliance with applicable Law, including applicable
cGMPs or Similar Laws; (ii)&nbsp;conformed to the specifications for the
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->46<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">manufacture, storage, and handling of such Product in effect at the time of delivery thereof;
(iii)&nbsp;were not adulterated or misbranded within the meaning of the FDCA or Similar Laws; and (iv)
conformed to the Certificate of Analysis and Conformity supplied with the shipment of such Product;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;there have been no seizures, recalls or withdrawals related to the Products; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;there have been no tampering incidents relating to the Products.
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IV</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Representations and Warranties of Alkermes</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Except as set forth in (i)&nbsp;the corresponding sections or subsections of the disclosure
schedule delivered to Elan by Alkermes on or prior to the date hereof (the &#147;<U>Alkermes Disclosure
Schedule</U>&#148;) or (ii)&nbsp;the Alkermes SEC Reports filed with the SEC since January&nbsp;1, 2010 and prior
to the date hereof (except for cautionary, predictive or forward-looking statements contained
therein), Alkermes hereby makes to Elan, as of the date hereof and as of the Closing, each of the
representations and warranties contained in this <U>Article&nbsp;IV</U>; it being understood that
disclosure of any item in any section or subsection of the Alkermes Disclosure Schedule shall also
be deemed disclosure with respect to any other section or subsection to which the relevance of such
item is readily apparent on its face.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.1. <U>Incorporation; Authorization.</U> (a)&nbsp;Alkermes and each of its Subsidiaries
is duly organized and validly existing and in good standing under the Laws of the jurisdiction of
its organization. Each of Alkermes and its Subsidiaries (i)&nbsp;has the requisite corporate or similar
power and authority to own its properties and assets and to carry on its business as it is now
being conducted and (ii)&nbsp;is duly qualified to transact business in each jurisdiction in which the
nature of property owned or leased by it or the conduct of its business requires it to be so
qualified, except where the failure to be so be duly qualified to transact business, or to have
such power and authority, would not, individually or in the aggregate, have or reasonably be
expected to have an Alkermes Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Alkermes has the requisite corporate power to execute and deliver this Agreement and the
Ancillary Agreements to which it will be a party and to perform its obligations hereunder and
thereunder and to consummate the transactions contemplated hereby and thereby. The execution and
delivery by Alkermes of this Agreement and the Ancillary Agreements, the performance by Alkermes of
its obligations hereunder and thereunder and the consummation by Alkermes of the transactions
contemplated hereby and thereby have been duly and validly authorized by the board of directors of
Alkermes and, except for the filing of the Articles of Merger with the Department of State of the
Commonwealth of Pennsylvania and except for obtaining the approval and adoption by the shareholders
of Alkermes of the Merger by the Required Alkermes Vote, no other corporate proceedings on the part
of Alkermes, its board of directors or shareholders are necessary therefor.
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->47<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The execution, delivery and performance of this Agreement and the Ancillary Agreements
will not (i)&nbsp;violate any provision of Alkermes&#146; Governing Documents, (ii)&nbsp;violate any provision of,
or be an event that is (or with the passage of time will result in) a violation of, or result in
the acceleration of or entitle any party to accelerate or exercise (whether after the giving of
notice or lapse of time or both) any obligation or right under, or result in the imposition of any
Lien upon or the creation of a security interest in any shares of capital stock of Alkermes or any
of Alkermes&#146; assets or properties pursuant to, any Lien, agreement, instrument, order, arbitration
award, judgment or decree to which Alkermes or any of its Subsidiaries is a party or by which any
of them is bound, or (iii)&nbsp;violate or conflict with any other restriction of any kind or character
to which Alkermes or any of its Subsidiaries is subject, that, in the case of clauses <U>(ii)</U>
or <U>(iii)</U> would, individually or in the aggregate, have or reasonably be expected to have a
Alkermes Material Adverse Effect. This Agreement has been duly executed and delivered by Alkermes,
and, assuming the due execution hereof by the Elan Parties, this Agreement constitutes the legal,
valid and binding obligation of Alkermes, enforceable against Alkermes in accordance with its
terms, subject to the effect of bankruptcy, insolvency, reorganization, liquidation, dissolution,
moratorium or other similar Laws relating to or affecting the rights of creditors generally and to
the effect of the application of general principles of equity (regardless of whether considered in
proceedings at law or in equity). At the Closing, each of the Ancillary Agreements to which
Alkermes is a party will be duly executed and delivered by Alkermes and, assuming the due execution
and delivery thereof by the other parties thereto, at the Closing will constitute the legal, valid
and binding obligations of Alkermes, enforceable against Alkermes in accordance with its terms,
subject to the effect of bankruptcy, insolvency, reorganization, liquidation, dissolution,
moratorium or other similar Laws relating to or affecting the rights of creditors generally and to
the effect of the application of general principles of equity (regardless of whether considered in
proceedings at law or in equity). Alkermes has made available to Elan true and correct copies of
the Governing Documents of Alkermes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.2. <U>Capitalization; Structure</U>. (a)&nbsp;As of March&nbsp;31, 2011, the authorized
capital stock of Alkermes consisted of (i)&nbsp;160,000,000 shares of Alkermes Common Stock, of which
(A)&nbsp;105,771,507 were issued and 95,702,299 were outstanding, (B)&nbsp;10,069,208 were held in the
treasury of Alkermes, (C)&nbsp;5,406,531 were reserved and available for issuance under Alkermes&#146;
stock-based incentive plans, (D)&nbsp;16,985,009 were subject to outstanding options to acquire shares
of Alkermes Common Stock (such options, collectively with any similar options granted after the
date hereof, the &#147;<U>Alkermes Options</U>&#148;), (E)&nbsp;1,925,515 were subject to outstanding stock
awards other than Alkermes Options (whether subject to service-based or performance-based vesting)
(such stock awards, collectively with any similar stock awards granted after the date hereof, the
&#147;<U>Alkermes Stock Awards</U>&#148;) (ii)&nbsp;450,000 shares of non-voting common stock, par value $0.01
per share, of which 382,632 were issued and outstanding, and (iii)&nbsp;3,000,000 shares of preferred
stock, par value $0.01 per share, of which 0 were outstanding and 3,000 of which have been
designated as 2002 Redeemable Convertible Preferred Stock and 110,000 of which have been designated
Series&nbsp;A Junior Participating Preferred Stock and reserved for issuance upon exercise of the rights
(the &#147;<U>Rights</U>&#148;) distributed to the holders of shares of Alkermes Common Stock pursuant to
the Alkermes Rights Agreement. Since March&nbsp;31, 2011 to the date of this Agreement, there have been
no issuances of shares of the capital stock of Alkermes other than issuances of shares (and the
related Rights) pursuant to options or rights outstanding as of March&nbsp;31, 2011 or granted since
such time under Alkermes&#146; stock-based incentive plans in the Ordinary Course of Business. All of
the issued and outstanding shares of
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->48<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">capital stock of Alkermes are duly authorized, validly issued, fully paid and non-assessable
and free of preemptive rights.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) <U>Section&nbsp;4.2(b)</U> of the Alkermes Disclosure Schedule sets forth a list of all of the
Subsidiaries of Alkermes as of the date of this Agreement. All of the outstanding shares of
capital stock or other equity interests of each of Alkermes&#146; Subsidiaries have been validly issued,
and are fully paid and nonassessable and free of preemptive rights, and are owned directly or
indirectly by Alkermes, free and clear of all Liens. Neither Alkermes nor any of its Subsidiaries
directly or indirectly owns any equity interest in any Person, other than the Subsidiaries of
Alkermes, that is or would be expected to be material to Alkermes and its Subsidiaries taken as a
whole. Except for (i)&nbsp;the Rights and (ii)&nbsp;options and other stock-based awards covering up to
18,910,524 shares of Alkermes Common Stock outstanding on March&nbsp;31, 2011, as of the date hereof
there are no outstanding options, warrants or other rights of any kind to acquire from Alkermes or
any of its Subsidiaries, or obligations of Alkermes or its Subsidiaries to issue, shares of capital
stock of any class of, or other equity interests in, Alkermes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.3. <U>Litigation; Orders</U>. Except as set forth in the Alkermes SEC Reports
filed prior to the date hereof or disclosed in <U>Section&nbsp;4.3</U> of the Alkermes Disclosure
Schedule, there are no Actions pending or, to the Knowledge of Alkermes, threatened against
Alkermes or any of its Subsidiaries that would, individually or in the aggregate, have or
reasonably be expected to have an Alkermes Material Adverse Effect. There are no judgments or
outstanding orders, injunctions, decrees, stipulations or awards (whether rendered by a court or
administrative agency, or by arbitration) against Alkermes or any of its Subsidiaries or any of
their respective properties or businesses that would, individually or in the aggregate, have or
reasonably be expected to have an Alkermes Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.4. <U>Authorizations; Consents.</U> <U>Section&nbsp;4.4</U> of the Alkermes Disclosure
Schedule contains a list of all registrations, filings, applications, notices, consents, approvals,
orders, qualifications and waivers required to be made, filed, given or obtained by Alkermes or any
of its Subsidiaries with, to or from any Persons or Governmental Authorities in connection with the
consummation of this Agreement (including the Merger) or the Ancillary Agreements or the other
transactions contemplated hereby or thereby, except for those with respect to which the failure to
make, file, give or obtain would not, individually or in the aggregate, have or reasonably be
expected to have an Alkermes Material Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.5. <U>Compliance with Laws</U>. Except as set forth in the Alkermes SEC Reports
filed prior to the date hereof, the conduct of the businesses of Alkermes and its Subsidiaries
complies with all Laws applicable thereto, except for those violations of Law which would not,
individually or in the aggregate, have or reasonably be expected to have an Alkermes Material
Adverse Effect.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.6. <U>SEC Reports; Financial Statements</U>. (a)&nbsp;Alkermes has filed all forms,
reports and documents (including all Exhibits, Schedules and Annexes thereto) required to be filed
by it with the SEC since January&nbsp;1, 2008, including any amendments or supplements thereto
(collectively, the &#147;<U>Alkermes SEC Reports</U>&#148;). As of their respective dates, none of the
Alkermes SEC Reports (and, if amended or superseded by a filing prior to the date of this
</DIV>




<P align="center" style="font-size: 10pt"><!-- Folio -->49<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Agreement or the Closing Date, then on the date of such filing) contained any untrue statement
of a material fact or omitted to state a material fact required to be stated therein or necessary
in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The financial statements (including all related notes and schedules thereto), contained in
the Alkermes SEC Reports (or incorporated therein by reference) (the &#147;<U>Alkermes Financial
Statements</U>&#148;) fairly present in all material respects the consolidated financial position and
results of operations and cash flows of Alkermes and its Subsidiaries for the respective periods or
as of the respective dates set forth therein, in each case in accordance with U.S. GAAP applied on
a consistent basis throughout the periods involved (except as otherwise indicated therein and
except, in the case of unaudited Alkermes Financial Statements, for changes resulting from normal
and recurring year-end adjustments).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.7. <U>No Undisclosed Liabilities</U>. Except for Liabilities (a)&nbsp;which are
reflected or reserved against in the audited balance sheet as of March&nbsp;31, 2010 (the &#147;<U>Alkermes
Balance Sheet Date</U>&#148;) or notes thereto included in Alkermes&#146; Annual Report on Form 10-K for the
period ended March&nbsp;31, 2010 (the &#147;<U>Alkermes Balance Sheet</U>&#148;), (b)&nbsp;set forth in <U>Section
4.7</U> of the Alkermes Disclosure Schedule or (c)&nbsp;incurred in the Ordinary Course of Business
since the Alkermes Balance Sheet Date, that, individually or in the aggregate, have not had and
would not reasonably be expected to have an Alkermes Material Adverse Effect, (i)&nbsp;Alkermes has no
Liabilities that would be required to be reflected on a balance sheet prepared in accordance with
U.S. GAAP, (ii)&nbsp;to the Knowledge of Alkermes, Alkermes has no Liabilities whether or not required
by U.S. GAAP to be reflected or reserved against on the Alkermes Balance Sheet.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.8. <U>Absence of Certain Changes</U>. Since the Alkermes Balance Sheet Date, there
has been no (a)&nbsp;change or development in or effect on Alkermes and its Subsidiaries taken as a
whole that has had, or would reasonably be expected to have, an Alkermes Material Adverse Effect,
(b)&nbsp;other than in connection with the transactions contemplated by this Agreement, action or
omission by Alkermes that was not in the Ordinary Course of Business or (c)&nbsp;action or omission
that, if taken from the date hereof through the Closing, would violate any of the provisions of
<U>Section&nbsp;5.4(b)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.9. <U>Brokers, Finders.</U> Except for the services of the Alkermes Financial
Advisor, neither Alkermes nor any of its Subsidiaries has employed, or is subject to any valid
claim of, any broker, finder, consultant or other intermediary in connection with the transactions
contemplated by this Agreement who might be entitled to a fee or commission in connection with such
transactions.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.10. <U>Opinions of Alkermes Financial Advisor</U>. The board of directors of
Alkermes has received the opinion of the Alkermes Financial Advisor, dated the date of this
Agreement, to the effect that the consideration to be paid by Alkermes in connection with the
Transactions is fair from a financial point of view to Alkermes, and such opinion contains the
consent of the Alkermes Financial Advisor to the inclusion in full of the text of such opinion in
any document delivered to the shareholders of Alkermes in connection with the transactions
contemplated by this Agreement.
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->50<!-- /Folio -->
</DIV>



<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.11. <U>Board Approval</U>. The board of directors of Alkermes, by resolutions duly
adopted by unanimous vote at a meeting duly called and held and not subsequently rescinded or
modified in any way, has duly (i)&nbsp;determined that the transactions contemplated by this Agreement
are fair to and in the best interests of Alkermes and its shareholders, (ii)&nbsp;approved and adopted
this Agreement and the Plan of Merger contained herein and (iii)&nbsp;determined to recommend to the
shareholders of Alkermes that such shareholders approve and adopt this Agreement and the
transactions contemplated hereby (including the Plan of Merger contained in this Agreement).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.12. <U>Required Shareholder Vote</U>. The affirmative vote of a majority of the
votes cast by all holders of the outstanding shares of Alkermes Common Stock entitled to vote on
the Merger is the only vote of the holders of any class of capital stock of Alkermes necessary to
approve the Merger (the &#147;<U>Required Alkermes Vote</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.13. <U>Antitakeover Statute</U>. Alkermes has taken or will take prior to the
Closing all action necessary to exempt the Merger and this Agreement and the transactions
contemplated hereby from the provisions of Subchapter 25D (including Section&nbsp;2538), and Subchapters
25E, 25F, 25G, 25H, 25I and 25J of the PBCL.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;4.14. <U>Financing</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Alkermes has delivered to Elan true and complete copies of the fully executed commitment
letter, dated May&nbsp;9, 2011 between Alkermes and Morgan Stanley Senior Funding, Inc., HSBC Securities
(USA)&nbsp;Inc. and HSBC Bank USA, N.A., including all exhibits, schedules, annexes and amendments to
such letter in effect as of the date of this Agreement, and excerpts of those portions of the fee
letter associated therewith that contain any conditions to funding or &#147;flex&#148; provisions or other
provisions (excluding provisions related solely to fees and economic terms) regarding the terms and
conditions of the financing to be provided thereby, pursuant to which and subject to the terms and
conditions thereof the lenders party thereto have agreed to lend the amounts set forth therein (the
provision of such funds as set forth therein, the &#147;<U>Financing</U>&#148;) (such commitment letter,
including all exhibits, schedules, annexes and amendments thereto and such fee letter, as modified
to add additional lenders and other parties, collectively, the &#147;<U>Commitment Letter</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;As of the date of this Agreement, the Commitment Letter is in full force and effect and
constitutes a valid and binding agreement of each of Alkermes and, to the Knowledge of Alkermes,
the parties thereto (subject to applicable bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and other Laws affecting creditors&#146; rights generally and general
principles of equity) and the commitments thereunder have not been withdrawn or terminated. As of
the date of this Agreement, the Commitment Letter has not been amended, supplemented or otherwise
modified in any respect. Other than as expressly set forth in the Commitment Letter, there are (i)
no conditions precedent or contingencies related to the funding of the full net proceeds of the
Financing (including pursuant to any &#147;flex&#148; provisions in connection therewith) and (ii)&nbsp;as of the
date of this Agreement, no agreements, side letters, arrangements or understandings that would, or
would reasonably be expected to, affect the availability of the Financing.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->51<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The net proceeds of the Financing, when and if funded, together with other financial
resources of Alkermes including cash on hand of Alkermes on the Closing Date, will, in the
aggregate, be sufficient for the payment of the Cash Payment. Assuming the accuracy of Elan&#146;s
representations and warranties contained in <U>Article&nbsp;III</U>, as of the date of this Agreement,
no event has occurred that would constitute a breach or default (or an event that with notice or
lapse of time or both would constitute a default), in each case, on the part of Alkermes under the
Commitment Letter. Alkermes has fully paid all commitment fees or other fees required pursuant to
the Commitment Letter to the extent required thereunder to be paid prior to the date of this
Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE V</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Covenants of the Parties</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.1. <U>Access to Information; Retention of Records; Confidentiality</U>. (a)&nbsp;From
the date hereof through the Closing, the Elan Parties shall, and shall cause their respective
Subsidiaries to, (i)&nbsp;afford to Alkermes and the Financing Parties and their respective accountants,
counsel and other Representatives reasonable access during regular business hours, upon reasonable
advance notice, to the offices, plants, properties, books and records and employees of New Alkermes
and the New Alkermes Group Entities and, to the extent related to the Business, Elan and its other
Subsidiaries, and their agents and consultants, and (ii)&nbsp;furnish to Alkermes and the Financing
Parties and their respective accountants, counsel and other Representatives all such information
and data concerning the Business and the Reorganization as Alkermes, the Financing Parties or their
respective Representatives may reasonably request (except to the extent that such information is
subject to attorney-client privilege), in each case, subject to any applicable Laws, in order that
Alkermes and the Financing Parties may make reasonable investigations of the affairs of the
Business, New Alkermes, and the New Alkermes Group Entities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;From the date hereof through the Closing, Alkermes shall, and shall cause its Subsidiaries
to, (i)&nbsp;afford to Elan and Elan&#146;s accountants, counsel and other Representatives reasonable access
during regular business hours, upon reasonable advance notice, to the offices, plants, properties,
books and records and employees of Alkermes and its Subsidiaries, and their agents and consultants,
and (ii)&nbsp;furnish to Elan and its accountants, counsel and other Representatives all such
information and data as Elan or such Representatives may reasonably request (except to the extent
that such information is subject to attorney-client privilege), in each case, subject to any
applicable Laws, in order that Elan may make reasonable investigations of the affairs of Alkermes
and its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;From the Closing Date until the seventh (7<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>) anniversary thereof, Elan shall,
and shall cause the Continuing Affiliates and each of their Representatives to, treat as
confidential and shall safeguard any and all information, know-how, knowledge and data (other than
historical financial reporting information) relating to the Business (the &#147;<U>Acquired
Confidential Information</U>&#148;), in each case in their respective possession by using the same
degree of care, but no less than a reasonable standard of care, to prevent the unauthorized use,
dissemination or disclosure of such information, know-how, knowledge and data as Elan used with
respect thereto prior to the date hereof. From the Closing Date until the seventh (7<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>)
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->52<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">anniversary thereof, New Alkermes and its Subsidiaries shall, and shall cause each of their
Representatives to, treat as confidential and shall safeguard any and all information, know-how,
knowledge and data (other than historical financial reporting information) relating to Elan&#146;s
business (other than the Business)(the &#147;<U>Retained Confidential Information</U>&#148;) in their
respective possession by using the same degree of care, but not less than a reasonable standard of
care, to prevent the unauthorized use, dissemination or disclosure of such information, know-how,
knowledge and data as New Alkermes uses with respect to the Acquired Confidential Information.
Prior to the seventh (7<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>) anniversary of the Closing Date, the Parties agree that each
of them and their respective Subsidiaries and Representatives may only disclose Acquired
Confidential Information or Retained Confidential Information, as the case may be, (i)&nbsp;to the
extent counsel to such Person advises that disclosure is required to comply with Law
(<U>provided</U> that such Party shall provide prior written notice to the other Parties of such
disclosure unless prohibited by Law) as promptly as practical and shall seek to limit any such
disclosure and to protect from public disclosure by way of a protective order or otherwise, in each
case, to the extent permitted by Law), and (ii)&nbsp;to its Representatives who reasonably need to know
such information for purposes of this Agreement or any Ancillary Agreement (<U>provided</U> that
each Party shall instruct any such Representative to keep such information confidential in
accordance with this Agreement). In no event shall Elan use, or permit any other Person to use,
the Acquired Confidential Information for any purpose other than as expressly contemplated under
this Agreement or any Ancillary Agreement. In no event shall New Alkermes use, or permit any other
Person to use, the Retained Confidential Information for any purpose other than as expressly
contemplated under this Agreement or any Ancillary Agreement. Notwithstanding the foregoing, the
Confidentiality Agreement between EPIL and Alkermes, dated December&nbsp;22, 2010 (the
&#147;<U>Confidentiality Agreement</U>&#148;) shall continue in full force and effect and survive the
Closing in accordance with the terms thereof; <U>provided</U>, that from and after the Closing,
the restrictions on the use and disclosure of &#147;Information&#148; (as defined in the Confidentiality
Agreement) set forth therein shall not apply to New Alkermes and its Affiliates and Representatives
in respect of any such Information relating to the Business, New Alkermes or the New Alkermes Group
Entities (in addition to, for the avoidance of doubt, constituting Acquired Confidential
Information under this Agreement). The Parties acknowledge that the confidentiality obligations
set forth in this <U>Section&nbsp;5.1(c)</U> shall not extend to information, knowledge and data that
(i)&nbsp;is or becomes publicly available through no act or omission of a Party owing a confidentiality
obligation imposed by this <U>Section&nbsp;5.1(c)</U> in respect of such information, knowledge and
data (a &#147;<U>Receiving Party</U>&#148;), (ii)&nbsp;is or becomes available to a Receiving Party on a
non-confidential basis from a source other than the Party to which such information, knowledge and
data relates; <U>provided</U>, that the source of such information, knowledge and data was not
known to the Receiving Party to be bound by confidentiality obligations to the Party to which such
information, knowledge and data relates, or (iii)&nbsp;the Receiving Party can establish that it
independently developed such information, knowledge and data without reference to information,
knowledge and data provided to such Receiving Party in connection with the transactions
contemplated hereby and, in the case of Elan, its Continuing Affiliates and each of their
Representatives, without reference to any Acquired Confidential Information.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Notwithstanding the restrictions contained in <U>Section&nbsp;5.1(c)</U>, Elan may disclose
such information as is required by applicable Law to a third party purchaser of any or all New
Alkermes Ordinary Shares held by Elan or any Continuing Affiliate in a privately-
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->53<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">negotiated transaction to the extent permitted by and pursuant to Section&nbsp;5.1(c)(ii) of the
Shareholder&#146;s Agreement; <U>provided</U>, that it shall be a condition to any such disclosure that
such third party purchaser shall have entered into a confidentiality agreement with New Alkermes in
respect of any such information on terms and conditions reasonably satisfactory to New Alkermes,
and in any event, containing restrictions on the disclosure and use of any such information no less
restrictive than those contained herein.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;No review pursuant to this <U>Section&nbsp;5.1</U> shall affect or be deemed to modify or
qualify any representation or warranty contained herein, the covenants or agreements of the Parties
or the conditions to the obligations of the Parties under this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Following the Closing until the seventh (7<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>) anniversary thereof, Elan shall,
and shall cause its Subsidiaries to, (i)&nbsp;retain those Books and Records that relate in part to the
Business but which do not relate primarily to the Business and (ii)&nbsp;afford to New Alkermes and New
Alkermes&#146; accountants, counsel and other Representatives reasonable access to inspect and copy
during regular business hours, upon reasonable advance notice, any such Books and Records retained
by Elan or any of its Subsidiaries, but such access need be given only with respect to the portion
of such Books and Records as are related to the operations of the Business. After the seventh
(7<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>) anniversary of the Closing, Elan shall give New Alkermes at least twenty (20)
Business Days&#146; notice of any intention to discard or destroy such Books and Records so that New
Alkermes may elect, at its own expense, to take possession of or otherwise copy any such Books and
Records.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Following the Closing until the seventh (7<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>) anniversary thereof, New Alkermes
shall, and shall cause its Subsidiaries to, (i)&nbsp;retain all Transferred Books and Records in the
possession of New Alkermes or the New Alkermes Group Entities as of the Closing or delivered
pursuant to this Agreement and (ii)&nbsp;afford to Elan and Elan&#146;s accountants, counsel and other
Representatives reasonable access to inspect and copy during regular business hours, upon
reasonable advance notice, any Transferred Books and Records (or parts thereof as are required) in
connection with matters that are the subject of indemnification under <U>Section&nbsp;9.2</U> or
otherwise necessary for Elan to comply with the terms of this Agreement or any applicable Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.2. <U>Filings; Other Actions; Notification</U>. (a)&nbsp;Each of the Parties shall use
(and shall cause its respective Subsidiaries, officers and directors, and shall use reasonable best
efforts to cause its Affiliates, attorneys, accountants and Representatives, to use) their
respective reasonable best efforts as soon as practicable to take or cause to be taken all actions,
and to do or cause to be done all things, necessary, proper or advisable on its part under
applicable Law, this Agreement and the Ancillary Agreements to consummate and make effective the
Merger and any other Transaction contemplated by this Agreement or the Ancillary Agreements,
including (i)&nbsp;preparing and filing with the SEC the filings described in <U>Section&nbsp;5.11</U> and
all necessary amendments or supplements to those filings; (ii)&nbsp;preparing, providing and filing all
documentation and other information to effect all necessary notices, reports, applications, filings
and other submissions, and to obtain as promptly as is practicable all consents, approvals,
waivers, licenses, permits, authorizations, registrations, qualifications, decisions,
determinations or other permissions or actions necessary or advisable to be obtained from any
Governmental Authority or any other Person in order to consummate the Merger or any other
transaction contemplated by this Agreement or the Ancillary Agreements; (iii)&nbsp;providing all such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->54<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">information concerning such Party, its Subsidiaries and its officers, directors, employees,
partners and Affiliates as may be necessary or reasonably requested in connection with any of the
foregoing; and (iv)&nbsp;avoiding the issuance or entry of, or have vacated or terminated, any decree,
order, injunction, judgment, decision or determination that would, in whole or in part, restrain,
prevent or delay the consummation of the Merger or any other transaction contemplated by this
Agreement or the Ancillary Agreements; <U>provided</U>, that Alkermes shall not be required to
offer, take or agree to any actions in connection with, or agree to, any hold separate order, sale,
divestiture or disposition of plants, assets or businesses (of Alkermes or the Business) and the
Elan Parties shall not do any of the foregoing without the consent of Alkermes (acting in its sole
discretion).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each of the Parties shall cooperate regarding, and keep the other Parties reasonably
apprised of the status of, matters relating to the completion of the transactions contemplated
hereby and work cooperatively in connection (i)&nbsp;with obtaining all necessary notices, reports,
applications, filings and other submissions, and to obtain as promptly as is practicable all
consents, approvals, waivers, licenses, permits, authorizations, registrations, qualifications,
decisions, determinations or other permissions or actions of any Governmental Authority and (ii)
all other communications with any Governmental Authority (which for purposes of this <U>Section
5.2</U> includes staff of Governmental Authorities and any elected member of a Governmental
Authority and their staff) with respect to the Merger or any of the other transactions contemplated
by this Agreement. In that regard, each Party shall: (A)&nbsp;promptly notify the other Parties of,
and, if in writing, furnish the others with copies of (or, in the case of oral communications,
advise the others orally of), any communications from or with any Governmental Authority with
respect to the Merger or any of the other transactions contemplated by this Agreement; (B)&nbsp;permit
the other Parties to review and discuss in advance, and consider in good faith the views of the
others in connection with, any proposed written (or any proposed oral) communication with any such
Governmental Authority with respect to the Merger or any of the other transactions contemplated by
this Agreement; (C)&nbsp;not participate in any meeting or oral communication with any such Governmental
Authority with respect to the Merger or any of the other transactions contemplated by this
Agreement unless it consults with the other Parties in advance and, to the extent permitted by such
Governmental Authority, gives the other Parties the opportunity to attend and participate thereat;
(D)&nbsp;furnish the other Parties with copies of all correspondence, filings and communications (and
memoranda setting forth the substance thereof, including summaries of any meetings or
communications the others are not permitted to participate in pursuant to clause <U>(C)</U> above)
between it and any such Governmental Authority with respect to the Merger or any of the other
transactions contemplated by this Agreement (except that the Parties shall only be required to
share with (and solely for review by) outside counsel of the other Parties their respective Item
4(c) documents submitted with their HSR Act filings or similar documents); and (E)&nbsp;furnish the
other Parties with such necessary information and reasonable assistance as the others may
reasonably request in connection with its preparation of necessary filings or submissions of
information to any such Governmental Authority. Each Party may, as each deems advisable and
necessary, reasonably designate any competitively sensitive material provided to the other Parties
under this <U>Section&nbsp;5.2</U> as &#147;outside counsel only.&#148; Such competitively sensitive material
and the information contained therein shall be given only to the outside legal counsel of the
recipient and will not be disclosed by such outside counsel to employees, officers, or directors of
the recipient unless express permission is obtained in advance from the source of the materials or
its legal counsel.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->55<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Without limiting the generality of the undertakings provided in this <U>Section&nbsp;5.2</U>,
the Parties hereto agree to take or cause to be taken the following actions: (i)&nbsp;the prompt
provision to any and all federal, supranational, state, local or non-U.S. Governmental Authority
with jurisdiction over enforcement of any applicable antitrust Laws (&#147;<U>Governmental Antitrust
Authority</U>&#148;) of information and documents requested by any Governmental Antitrust Authority or
necessary, proper or advisable to permit consummation of the Merger, the Reorganization or any
other transaction contemplated by this Agreement or the Ancillary Agreements, and, in any event,
the Parties will use their reasonable best efforts to make all filings with such Governmental
Antitrust Authorities (including all filings required under the HSR Act, with the Federal Trade
Commission or the United States Department of Justice) within ten (10)&nbsp;Business Days from the date
hereof (or, in the case of filings required with other Governmental Antitrust Authorities, within
ten (10)&nbsp;Business Days following the identification by a Party that such filing is so required) and
(ii)&nbsp;subject to the proviso of <U>Section&nbsp;5.2(a)</U>, use reasonable best efforts to take
promptly, in the event that any permanent or preliminary injunction or other decree, order,
judgment, decision or determination is entered or issued, or becomes reasonably foreseeable to be
entered or issued, in any lawsuit, investigation, inquiry, action or proceeding that would make
consummation, in whole or in part, of the Merger or any other transaction contemplated by this
Agreement or the Ancillary Agreements unlawful or that would prevent or delay, in whole or in part,
consummation of the Merger or any other transaction contemplated by this Agreement or the Ancillary
Agreements, any and all steps (including the taking of any appeal, the posting of any bond or the
taking of the steps contemplated by clause <U>(ii)</U>) necessary to vacate, modify or suspend
such injunction, decree, order, judgment, decision or determination so as to permit such
consummation on a schedule as close as possible to that contemplated by this Agreement and the
Ancillary Agreements.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.3. <U>Further Assurances</U>. The Parties agree that, from time to time, whether
before, at or after the Closing Date, each of them will execute and deliver such further
instruments of conveyance and transfer and take such other actions as may be necessary to carry out
the purposes and intents of this Agreement (including the Elan Parties stamping any documents of
title as are reasonably necessary to delivery good title to the Business Assets where it is
reasonably agreed by the Parties that such stamping is required). Without limiting the generality
of the foregoing:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Between the date hereof and the Closing (i)&nbsp;the Elan Parties shall, and shall cause their
Subsidiaries to, take such steps as are necessary (A)&nbsp;to effect the Reorganization specifically as
described on <U>Schedule&nbsp;1</U> hereto or as otherwise mutually and reasonably agreed by Elan and
Alkermes and (B)&nbsp;ensure that New Alkermes and the New Alkermes Group Entities hold all of the
assets and liabilities of the Business (including any Designated Assets and the EDDI Contracts) and
no other assets or liabilities (including assets or liabilities relating to any Excluded Assets)
other than the Additional Assets, and (ii)&nbsp;Alkermes shall take and shall cause its Subsidiaries to
take such steps as are necessary to effect those portions of the Reorganization that are reflected
in <U>Schedule&nbsp;1</U> as being consummated by Alkermes and its Subsidiaries in connection with the
Reorganization and the transactions contemplated by this Agreement and the Ancillary Agreements.
If the Parties agree to a deviation from <U>Schedule&nbsp;1</U> in accordance with this <U>Section
5.3(a)</U> (in which case, the Parties shall cause <U>Schedule&nbsp;1</U> to be revised accordingly),
then for purposes of this Agreement, all references to <U>Schedule&nbsp;1</U> shall be deemed to be
references to <U>Schedule&nbsp;1</U> as so revised. Elan shall make available to Alkermes in a timely
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->56<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">manner for review and comment all drafts of the Reorganization Transfer Agreements or other
instruments or documentation relating to the Reorganization Transfers or the Reorganization, and
Elan shall not, and shall cause its Affiliates not to, execute any such Reorganization Transfer
Agreements or other instruments or documentation, or take any actions or consummate any steps or
transactions contemplated thereby, in each case, that is not reasonably satisfactory to Alkermes.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;With respect to Business Assets that are EDDI Contracts, Elan shall use its reasonable
best efforts to cause EDDI to assign all of EDDI&#146;s right, title and interest in an to such
contracts, free and clear of all Liens other than Permitted Liens, to the U.S. Acquired Entities or
another New Alkermes Group Entity designated by Alkermes as part of the Reorganization Transfers.
With respect to all Business Assets that are contracts (including EDDI Contracts), Elan shall, and
shall cause its Subsidiaries to, use reasonable best efforts to obtain all necessary consents,
waivers or approvals of any parties to such contracts as are required thereunder in connection with
the Transactions or for any such contracts to remain in full force and effect, all of which are
required to be listed on <U>Section&nbsp;3.3</U> of the Elan Disclosure Schedule, so as to preserve all
rights of, and benefits to, the Business under such contracts from and after the Closing. If any
such contracts may not be transferred without the consent, waiver or approval of any Person or as a
result of any Law restricting such transfer, Elan shall, and shall cause its Subsidiaries to, use
reasonable best efforts to secure such consent, waiver or approval. If, notwithstanding such
reasonable best efforts, Elan and its Subsidiaries are unable to secure any such consent, waiver or
approval, then no transfer of such contacts will occur if to do so without such consent, waiver or
approval would constitute a breach or other contravention of the rights of such Person until such
consent, waiver or approval is obtained, and any assignment or transfer shall be made subject to
such consent, waiver or approval being obtained. To the extent any such consent, waiver or
approval is not obtained, Elan shall, and shall cause its Subsidiaries to, continue, upon the
request of Alkermes, to use its reasonable best efforts to secure such consent, waiver or approval
and the Parties will mutually agree in good faith on reasonable alternative arrangements that would
result in New Alkermes and the New Alkermes Group Entities receiving all the benefits of such
contracts until such time as such consent, waiver or approval has been obtained and such assignment
effected.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Following the Closing, to the extent any assets or rights of the Business have been
retained by Elan and the Continuing Affiliates, Elan shall and shall cause the Continuing
Affiliates to use their best efforts to convey such assets or rights to New Alkermes, the Surviving
Corporation and the New Alkermes Group Entities as promptly as practicable (and pending such
conveyance to provide New Alkermes, the Surviving Corporation and the New Alkermes Group Entities
with the benefit of such assets).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The Parties will, and will cause their respective Subsidiaries and Affiliates to, enter
into, at or prior to the Closing, each of the Ancillary Agreements to which they are intended to be
a party substantially in accordance with the attached form agreements or, if no form agreement is
attached and except as otherwise provided in this Agreement, in a form reasonably satisfactory to
each of the Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;As soon as reasonably practicable, Elan shall and shall cause its Subsidiaries and
Affiliates to use their reasonable best efforts to terminate all sale and leaseback
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->57<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">arrangements (including any defeasance leases) entered into by Elan or any of its Subsidiaries
in respect of any Business Assets and upon such termination provide Alkermes with evidence that (i)
all sale and leaseback arrangements (including any defeasance leases) entered into by Elan or its
Subsidiaries in respect of any Business Assets have been terminated, (ii)&nbsp;all amounts due under
such arrangements, including any termination payments, have been discharged in full, (iii)&nbsp;all
security granted in relation to any such arrangements has been fully and unconditionally released,
and (iv)&nbsp;title to such Business Assets is held by New Alkermes or a New Alkermes Group Entity, as
appropriate. If any such sale and leaseback arrangements are not terminated prior to the Closing,
then Elan shall and shall cause its Subsidiaries and Affiliates to continue to use their reasonable
best efforts to terminate such arrangements until such termination is obtained, and the Parties
will mutually agree in good faith on alternative arrangements that would result in New Alkermes and
the New Alkermes Group Entities receiving all the benefits of ownership of the underlying Business
Assets (to the fullest extent permitted by applicable Law) until such time as the termination has
been effected; <U>provided</U>, that in no event shall any alternative arrangements or the
termination of such sale and leaseback arrangements result in New Alkermes or any of its
Subsidiaries being required to pay any amount or relinquish any right.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Notwithstanding the foregoing, to the extent any real property or other assets or
facilities, or any rights or services, are determined to be shared or used jointly by the Business,
on the one hand, and the businesses of Elan and its Subsidiaries other than the Business, on the
other hand, the Parties will use their reasonable best efforts to reach equitable arrangements
under which such real property, assets, facilities, rights and services will cease to be shared at
or prior to the Closing. If no such arrangement is reached, the Parties will mutually agree in
good faith on reasonable transition arrangements on reasonable commercial terms (in addition to
those set forth in the Transition Services Agreement) that will allow such sharing to cease as soon
as practicable following the Closing (except to the extent the Parties agree on longer term sharing
arrangements, which shall be agreed on an arm&#146;s-length basis).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;As soon as reasonably practicable following the Closing, to the extent any Transferred
Books and Records are not delivered at the Closing pursuant to and as permitted by <U>Section
2.13(iii)</U>, Elan shall, and shall cause the Continuing Affiliates to, deliver such Transferred
Books and Records to New Alkermes. In addition, to the extent that certain Books and Records held
by Elan or any Continuing Affiliate contain information relating to the Business but such Books and
Records relate primarily to businesses other than the Business, such Books and Records shall be
retained by Elan or any Continuing Affiliate, who shall, to the extent requested to do so, provide
copies of the relevant portions thereof to New Alkermes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;Prior to the Closing, Elan shall, and shall cause its Subsidiaries to, take such steps as
are reasonably requested by Alkermes to provide for the governance of New Alkermes and the New
Alkermes Group Entities from and after the Effective Time, including to (i)&nbsp;form appropriate
committees of the board of directors of New Alkermes or any New Alkermes Group Entity, (ii)
nominate and cause to be elected, effective as of the Effective Time, such directors of the New
Alkermes Group Entities as Alkermes may designate, (iii)&nbsp;appoint, effective as of the Effective
Time, to any committee of the board of directors of New Alkermes or any New Alkermes Group Entity
such directors as Alkermes may designate, (iv)&nbsp;adopt and approve such committee charters, codes of
conduct or other guidelines, principles or codes of
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->58<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">conduct for New Alkermes and the New Alkermes Group Entities as Alkermes may reasonably
require, (v)&nbsp;adopt and approve such employee benefit plans, including equity-based plans, of New
Alkermes and the New Alkermes Group Entities as Alkermes may reasonably require and (vi)&nbsp;take such
other corporate actions and adopt such other resolutions of the board of directors of New Alkermes
or of the shareholders of New Alkermes as Alkermes may reasonably request, subject to the approval
of Elan, which shall not be unreasonably withheld, delayed or conditioned.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;Prior to the Closing, Elan shall, or shall cause its Subsidiaries to, use their reasonable
best efforts to provide to Alkermes: (i)&nbsp;written confirmation that the deeds of transfer in respect
of the Monksland industrial premises and the castle at Moyvannon (the &#147;<U>Deeds of Transfer</U>&#148;)
have been duly stamped, either at the ad valorem rate or adjudged exempt under inter-companies
relief; <U>provided</U>, that if, despite the use of reasonable best efforts, such stamping is not
available at the Closing, the relevant amounts of stamp duty should be placed in an escrow account
agreed to by Elan and Alkermes, each acting in good faith, pending such stamping; (ii)&nbsp;written
confirmation that the Deeds of Transfer have been lodged in the Irish Land Registry, with a copy of
the dealing and an undertaking to assist New Alkermes and its Subsidiaries with Irish Land Registry
queries when and if made; <U>provided</U>, if such copy is not available at the Closing, the
appropriate dealing shall be prepared (albeit not lodged) and all Irish Land Registry fees in
relation thereto shall have been paid by Elan; (iii)&nbsp;definitive confirmation from Galway County
Council it is willing to proceed upon the basis of a compulsory acquisition agreement entered into
by it with EPIL, notwithstanding that EPIL does not have documentary title to the lands in
question; and (iv)&nbsp;evidence that Elan or one of its Subsidiaries has applied to the relevant local
authority for confirmation that the Monksland industrial premises are served by public roads.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;Elan hereby covenants that, as soon as reasonably practicable after completion of the
stamping of the Deeds of Transfer referred to in this <U>Section&nbsp;5.3(j)</U>, it shall instruct A&#038;L
Goodbody solicitors to lodge in the Land Registry with all appropriate fees and supporting
documentation (A)&nbsp;the Deed of Transfer dated 20 December&nbsp;2007 (1)&nbsp;Elan Holdings Limited and (2)
Elan Pharma International Limited; and (B)&nbsp;the Deed of Transfer dated 20 December&nbsp;2007 (1)&nbsp;Elan
Corporation plc and (2)&nbsp;Elan Pharma International Limited. Elan shall provide all assistance as
may be required by A&#038;L Goodbody to deal with any reasonably land registry queries that may be
raised in connection with the registration of the same.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.4. <U>Conduct of Business</U>. (a) <I>Conduct of the Business</I>. The Elan Parties
agree, as to themselves and their respective Subsidiaries, that, from the date hereof until the
Effective Time, except as set forth in <U>Section&nbsp;5.4</U> of the Elan Disclosure Schedule, as
expressly required by this Agreement (including (A)&nbsp;actions taken pursuant to <U>Section&nbsp;5.2</U>,
(B)&nbsp;transactions required by the Reorganization subject to <U>Section&nbsp;5.3(a)</U>, or (C)&nbsp;as
required by applicable Law), or as otherwise agreed to in writing by Alkermes (such consent not to
be unreasonably withheld or delayed), (x)&nbsp;the Business shall be conducted in the Ordinary Course of
Business and, to the extent consistent therewith (and subject to the restrictions set forth in this
<U>Section&nbsp;5.4(a)</U>), (y)&nbsp;the Elan Parties will (and will cause their Subsidiaries to) use all
reasonable best efforts to preserve and maintain existing relations and goodwill with Governmental
Authorities, employees, customers, brokers, suppliers and other Persons with which the Business has
significant business relations and (z)&nbsp;subject to applicable Law as agreed in good faith by
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->59<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">counsel to Alkermes, the Elan Parties shall not and shall cause their respective Subsidiaries
not to, directly or indirectly do, or commit to do, any of the following:
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) repurchase, redeem or otherwise acquire any shares of capital stock or
other securities of, or other ownership interests in, New Alkermes or any of the New
Alkermes Group Entities;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) issue, deliver, pledge, encumber or sell any shares of capital stock of or
other equity interests in New Alkermes or any New Alkermes Group Entity, or any
securities convertible into any such shares of capital stock or other equity
interests, or any rights, warrants or options to acquire any such shares of capital
stock or other equity interests;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) amend or otherwise alter (or propose any amendment or alteration to) the
Governing Documents of New Alkermes or any New Alkermes Group Entity or amend any
terms of the outstanding securities of New Alkermes or any New Alkermes Group
Entity;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) with respect to the Business, New Alkermes and the New Alkermes Group
Entities only, merge or consolidate with any other Person, make any investment in
any other Person, including any joint venture, or acquire the stock or assets or
rights of any other Person other than, in each case, in the Ordinary Course of
Business;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) sell, lease, license, assign, transfer, abandon, convey or otherwise
dispose of (1)&nbsp;any assets, securities, rights or property of New Alkermes or any New
Alkermes Group Entity or (2)&nbsp;any asset, rights or properties used in the Business,
other than in each case (A)&nbsp;sales of inventory and equipment in the Ordinary Course
of Business, (B)&nbsp;transactions that are in the Ordinary Course of Business and not
individually in excess of $1,000,000, (C)&nbsp;transfers of cash and cash equivalents to
or as directed by Elan or (D)&nbsp;transactions set forth on <U>Schedule&nbsp;5.4(a)(v)</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) manage Modified Working Capital and the Net Cash Amount other than in the
Ordinary Course of Business, or take any action for the purpose of changing the
calculation or amount of Modified Working Capital or Net Cash Amount;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) fail to maintain inventory of the Business (as determined in accordance
with U.S. GAAP) at a level between 85% and 115% of inventory reflected on the
Business Balance Sheet;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) with respect to New Alkermes and the New Alkermes Group Entities, incur
any Indebtedness, enter into any new or amend existing facilities relating to
Indebtedness, issue or sell any debt securities or warrants or other rights to
acquire any debt securities or guarantee any debt securities;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->60<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) create or permit the creation of (A)&nbsp;any Lien on the Purchased Interests
or (B)&nbsp;any Lien (other than a Permitted Lien) on any asset of the Business other
than in the Ordinary Course of Business or that would not materially and adversely
affect the ability to conduct the Business following the Closing in the same manner
as currently conducted;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) except in the Ordinary Course of Business, enter into or adopt any new, or
amend or terminate any existing, Employee Plan (including any trust or other funding
arrangement), other than as required by Law;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) except to the extent required by Employee Plans existing on the date of
this Agreement, or as set forth on <U>Section&nbsp;3.20(c)</U> of the Elan Disclosure
Schedule, make any new grants or awards to, vest, accelerate or otherwise modify any
grant, benefit or awards made to, or increase the compensation payable or to become
payable to its officers, directors or employees or pay any severance or bonus not
otherwise due to its officers, directors or employees;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) enter into or forgive any loan to employees, directors, or consultants;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiii) enter into any new collective bargaining agreement or agreement with a
trade union;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xiv) contribute any material amount to any trust or other arrangement funding
any Employee Plan, except to the extent required by the existing terms of such
Employee Plan, trust or other funding arrangement, by any collective bargaining
agreement, by any written employment agreement existing on the date of this
Agreement, or by applicable Law;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xv) (A)&nbsp;adopt a plan of complete or partial liquidation, dissolution, merger,
consolidation, restructuring, recapitalization or other reorganization or (B)&nbsp;enter
into any agreement or exercise any discretion providing for acceleration of payment
or performance as a result of a change of control of New Alkermes or any New
Alkermes Group Entity;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvi) renew or (except pursuant to the transactions set forth on <U>Schedule
5.4(a)(v)</U>) enter into any non-compete, exclusivity or similar agreement that
would restrict or limit the operations of New Alkermes or the New Alkermes Group
Entities or, after the Effective Time, of Alkermes or its Subsidiaries;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xvii) modify in any material respect, amend in any material respect or
terminate any Business Material Contract;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xviii) enter into any contract other than (A)&nbsp;as a result of the transactions
set forth on <U>Schedule&nbsp;5.4(a)(v)</U> or (B)&nbsp;in the Ordinary Course of Business
and that does not require (x)&nbsp;a term in excess of one year or (y)&nbsp;payments by New
Alkermes or any New Alkermes Group Entity in excess of $1,000,000;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->61<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xix) settle or compromise any material litigation relating to the Business
(unless such settlement calls only for the payment of money by Elan or a Continuing
Affiliate), or waive, release or assign any material claims relating to the
Business, including with respect to any Business Intellectual Property Rights;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xx) adopt any change, other than as required by applicable generally accepted
accounting principles, in its accounting policies, procedures or practices;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxi) license (except pursuant to the transactions set forth on <U>Schedule
5.4(a)(v)</U>) or permit any rights to lapse in any Business Intellectual Property
Rights;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxii) with respect to any New Alkermes Group Entity, (A)&nbsp;make any change in
any annual accounting period or adopt or change a method of accounting for Tax
purposes, except as required by applicable Law, (B)&nbsp;make or change any Tax election,
(C)&nbsp;file or amend any Tax Return or (D)&nbsp;enter into any closing agreement, settle any
Tax claim or assessment relating to any of the Elan Parties or any of their
Subsidiaries, surrender any right to claim a refund of Taxes, or consent to any
extension or waiver of the limitation period applicable to any Tax claim or
assessment relating to any Elan Party or any of its Subsidiaries, other than
elections, filings, settlements, closing agreements, extensions or waivers made in
the Ordinary Course of Business;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxiii) fail to make any capital expenditures with respect to the Business
consistent with the Ordinary Course of Business; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xxiv) agree or commit to do any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<I>Conduct by Alkermes</I>. Alkermes agrees that from the date hereof until the Effective Time,
except as set forth in <U>Section&nbsp;5.4</U> of the Alkermes Disclosure Schedule, as expressly
contemplated by this Agreement (including actions taken pursuant to <U>Section&nbsp;5.2</U> or as
required by applicable Law), or as otherwise agreed to in writing by Elan (such consent not to be
unreasonably withheld or delayed), the business of Alkermes and its Subsidiaries shall be conducted
in the ordinary and usual course and, to the extent consistent therewith (and subject to the
restrictions set forth in this <U>Section&nbsp;5.4(b)</U>), Alkermes and its Subsidiaries will use all
reasonable best efforts to preserve and maintain existing relations and goodwill with employees,
customers, brokers, suppliers and other Persons with which Alkermes and its Subsidiaries as a group
have significant business relations. Without limiting the foregoing, Alkermes agrees, as to itself
and its Subsidiaries, that, from the date hereof until the Effective Time, except as set forth in
<U>Section&nbsp;5.4</U> of the Alkermes Disclosure Schedule, as expressly contemplated by this
Agreement (including actions taken pursuant to <U>Section&nbsp;5.2</U> or as required by applicable
Law), or as otherwise agreed to in writing by Elan, Alkermes shall not and shall cause its
Subsidiaries not to, directly or indirectly do, or commit to do, any of the following:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) in the case of Alkermes only, amend or otherwise change its Governing
Documents, or amend, modify or terminate the Alkermes Rights Agreement;
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->62<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) in the case of Alkermes only, (A)&nbsp;declare, set aside, make or pay any
dividend or other distribution, payable in stock, with respect to any of its capital
stock, (B)&nbsp;split, combine or reclassify its outstanding shares of capital stock, or
(C)&nbsp;repurchase, redeem or otherwise acquire, except in connection with any employee
benefit plans or arrangements and except pursuant to Alkermes&#146; ongoing stock
repurchase program or hedging activities, or permit any of its Subsidiaries to
purchase or otherwise acquire, any shares of Alkermes&#146; capital stock or any
securities convertible into or exchangeable or exercisable for any shares of
Alkermes&#146; capital stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) in the case of Alkermes only, adopt a plan of complete or partial
liquidation or dissolution;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) in the case of Alkermes only, issue, sell, pledge, dispose of or encumber
any shares of, or securities convertible into or exchangeable for, or options,
warrants, calls, commitments or rights of any kind to acquire, any shares of its
capital stock of any class or other equity interests, other than (A)&nbsp;issued upon the
exercise of Alkermes Options or other rights outstanding as of the date hereof, (B)
issuable pursuant to any employee option or benefit plan or arrangement, (C)&nbsp;issued
in connection with any merger, consolidation or acquisition permitted by clause
<U>(v)</U> below, and (D)&nbsp;issued in other issuances that do not, in the aggregate,
represent more than 5% of the outstanding Alkermes Common Stock;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) acquire by merger, consolidation or acquisition of stock or assets (from
any Person other than Alkermes or a Subsidiary of Alkermes) any corporation,
partnership or other business organization or division thereof if such acquisition
would be reasonably likely to prevent the Merger from occurring prior to the
Termination Date; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) agree or commit to do any of the foregoing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.5. <U>Public Announcements</U>. The Parties shall cooperate in promptly issuing
the joint announcement of the execution of this Agreement in the Agreed Form as attached as
<U>Schedule&nbsp;H</U>. Subject to their respective legal obligations (including requirements of stock
exchanges and other similar regulatory bodies), Alkermes and Elan will consult with each other
before issuing, or permitting any agent or Affiliate to issue (and will use reasonable best efforts
to agree upon the text of), any other press releases or otherwise making or permitting any agent or
Affiliate to make, any public statements with respect to this Agreement and the transactions
contemplated hereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.6. <U>Guarantees</U>. New Alkermes shall use its reasonable best efforts to cause
itself or one or more of its Affiliates to be substituted in all respects for Elan or any
Continuing Affiliate, effective as of the Closing, in respect of all obligations of Elan and any
Continuing Affiliate under each of the guarantees, bonding arrangements, letters of credit and
letters of comfort given by Elan or any of its Continuing Affiliates for the benefit of New
Alkermes, the New Alkermes Group Entities or the Business, which guarantees, performance
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->63<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">bonds, letters of credit and letters of comfort are set forth in <U>Section&nbsp;5.6</U> of the
Elan Disclosure Schedule. Elan shall use its reasonable best efforts to cause itself or one or
more of the Continuing Affiliates to be substituted in all respects for New Alkermes or any New
Alkermes Group Entity, effective as of the Closing, in respect of all obligations of any of New
Alkermes or any New Alkermes Group Entity under each guarantee, bonding arrangement, letter of
credit and letter of comfort given by New Alkermes or any of the New Alkermes Group Entities for
the benefit of Elan or any of the Continuing Affiliates and not related to the Business.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.7. <U>Affiliate Agreements</U>. (a)&nbsp;Except for this Agreement, the Ancillary
Agreements, those agreements set forth on <U>Section&nbsp;5.7</U> of the Elan Disclosure Schedule or as
otherwise provided by <U>Section&nbsp;5.7(b)</U>, Elan shall, and shall cause its Subsidiaries to,
terminate all Affiliate Agreements at or prior to the Effective Time, in each case without any
remaining Liability of any kind on the part of New Alkermes or any New Alkermes Group Entity as a
result of or in connection with such termination or such Affiliate Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Elan shall, or shall cause the relevant Continuing Affiliate to, enter into a research,
development and manufacturing agreement with New Alkermes in respect of ELN005 (the &#147;<U>ELN005
Agreement</U>&#148;), which agreement shall be reasonably acceptable to Alkermes and be on terms and
conditions that, in the aggregate, are no less favorable to New Alkermes, the New Alkermes Group
Entities and their respective Subsidiaries (including, after the Closing, the Surviving
Corporation) than could have been obtained from unrelated Persons in a similar agreement entered
into on an arm&#146;s length commercial basis as of the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.8. <U>No Solicitation</U>. (a)&nbsp;Until the earlier of (i)&nbsp;the Closing and (ii)&nbsp;the
date of termination of this Agreement pursuant to <U>Section&nbsp;10.1</U>, the Elan Parties shall not,
and shall not authorize or permit any of their respective Subsidiaries or any of their or their
Subsidiaries&#146; respective Representatives or Affiliates to, directly or indirectly, take any of the
following actions: (A)&nbsp;solicit, initiate, encourage or facilitate any EDT Acquisition Proposal or
EDT Alternative Transaction, (B)&nbsp;participate in any discussions or negotiations relating to, assist
or cooperate with any Person (other than Alkermes and its designees) to make, or furnish any Person
(other than Alkermes and its designees) with information in connection with, or take any other
action to facilitate, any EDT Acquisition Proposal or EDT Alternative Transaction, (C)&nbsp;disclose any
information to any Person (other than Alkermes and its designees) concerning the business,
technologies or properties of the Business, or afford to any Person (other than Alkermes and its
designees) access to the properties, technologies or Books and Records of the Business, other than
in the Ordinary Course of Business or as required by applicable Law, or (D)&nbsp;propose, authorize or
enter into any agreement or understanding (whether binding or nonbinding, written or oral) relating
to, or engage in or consummate, any EDT Alternative Transaction or any agreement or understanding
requiring the Elan Parties to abandon, terminate or fail to consummate the Merger and the other
transactions contemplated by this Agreement or breach their obligations hereunder, except, in the
case of clause <U>(B)</U>, for any notification by Elan to any such Person that Elan is
contractually restricted from engaging in any such discussions or negotiations. Elan shall
promptly (but in any event within one (1)&nbsp;Business Day) notify Alkermes orally and in writing of
any EDT Acquisition Proposal or any inquiry regarding the making of any EDT Acquisition Proposal or
request for disclosure or access reasonably likely to be related to the making of an EDT
Acquisition Proposal, indicating, in connection with such notice, the identity of the Person making
such EDT Acquisition Proposal or inquiry or request
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->64<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">and the terms and conditions of any such EDT Acquisition Proposal or inquiry or request,
including all written documentation relating thereto. Elan agrees that it shall take the necessary
steps promptly to inform its Subsidiaries and any of its or their Representatives or Affiliates of
the obligations undertaken by it in this <U>Section&nbsp;5.8(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Until the earlier of (i)&nbsp;the Closing and (ii)&nbsp;the date of termination of this Agreement
pursuant to the provisions of <U>Section&nbsp;10.1</U>, Alkermes shall not, and shall not authorize or
permit any of its Subsidiaries or any of its or its Subsidiaries&#146; respective Representatives or
Affiliates to, directly or indirectly, take any of the following actions: (A)&nbsp;solicit, initiate,
encourage or facilitate any Alkermes Acquisition Proposal or Alkermes Alternative Transaction, (B)
participate in any discussions or negotiations relating to, assist or cooperate with any Person
(other than Elan and its designees) to make, or furnish any Person (other than Elan and its
designees) with information in connection with, or take any other action to facilitate, any
Alkermes Acquisition Proposal or Alkermes Alternative Transaction, (C)&nbsp;disclose any information to
any Person (other than Elan and its designees) concerning the business, technologies or properties
of Alkermes, or afford to any Person (other than Elan and its designees) access to the properties,
technologies or Books and Records of Alkermes, other than in the Ordinary Course of Business or as
required by applicable Law, of (D)&nbsp;propose, authorize or enter into any agreement or understanding
(whether binding or nonbinding, written or oral) relating to, or engage in or consummate, any
Alkermes Alternative Transaction or any agreement or understanding requiring Alkermes to abandon,
terminate or fail to consummate the Merger and the other transactions contemplated by this
Agreement or breach its obligations hereunder, except, in the case of clause <U>(B)</U>, for any
notification by Alkermes to any such Person that Alkermes is contractually restricted from engaging
in any such discussions or negotiations. Alkermes shall promptly (but in any event within one (1)
Business Day) notify Elan orally and in writing of any Alkermes Acquisition Proposal or any inquiry
regarding the making of any Alkermes Acquisition Proposal or request for disclosure or access
reasonably likely to be related to the making of an Alkermes Acquisition Proposal, indicating, in
connection with such notice, the identity of the Person making such Alkermes Acquisition Proposal
or inquiry or request and the terms and conditions of any such Alkermes Acquisition Proposal or
inquiry or request, including all written documentation relating thereto. Alkermes agrees that it
shall take the necessary steps promptly to inform its Subsidiaries and any of its or their
Representatives or Affiliates of the obligations undertaken by it in this <U>Section&nbsp;5.8(b)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.9. <U>Non-Compete; Employment Non-Solicitation</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Elan agrees that for the period commencing at the Closing and expiring on the third
(3<SUP style="FONT-size: 85%; vertical-align: text-top">rd</SUP>) anniversary of the Closing, neither it nor any of its Subsidiaries shall, either
directly or indirectly, alone or with others, (i)&nbsp;engage in any Competing Business, (ii)&nbsp;own an
interest in (whether as a stockholder, member or partner, but in each case excluding any such
interest not exceeding 5% of any class of security that is listed and traded on any national or
international securities exchange), or manage, operate, or Control, or participate in or be
connected with as a director, any Person engaged in a Competing Business (other than New Alkermes
and its Affiliates), or (iii)&nbsp;manufacture, market or distribute, or allow the manufacturing,
marketing or distributing of, any products or services under, or use in any way, the Transferred IP
in connection with a Competing Business. Notwithstanding the foregoing, it shall not be a
violation of this <U>Section&nbsp;5.9(a)</U> if Elan or any Affiliate thereof licenses drug
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->65<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">delivery technology from another Person or develops any drug delivery technology itself, in
each case, for use by Elan and its Affiliates in the production of pharmaceutical products by Elan
and its Affiliates. Notwithstanding the foregoing, if any Person that is already engaged in a
Competing Business shall, in a single transaction or in a related series of transactions, whether
by way of purchase, acquisition, tender, exchange or other similar offer or recapitalization,
reclassification, consolidation, merger, share exchange, scheme of arrangement or other business
combination transaction, acquire Beneficial Ownership of more than fifty percent (50%) of the
combined voting power of the outstanding capital stock entitled to vote generally in the election
of directors of Elan, such acquisition and the continued operation by such Person of its existing
Competing Business shall not be deemed a violation of this <U>Section&nbsp;5.9(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Until the eighteen (18)&nbsp;month anniversary of the Closing, Elan and its Affiliates shall
not, directly or indirectly, (i)&nbsp;solicit for employment or any similar arrangement any New Alkermes
Employee or (ii)&nbsp;hire any New Alkermes Employee; <U>provided</U>, that this <U>Section&nbsp;5.9(b)</U>
shall not apply to New Alkermes Employees whose employment has been terminated by New Alkermes and
its Subsidiaries and clause <U>(i)</U> hereof shall not prohibit general solicitations for
employment through advertisements or other means not targeted specifically to New Alkermes
Employees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.10. <U>Notices of Certain Events</U>. Prior to the Closing, each of the Elan
Parties, on the one hand, and Alkermes, on the other hand, shall (and shall cause their
Subsidiaries to) promptly notify the other of (a)&nbsp;the occurrence of any event that is likely to
cause any representation or warranty of Elan or Alkermes, as the case may be, contained in this
Agreement be inaccurate or untrue at or prior to the Closing, and (b)&nbsp;any failure of the Elan
Parties or Alkermes, as the case may be, to comply with or satisfy any covenant, condition or
agreement to be complied with or satisfied by it under this Agreement; <U>provided</U>, that the
delivery of any notice or the making of any disclosure pursuant to this <U>Section&nbsp;5.10</U> shall
not (i)&nbsp;limit or otherwise affect any rights or remedies to the party receiving such notice or (ii)
be deemed to amend or supplement the Elan Disclosure Schedule or the Alkermes Disclosure Schedule,
as the case may be, or prevent or cure any misrepresentation, breach of warranty or breach of
covenant.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.11. <U>Preparation of SEC Documents</U>. (a)&nbsp;Each of Alkermes and Elan shall
cooperate and promptly prepare and Alkermes shall file a preliminary form of the proxy statement to
be sent to Alkermes shareholders in connection with the Alkermes Shareholders Meeting (the
&#147;<U>Alkermes Proxy Statement</U>&#148;) and Elan shall file, or cause New Alkermes to file, the
Registration Statement. Alkermes will cause the Alkermes Proxy Statement to comply as to form in
all material respects with the applicable provisions of the Exchange Act and the rules and
regulations thereunder. Elan will cause the Registration Statement to comply as to form in all
material respects with the applicable provisions of the Securities Act and the rules and
regulations thereunder. Each of Alkermes and Elan shall use its respective reasonable best efforts
to have the Alkermes Proxy Statement cleared by the SEC as promptly as practicable after such
filing. Alkermes will advise Elan, promptly after it receives notice thereof, of any request by
the SEC for amendment of the Alkermes Proxy Statement or comments thereon. Each of Alkermes and
Elan shall use reasonable best efforts to have the Registration Statement declared effective under
the Securities Act as long as necessary to consummate the Merger and the other transactions
contemplated hereby. Elan will advise Alkermes, promptly after it
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->66<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">receives notice thereof, of any request by the SEC for amendment of the Registration Statement
or comments thereon. The Parties shall take any action required to be taken under any applicable
state securities Laws in connection with the issuance of New Alkermes Ordinary Shares in the
Merger, and Alkermes shall furnish all information concerning Alkermes and the holders of Alkermes
Common Stock as may be reasonably requested in connection with any such action.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;No filing of, or amendment or supplement to, the Registration Statement or the Alkermes
Proxy Statement will be made by the Elan Parties or Alkermes, as applicable, without the prior
consent of the other Parties (which shall not be unreasonably withheld, delayed or conditioned) and
without providing the other Parties the opportunity to review and comment thereon. The Parties
will advise the other Parties promptly after receiving oral or written notice thereof, of the time
when the Registration Statement has become effective or any supplement or amendment has been filed,
the issuance of any stop order, the suspension of the qualification of the New Alkermes Ordinary
Shares issuable in connection with the Merger for offering or sale in any jurisdiction, or any oral
or written request by the SEC for amendment of the Alkermes Proxy Statement or the Registration
Statement or comments thereon and responses thereto or requests by the SEC for additional
information and will promptly provide the other Parties with copies of any written communication
from the SEC or any state securities commission.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Alkermes and Elan each agrees, as to itself and its Affiliates, that none of the
information supplied or to be supplied by it or its Affiliates for inclusion or incorporation by
reference in the Alkermes Proxy Statement or the Registration Statement, and any amendments or
supplements to each of them will, at the date of mailing to shareholders and at the time or times
of the Alkermes Shareholders Meeting, contain any untrue statement of a material fact or omit to
state any material fact required to be stated therein or necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. If at any
time prior to the Effective Time any information relating to Alkermes or Elan, or any of their
respective Affiliates, officers or directors, should be discovered by Alkermes or Elan to be
inaccurate or to have been omitted that should be set forth in an amendment or supplement to the
Registration Statement or the Alkermes Proxy Statement, so that any such documents would not
include any misstatement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein, in the light of the circumstances under
which they were made, not misleading, the Party that discovers such information shall promptly
notify the other Parties and, to the extent required by applicable Law, an appropriate amendment or
supplement describing such information shall be filed promptly with the SEC and, to the extent
required by Law, disseminated to the Alkermes shareholders.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Alkermes will use its reasonable best efforts to cause the Alkermes Proxy Statement to be
mailed to its shareholders as promptly as practicable after the Registration Statement is declared
effective under the Securities Act.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.12. <U>Shareholder Meetings; Board Recommendations</U>. (a)&nbsp;Alkermes will take
all action necessary to convene a meeting of the shareholders of Alkermes at which the shareholders
of Alkermes shall consider the approval and adoption of the Plan of Merger contained in this
Agreement (the &#147;<U>Alkermes Shareholders Meeting</U>&#148;) as promptly as practicable
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->67<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">after the Alkermes Proxy Statement has been cleared, and the Registration Statement has been
declared effective, by the SEC.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Subject to the requirements of applicable Law, the board of directors of Alkermes shall
recommend to its shareholders the approval and adoption of the matters to be submitted to its
shareholders at the Alkermes Shareholders Meeting, which recommendation shall be set forth in the
Alkermes Proxy Statement and the Registration Statement, and shall use reasonable best efforts to
solicit such approval. Notwithstanding the foregoing, the board of directors of Alkermes may omit
its recommendation from such documents or withdraw or modify its recommendation if, prior to
receipt of the Alkermes Shareholder Approval, the board of directors of Alkermes receives an
Alkermes Acquisition Proposal as to which the board of directors of Alkermes determines in good
faith, after consultation with its financial advisors and outside counsel, that (A)&nbsp;the Alkermes
Alternative Transaction contemplated by such Alkermes Acquisition Proposal is superior to the
transactions provided for by this Agreement from a financial point of view to Alkermes and its
shareholders and (B)&nbsp;the failure to take such action would be inconsistent with its fiduciary
duties to the shareholders of Alkermes under applicable Law; and
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Alkermes Shareholders Meeting shall be held for the purposes of seeking and obtaining
the approval of the shareholders of Alkermes of the requisite proposals needed for the approval of
this Agreement and the consummation of transactions contemplated hereby, regardless of any Alkermes
Change in Recommendation, unless this Agreement is terminated pursuant to <U>Section&nbsp;8.1</U> prior
to such meetings.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.13. <U>Stock Exchange Listing</U>. New Alkermes shall use its reasonable best
efforts to cause the New Alkermes Ordinary Shares to be issued in the Merger to be approved for
listing on NASDAQ, subject to official notice of issuance, prior to the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.14. <U>Insurance</U>. From the date hereof to the Effective Time, Elan and
Alkermes will cooperate reasonably to develop and implement a transition plan with respect to
insurance coverage for New Alkermes and the New Alkermes Group Entities, with the goal of ensuring
continuing insurance coverage through the Effective Time and transfer at the Effective Time of the
responsibility for risk management relating to New Alkermes and the New Alkermes Group Entities
from Elan and the Continuing Affiliates to New Alkermes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.15. <U>Indebtedness</U>. Elan shall cause New Alkermes and its Subsidiaries
(including, for these purposes U.S. Acquired Entities), at the Closing, to have no Indebtedness
(other than Elan Reorganization Indebtedness and Indebtedness in respect of the IP Transfer Loan
Note).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.16. <U>Alkermes Common Stock</U>. During the period from the date hereof to the
Closing, Elan shall not, and shall cause each of its Affiliates not to, directly or indirectly,
alone or in concert with any other Person, acquire, offer to acquire or agree to acquire Beneficial
Ownership of any shares of Alkermes Common Stock.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->68<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.17. <U>Resignations</U>. Elan shall use its reasonable best efforts to cause each
officer or director of New Alkermes and the New Alkermes Group Entities to resign in such capacity,
other than individuals identified by Alkermes as continuing in such capacity following the Closing,
such resignations to be effective as of the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.18. <U>Designated Assets</U>. Alkermes shall have the right to designate certain
of the Excluded Assets owned by EDDI as Business Assets (the &#147;<U>Designated Assets</U>&#148;) to be
included in the Reorganization Transfers and included in the Business Assets at the Closing, in
which case Elan shall and shall cause its Subsidiaries to take all necessary steps to include such
Designated Assets in the Reorganization Transfers and in the Business Assets as of the Closing.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.19. <U>Directors and Officers Indemnification</U>. Alkermes and Elan agree that
all rights to exculpation, indemnification and advancement of expenses for acts or omissions
occurring at or prior to the Closing, whether asserted or claimed prior to, at or after the
Closing, now existing in favor of the current or former directors, officers or employees, as the
case may be, of Alkermes or its Subsidiaries, or of any New Alkermes Group Entity (whether provided
in the respective Governing Documents of such entity or in any agreement as in effect on the date
hereof) shall survive the Closing and remain in full force and effect. Alkermes and Elan shall use
their reasonable best efforts to cause New Alkermes or one of its Subsidiaries to enter into
agreements effective as from the Closing with the directors, company secretary and officers of New
Alkermes providing such individuals with such exculpation, indemnification and advancement of
expenses in respect of claims against such individual in such capacity as may, under applicable
Law, be provided by such entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.20. <U>Additional Financial Statements</U>. (a)&nbsp;As promptly as practicable
following the execution of this Agreement (using reasonable best efforts to comply by June&nbsp;17,
2011), Elan shall deliver to Alkermes true and complete copies of the Audited Financial Statements
along with selected financial data for the five years ended December&nbsp;31, 2010, as required by
Regulation&nbsp;S-X under the Securities Act, the information for the first two years of such period
need not be audited.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;From the date hereof through the Effective Time, Elan shall furnish to Alkermes,
concurrently with the delivery thereof to management of Elan or any of its Subsidiaries, such
monthly, quarterly and annual financial statements and data relating to the Business as are
prepared for distribution to management of Elan or any its Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.21. <U>Financing</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Alkermes shall use its reasonable best efforts to take, or cause to be taken, all actions,
and to do, or cause to be done, all things reasonably necessary to consummate and obtain the
Financing on the terms and conditions described in the Commitment Letter, including using
reasonable best efforts to (i)&nbsp;maintain in effect the Commitment Letter and, if entered into prior
to the Closing, the definitive documentation with respect to the Financing contemplated by the
Commitment Letter (the &#147;<U>Definitive Financing Agreements</U>&#148;), and (ii)&nbsp;negotiate and execute
Definitive Financing Agreements on terms and conditions contemplated by the Commitment Letter
(including any &#147;flex&#148; provisions contained therein), and, upon execution thereof, deliver a
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->69<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">copy thereof to Elan. In the event that all conditions to the Financing have been satisfied,
Alkermes shall use its reasonable best efforts to cause the lenders and the other Persons providing
such Financing to fund on the Closing Date the portion of the Financing required to pay the Cash
Payment, including using its reasonable best efforts to enforce its rights under the Commitment
Letter, to cause such lenders or other Persons to fund such portion of the Financing. Alkermes
shall have the right from time to time to amend, replace, supplement or otherwise modify, or waive
any of its rights under, the Commitment Letter or Definitive Financing Agreements, and/or
substitute other debt or equity financing for all or any portion of the Financing from the same
and/or alternative financing sources; <U>provided</U>, that any such amendment, replacement,
supplement or other modification to or waiver of any provision of the Commitment Letter or
Definitive Financing Agreements that amends the Financing and/or substitution of all or any portion
of the Financing (A)&nbsp;shall not expand upon the conditions precedent or contingencies to the
Financing as set forth in the Commitment Letter and (B)&nbsp;would not reasonably be expected to prevent
or impede or delay the availability of the Financing and/or the consummation of the Transactions
and the transactions contemplated by this Agreement. Alkermes shall be permitted to reduce the
amount of Financing under the Commitment Letter or Definitive Financing Agreements in its
reasonable discretion; <U>provided</U>, <U>further</U>, that Alkermes shall not reduce the
committed amount of the Financing to an amount below the amount that is required, together with the
financial resources of Alkermes, including cash on hand of Alkermes, to pay the Cash Payment;
<U>provided,</U> <U>further,</U> that any such reduction (A)&nbsp;shall not expand upon the conditions
precedent or contingencies to the Financing as set forth in the Commitment Letter and (B)&nbsp;would not
reasonably be expected to prevent or impede or delay the availability of the Financing and/or the
consummation of the Transactions and the transactions contemplated by this Agreement. If any
portion of the Financing becomes unavailable or Alkermes becomes aware of any event or circumstance
that makes any portion of the Financing unavailable, in each case, on the terms and conditions
contemplated in the Commitment Letter (including any &#147;flex&#148; provisions contained therein), and such
portion is reasonably required to pay the Cash Payment, Alkermes shall use its reasonable best
efforts to arrange and obtain as promptly as practicable following the occurrence of such event
alternative financing from the same and/or alternative financing sources in an amount sufficient to
pay the Cash Payment upon conditions no less favorable to Alkermes and its Subsidiaries than those
contained in the Commitment Letter and, if obtained, will provide Elan with a copy of the
documentation with respect to such alternative financing. Alkermes shall give Elan prompt oral and
written notice (but in any event not later than twenty-four (24)&nbsp;hours) after Alkermes becoming
aware of the occurrence of any material breach by any party to the Commitment Letter or Definitive
Financing Agreements or of any condition not likely to be satisfied, or of any termination or
waiver, amendment or other modification of the Commitment Letter. Alkermes shall keep Elan
informed on a reasonably current basis of the status of its efforts to arrange, obtain and/or
consummate the Financing and shall provide copies of the principal documents related to the
Financing (excluding fee letters, except excerpts of those portions thereof that contain any
conditions to funding or &#147;flex&#148; provisions (excluding provisions related solely to fees and
economic terms)). For the avoidance of doubt, the syndication of the Financing to the extent
permitted by the Commitment Letter shall not be deemed to violate Alkermes&#146; obligations under this
Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Elan shall, and shall cause its Subsidiaries to, and shall use its reasonable best efforts
to cause each of its and their respective Representatives, including legal, tax, regulatory and
accounting, to provide all cooperation reasonably requested by Alkermes and/or
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->70<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Financing Parties in connection with the Financing (provided that such requested
cooperation does not unreasonably interfere with the ongoing operations of Elan and its
Subsidiaries), including
</DIV>



<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) providing information relating to the Business to Alkermes and the lenders
and other financial institutions and investors that are or may become parties to the
Financing (including the parties to the Commitment Letter and the Definitive
Financing Agreements) (the &#147;<U>Financing Parties</U>&#148;) (including information to be
used in the preparation of an information package regarding the business,
operations, financial projections and prospects of the Business customary for such
financing or reasonably necessary for the completion of the Financing by the
Financing Parties) to the extent reasonably requested by Alkermes to assist in
preparation of customary offering or information documents to be used for the
completion of the Financing as contemplated by the Commitment Letter or the
Definitive Financing Agreements, including, in addition (to the extent different) to
the financial statements required to be delivered pursuant to <U>Section
5.20(a)</U>, all information and data necessary to satisfy the conditions set forth
in paragraphs 3 and 4 of Exhibit&nbsp;C of the Commitment Letter (information and data
required to be delivered pursuant to this clause <U>(i)</U> being referred to as
the &#147;<U>Required Financial Information</U>&#148;);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) participating, upon reasonable notice, in a reasonable number of meetings
(including customary one-on-one meetings with the parties acting as lead arrangers
for the Financing and senior management and Representatives, with appropriate
seniority and expertise, of Elan), presentations, road shows, drafting sessions, due
diligence sessions (including accounting due diligence sessions) and sessions with
the rating agencies;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) assisting in the preparation of customary documents and materials,
including (A)&nbsp;any customary offering documents and bank information memoranda
(including public and private versions thereof) for the Financing, and (B)&nbsp;materials
for rating agency presentations;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) cooperating with the marketing efforts for the Financing (including
consenting to the use of Elan&#146;s and its Subsidiaries&#146; logos to the extent used in
the Business; <U>provided</U>, that such logos are used solely in a manner that is
not intended to or reasonably likely to harm or disparage Elan or its Subsidiaries,
including the Business, or the reputation or goodwill of Elan or any of its
Subsidiaries, including the Business);
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(v) assisting in the preparation of, and causing New Alkermes and the New
Alkermes Group Entities to execute and deliver (or using reasonable best efforts to
obtain from its advisors), customary certificates, comfort letters, legal opinions,
surveys, title insurance or other documents and instruments relating to guarantees
or security interests and other matters ancillary to the Financing, in each case on
terms reasonably satisfactory to Elan and as may be reasonably requested by Alkermes
and necessary and customary in connection with the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->71<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">Financing; <U>provided</U>, that no obligation of New Alkermes or any New
Alkermes Group Entity under any such document or instrument shall be effective until
the Effective Time;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vi) reasonably cooperating with Alkermes&#146; legal counsel in connection with any
legal opinions that such legal counsel may be required to deliver in connection with
the Financing;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(vii) assisting in the preparation of, and causing New Alkermes and the New
Alkermes Group Entities to execute and deliver, one or more credit agreements,
indentures, pledge and security documents, mortgages, guarantees, currency or
interest hedging agreements, and any other definitive financing documents, in each
case on terms reasonably satisfactory to Elan and as may be reasonably requested by
Alkermes and necessary and customary in connection with the Financing;
<U>provided</U>, that no obligation of New Alkermes or any New Alkermes Group
Entity under any such document or instrument shall be effective until the Effective
Time;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(viii) using its reasonable best efforts, as appropriate, to have its
independent accountants, consistent with their customary practice, provide their
reasonable cooperation and assistance, including participation in due diligence
sessions on customary terms and consistent with their customary practices in
connection with financings similar to the Financing;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ix) using its reasonable best efforts to permit any cash and marketable
securities included in the Business and any stock certificates or instruments of New
Alkermes and any New Alkermes Group Entity to be pledged or made available to
Alkermes at the Closing;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(x) providing authorization letters to the Financing Parties authorizing the
distribution of information to prospective lenders and containing a representation
to the Financing Parties that the public side versions of such documents, if any, do
not include material non-public information about Elan or its Affiliates or
securities;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xi) cooperating reasonably with the Financing Parties&#146; due diligence and
investigation (including the Financing Parties&#146; evaluation of the Business&#146;s
inventory, current assets, cash management and accounting systems, policies and
procedures relating thereto for the purpose of establishing collateral arrangements
and with their efforts to obtain guarantees from New Alkermes and the New Alkermes
Group Entities and obtaining perfected first-priority security interests in the
assets included in the Business intended to constitute collateral securing the
Financing, with such cooperation occurring prior to or simultaneously with the
Closing, but the execution of any guarantees or security arrangements not taking
effect until the Closing, in each case, to the extent customary and reasonable and
to the extent not unreasonably interfering with the business of Elan and its
Subsidiaries; and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->72<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(xii) providing all documentation and other information about Elan and each of
its Subsidiaries as is reasonably requested in writing by Alkermes at least ten days
prior to the Closing Date in connection with the Financing and relating to
applicable &#147;know your customer&#148; and anti-money laundering rules and regulations
including the USA PATRIOT Act; <U>provided</U>, that, notwithstanding anything in
this <U>Section&nbsp;5.21(b)</U> to the contrary, until the Effective Time occurs, none
of New Alkermes, the New Alkermes Group Entities or any of their respective
Subsidiaries shall (A)&nbsp;be required to pay any commitment or other similar fee
relating to the Financing, (B)&nbsp;have any liability or any obligation under any credit
agreement or any related document or any other agreement, document, certificate or
representation related to the Financing or (C)&nbsp;be required to incur any other
Liability in connection with the Financing; <U>provided</U>, <U>further,</U> that
all non-public or other confidential information provided by Elan or any of its
Representatives pursuant to this <U>Section&nbsp;5.21(b)</U> shall be kept confidential
in accordance with the Confidentiality Agreement, except that Alkermes shall be
permitted to disclose such information to Lenders, prospective Lenders, Moody&#146;s
Investors Service, Inc. and Standard &#038; Poor&#146;s Rating Services on a confidential
basis in connection with the Financing in accordance with the Commitment Letter.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Alkermes (i)&nbsp;shall promptly, upon request by Elan, reimburse Elan for all reasonable
out-of-pocket costs (including reasonable attorneys&#146; and accountants&#146; fees) incurred by Elan, any
of its Subsidiaries or their respective Representatives in connection with the cooperation of Elan,
its Subsidiaries and their respective Representatives contemplated by this <U>Section&nbsp;5.21</U>
(other than in connection with the provision of the Required Financial Information), (ii)
acknowledges and agrees none of New Alkermes, the New Alkermes Group Entities or their respective
Subsidiaries and their respective Representatives shall incur any liability to any Person prior to
the Effective Time under the Financing and (iii)&nbsp;shall indemnify and hold harmless Elan, its
Subsidiaries and their respective Representatives from and against any and all losses, damages,
claims, costs or expenses suffered or incurred by any of them in connection with the arrangement of
the Financing and any information used in connection therewith, except (A)&nbsp;with respect to any
information provided by Elan or any of its Subsidiaries in writing for inclusion in customary
offering documents and (B)&nbsp;to the extent the same is the result of willful misconduct by Elan, any
such Subsidiary or their respective Representatives.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;In the event that the Commitment Letter or Definitive Financing Agreements are amended,
replaced, supplemented or otherwise modified, including as a result of obtaining alternative
financing or if Alkermes substitutes other debt or equity financing for all or a portion of the
Financing in accordance with <U>Section&nbsp;5.21(a)</U>, each of Alkermes and Elan shall comply with
its covenants in <U>Section&nbsp;5.21(a)</U> and <U>Section&nbsp;5.21(b)</U> respectively, with respect to
the Commitment Letter or Definitive Financing Agreements, as applicable, as so amended, replaced,
supplemented or otherwise modified and with respect to such other debt or equity financing to the
same extent that Alkermes and Elan would have been obligated to comply with respect to the
Financing. References to &#147;Financing&#148; shall include the financing contemplated under the Commitment
Letter as permitted by this <U>Section&nbsp;5.21(d)</U> to be amended, modified, or replaced and
references to &#147;Commitment Letter&#148; shall include such documents as permitted by this
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->73<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>Section&nbsp;5.21(d)</U> to be amended, modified or replaced, in each case from and after such
amendment, modification or replacement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Elan shall and shall cause its Subsidiaries to use their respective reasonable best
efforts to ensure that, insofar as required in order to address any Irish financial assistance
issues arising under the steps provided in <U>Schedule&nbsp;1</U>, the validation procedure provided
for under Section&nbsp;60 of the Irish Companies Act 1963 is undertaken by New Alkermes as soon as
possible after the date of this Agreement, and in any event prior to the Registration Statement
being filed with the SEC, and by Interco prior to the Closing, and Alkermes shall provide such
information as Elan and New Alkermes may reasonably require, including, in the case of New
Alkermes, a working capital statement approved by the board of directors of Alkermes, prepared by a
reputable international accounting firm acceptable to Elan and the board of directors of New
Alkermes, and in a form acceptable to Elan and the board of directors of New Alkermes, in respect
of a period of not more than 18&nbsp;months following the making of any statutory declaration given in
respect of any such validations. In respect of the validation for New Alkermes, such information
is to be provided as promptly as possible and in any event within twenty (20)&nbsp;Business Days of the
date hereof. Any information required in respect of the validation for Interco will be provided no
less than fifteen (15)&nbsp;Business Days prior to the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.22. <U>Re-registration</U>. Elan shall, or shall cause its Subsidiaries to, use
reasonable best efforts to ensure that all necessary filings are prepared and made as required
under the Irish Companies (Amendment) Act 1983 in order to effect the re-registration of New
Alkermes as a public limited company prior to the Registration Statement being filed with the SEC.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.23. <U>Change of Name of Antler Science One Public Limited Company</U>. Elan shall
procure that the name of Antler Science One Public Limited shall be amended to Alkermes Public
Limited Company in accordance with the provisions of Section&nbsp;23 of the Irish Companies Act 1963 and
that all necessary filings in respect of this change of name will be filed with the Irish Companies
Registration Office on the date of this Agreement. Furthermore, Elan shall, and shall cause its
Subsidiaries to, object to any letter requesting its consent to the use of the name &#147;Alkermes&#148; in
the name of any entity registered in Ireland with the Irish Companies Registration Office, unless
such request is from Alkermes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.24. <U>Reduction of Share Capital</U>. Elan shall procure that a resolution of the
shareholders of New Alkermes is passed prior to the Closing permitting a reduction of the share
premium account of New Alkermes in order to allow an application to be made under Section&nbsp;72 of the
Irish Companies Act 1963 to the Irish High Court to allow for the creation of distributable
reserves, the wording of such resolution to be subject to the prior approval of Alkermes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.25. <U>Acquisition of Ordinary Shares of New Alkermes Denominated in Euro</U>.
Elan shall procure that all ordinary shares of New Alkermes denominated in euro and in issue prior
to the Closing will be acquired by New Alkermes for nil consideration pursuant to section 41(2) of
the Irish Companies (Amendment) Act 1983, or otherwise, before the Closing and that all necessary
filings will be made in respect thereof.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->74<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.26. <U>Purchase of Own Shares and Re-issue of Treasury Shares</U>. Elan shall
procure that resolutions of the shareholders of New Alkermes are passed prior to the Closing
authorizing New Alkermes, subject to the provisions of the Irish Companies Act 1990, to effect
market purchases of its own shares and to determine the price at which any shares of New Alkermes
held in treasury, as defined under the Irish Companies Act 1990, may be reissued, the wording of
such resolutions to be subject to the prior approval of Alkermes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.27. <U>Transfer and Assumption of Alkermes Equity Incentive Plans</U>. Elan shall
procure that resolutions of the shareholders of New Alkermes are passed prior to the Closing
authorizing effective at the Closing: (i)&nbsp;the transfer and assumption of the rights and obligations
of Alkermes under existing Alkermes equity plans and other similar employee awards by New Alkermes,
and (ii)&nbsp;for the purposes of Section&nbsp;29(1) of the Irish Companies Act 1990, any arrangement for the
payment of compensation to any director of New Alkermes in the form of shares in New Alkermes;
<U>provided</U>, that such compensation is disclosed in the accounts of New Alkermes from time to
time, the wording of such resolutions to be subject to the prior approval of Alkermes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;5.28. <U>Transfer Out of Irish Dormant Companies</U>. Elan shall procure that it
will effect a transfer or transfers of EDT Pharma Limited, EDT Investment Company Limited and EDT
Management Limited to a third party other than a New Alkermes Group Entity within five (5)&nbsp;Business
Days of the date hereof.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VI</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Employee Benefits Matters</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.1. <U>Employee Plans</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Generally</U>. Except as specifically set forth in this <U>Section&nbsp;6.1</U>, none of
New Alkermes or its Subsidiaries shall assume responsibility for any liability, cost, expense or
obligation under, or sponsorship of, any Employee Plan, or, in respect of the U.S. Acquired Entity,
continue following the Closing Date to be a participating employer under any Employee Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Transition Bonus Arrangement</U>. For purposes of this Agreement, the term
&#147;<U>Accrued Bonus Expense</U>&#148; means the liability included in the Estimated Modified Working
Capital in respect of bonus amounts under the Elan Cash Bonus Plan with respect to the performance
of Transferred Employees in 2011. New Alkermes shall maintain a performance bonus plan (the
&#147;<U>New Alkermes Transition Bonus Plan</U>&#148;) for the benefit of Transferred Employees for calendar
year 2011, the terms, conditions, targets and performance measures under which shall be established
in the discretion of the board of directors of New Alkermes or the compensation committee thereof
following the Closing. In any event, New Alkermes shall pay bonuses under the New Alkermes
Transition Bonus Plan to Transferred Employees that are not less than the sum of (i)&nbsp;the Accrued
Bonus Expense for services through the Closing Date, and (ii)&nbsp;an additional amount based on actual
results for New Alkermes and the New Alkermes Group Entities, on a consolidated or business unit
basis, for the period from the Closing Date through December&nbsp;31, 2011, that is consistent for each
Transferred Employee with the bonus
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->75<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">opportunity that such Transferred Employee had under the Elan Cash Bonus Plan for 2011. The
parties intend that this clause <U>(b)</U> shall not have any effect if the Closing Date occurs
after December&nbsp;31, 2011.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Vacation</U>. The Estimated Modified Working Capital shall reflect a liability in
respect of accrued but unused vacation and related taxes if any for Transferred Employees based on
rates of base pay as of the Closing Date. New Alkermes shall credit Transferred Employees with an
amount of accrued but unused vacation immediately following the Closing Date equal to the amount of
accrued but unused vacation time taken into account for purposes of such accrual, subject to the
generally applicable terms of the applicable vacation program of New Alkermes or its Subsidiaries
as in effect from time to time but with no diminution in the amount of accrued but unused vacation
for any Transferred Employee.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Service Credit</U>. Transferred Employees shall be given credit under each
Post-Closing Employee Plan in which they are eligible to participate for all service with Elan or
any of its Subsidiaries (to the extent such credit was given under the applicable Employee Plan
maintained by Elan or its Subsidiaries) for purposes of eligibility and vesting, and, solely for
purposes of any vacation pay plan and stock option accelerated vesting and extended exercise
period, for benefit accrual purposes. For the sake of clarity, the employee stock option
retirement provision and the vacation accrual policy are the only Post-Closing Employee Plans that
are expected to provide benefits based on service credit.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>Credit for Deductibles</U>. New Alkermes shall give each Transferred Employee credit
for the amount of deductibles borne by such Transferred Employee (and his or her eligible
dependents) prior to the Closing Date under an Employee Plan that is a welfare benefit plan for
purposes of satisfying the deductible limitations under each Post-Closing Employee Plan that is a
corresponding welfare benefit plan, subject to receipt of relevant information or documentation
confirming the amount of such deductibles.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.2. <U>U.S. Employees</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Benefit Continuation</U>. For one year following the Closing Date, New Alkermes or
its applicable Subsidiary shall continue to provide all U.S. Employees with base compensation no
less than the base compensation in effect for such U.S. Employees immediately prior to the Closing.
For one year following the Closing Date, New Alkermes and its Subsidiaries shall maintain
Post-Closing Employee Plans which provide benefits to U.S. Employees that are no less favorable in
the aggregate than those provided under the Employee Plans in effect on the Closing Date covering
U.S. Employees (excluding equity-based compensation, but including a flexible spending account
under which each U.S. Employee shall be credited with an opening balance equal to that as
immediately prior to the Closing Date under the comparable plan of Elan and its Subsidiaries as in
effect immediately prior to the Closing Date) or, at the election of New Alkermes, Post-Closing
Employee Plans that are no less favorable in the aggregate than those provided to similarly
situated employees of Alkermes (excluding equity-based compensation, but including a flexible
spending account under which each U.S. Employee shall be credited with an opening balance equal to
that as immediately prior to the Closing Date under the comparable plan of Elan and its
Subsidiaries as in effect immediately prior to the Closing Date); <U>provided</U>, that nothing
herein shall require New
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->76<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Alkermes or its Subsidiaries to continue the employment of any Transferred Employee for any
period or to duplicate any benefits.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>COBRA</U>. Elan shall remain responsible for satisfying obligations under Section&nbsp;601
<U>et</U> <U>seq.</U> of ERISA and Section&nbsp;4980B of the Code (&#147;<U>COBRA coverage</U>&#148;) and any
applicable similar state laws, to provide continuation coverage to or with respect to any U.S.
Employee in accordance with Law with respect to any &#147;qualifying event&#148; prior to the Effective Time.
New Alkermes shall be responsible for COBRA coverage for any U.S. Employees who has a qualifying
event following the Effective Time.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>401(k) Plan</U>. Effective as of the Closing Date, New Alkermes shall have in effect
a qualified defined contribution plan (the &#147;<U>New Alkermes 401(k) Plan</U>&#148;) that includes a
qualified cash or deferred arrangement within the meaning of Section 401(k) of the Code designed to
provide benefits as of the Closing Date to the U.S. Employees, subject to the terms and conditions
thereof. Effective as of the Closing Date, each U.S. Employee who was a participant in the Elan
U.S. 401(k) Plan shall be entitled to a distribution of his or her respective account balance in
accordance with the terms of the Elan U.S. 401(k) Plan and as permitted by the Code. The New
Alkermes 401(k) Plan shall provide for the receipt of individual rollovers of benefits so
distributed from the Elan U.S. 401(k) Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.3. <U>Ireland Employees</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Elan and its Continuing Affiliates and New Alkermes acknowledge and agree that the
Reorganization Transfers provided for in steps 3,4 and 6 of <U>Schedule&nbsp;1</U> each constitute a
TUPE Transfer. Upon the occurrence of any such TUPE Transfer, subject to <U>Section&nbsp;6.3(d)</U>
and <U>Schedule&nbsp;J</U> and except in respect of any equity based compensation, the contracts of
employment of each of the Ireland Employees whose employment transfers pursuant to any such TUPE
Transfer will have effect from the applicable TUPE Transfer Date as if originally made between ES5
or Interco (as the case may be) and each such Ireland Employee. Elan and its Subsidiaries and New
Alkermes agree that the provisions of this <U>Section&nbsp;6.3</U> shall not operate to increase the
obligations of the parties beyond those pursuant to the Transfer Regulations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Elan and New Alkermes shall together deliver to the Ireland Employees letters and notices,
in the Agreed Form, between them notifying the Ireland Employees of the transfer of their
employment under any TUPE Transfer, which Agreed Form will include the provisions set forth in
<U>Schedule&nbsp;I</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Elan and its Subsidiaries shall ensure that all salaries and wages of, and all other
employer&#146;s obligations relating to, the Ireland Employees are discharged or accrued and all tax
deductions and pay-related social insurance obligations and Transfer Regulations relative to the
Ireland Employees are complied with and made by Elan and its Subsidiaries in respect of all periods
up to the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;For one year following the Closing Date, New Alkermes or its applicable Subsidiary shall
continue to provide all Ireland Employees with base compensation no less than the base compensation
in effect for such Ireland Employees immediately prior to the Closing. Except as provided in
<U>Schedule&nbsp;J</U>, with which the Parties agree to comply, for one year following
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->77<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the Closing Date, New Alkermes and its Subsidiaries shall maintain Post-Closing Employee Plans
which provide benefits to each Ireland Employee required to be continued after the Effective Time
by the Transfer Regulations or, in respect of pension and death benefits, required to be continued
after the Effective Time under <U>Schedule&nbsp;J</U>, no less favorable in the aggregate than those
provided under the applicable Employee Plans of Elan and its Subsidiaries in effect on the
applicable TUPE Transfer Date (excluding equity-based compensation, which shall be determined in
the sole discretion of the compensation committee of the New Alkermes board of directors);
<U>provided</U>, that, subject to compliance with applicable Law, nothing herein shall require New
Alkermes or its Subsidiaries to continue the employment of any Transferred Employee for any period
or to duplicate any benefits.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;In respect of all periods after and including the Closing Date, New Alkermes shall
discharge all salaries and wages and all other employer&#146;s obligations relating to the Ireland
Employees and shall comply with all tax deductions and pay-related social insurance obligations and
Transfer Regulations relating to the Ireland Employees.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Each of Elan and its Continuing Affiliates and Interco shall comply with its respective
obligations arising under the Transfer Regulations, including Regulation&nbsp;8.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Prior to any Ireland Employee&#146;s employment transferring to Interco, and if Interco or any
Subsidiary of Interco acts as a principal employer or as a participating employer in the EDT Pharma
Pension Schemes and any such scheme has not been wound up by that date, Interco or any such
Subsidiary shall cease to act as principal employer of or as a participating employer in the EDT
Pharma Pension Schemes by executing all appropriate documentation in an Agreed Form.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;6.4. <U>Miscellaneous</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>No Right to Employment</U>. Nothing in this Agreement, express or implied, shall
create any right to employment or continued employment for any specified period, of any nature or
kind whatsoever. Nothing in this Agreement is intended to be, or shall be construed as, an
amendment to any employee benefit plan, program, arrangement, policy or agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Assistance with Claims</U>. Notwithstanding anything to the contrary in this
<U>Article&nbsp;VI</U>, each of Elan and its Continuing Affiliates, and New Alkermes and its
Subsidiaries shall at its own expense give the other party such assistance as the other party may
reasonably require to contest any claim by any person employed in the Business at or prior to the
Closing which results from or is in connection with this Agreement.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VII</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Tax Matters</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.1. <U>Tax Representations of Elan</U>. Elan hereby represents and warrants to
Alkermes and Merger Sub as follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Except as set forth in <U>Section&nbsp;7.1(a)</U> of the Elan Disclosure Schedule, New
Alkermes and the New Alkermes Group Entities have timely filed or caused to be filed (or had
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->78<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">filed on their behalf) all material federal, state, local and non-U.S. Tax Returns (including
those filed on a consolidated, combined or unitary basis) required to have been filed by (or on
behalf of) any of them. All of the foregoing Tax Returns are true, correct and complete in all
material respects, and set forth all items to the extent required to be reflected or included in
such Tax Returns. New Alkermes and the New Alkermes Group Entities have, within the time and
manner prescribed by applicable Law, paid all material Taxes required to be paid in respect of the
periods covered by such Tax Returns or otherwise due to any Taxing Authority (whether or not shown
on any Tax Return). None of New Alkermes or the New Alkermes Group Entities has requested or filed
any document having the effect of causing any extension of time within which to file any Tax
Returns in respect of any fiscal year which have not since been filed. No deficiencies for any Tax
have been proposed, asserted or assessed, in each case, by any Taxing Authority, against any of New
Alkermes or the New Alkermes Group Entities. There are no pending requests for waivers of the time
to assess any Tax, other than those made in the ordinary course and for which payment has been
made. None of New Alkermes or the New Alkermes Group Entities has waived any statute of
limitations in respect of any Taxes or agreed to any extension of time with respect to any Tax
assessment or deficiency. There are no material Liens with respect to Taxes upon any of the
properties or assets, real or personal, tangible or intangible of any of New Alkermes or the New
Alkermes Group Entities, or the Business Assets (other than Liens for Taxes not yet due and
payable). No claim has ever been made in writing by a Taxing Authority in a jurisdiction where New
Alkermes or any New Alkermes Group Entity does not file Tax Returns that such Person is or may be
subject to taxation by that jurisdiction.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;None of New Alkermes or the New Alkermes Group Entities is the subject of any currently
pending material Tax audit or administrative or judicial Tax proceeding, and no Elan Party expects
any authority to assess any additional material Taxes for any period for which Tax Returns have
been filed. None of New Alkermes or any New Alkermes Group Entity has received from any Taxing
Authority any notice indicating an intent to open an audit or other review.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;New Alkermes and the New Alkermes Group Entities have withheld and paid or have caused to
be withheld and paid all material Taxes required to have been withheld and paid in connection with
amounts paid or owing to any employee, independent contractor, creditor, shareholder or other third
party.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;None of New Alkermes or any New Alkermes Group Entity that is a corporation for U.S.
federal income tax purposes has constituted either a &#147;distributing corporation&#148; or a &#147;controlled
corporation&#148; within the meaning of Section&nbsp;355(a)(1)(A) of the Code in a distribution of stock
intended to qualify for tax-free treatment under Section&nbsp;355 of the Code in the two years prior to
the date of this Agreement (or will constitute such a corporation in the two years prior to the
Closing Date) or in a distribution which otherwise constitutes part of a &#147;plan&#148; or &#147;series of
related transactions&#148; within the meaning of Section 355(e) of the Code in conjunction with the
Merger.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;None of New Alkermes or the New Alkermes Group Entities has been a United States real
property holding corporation within the meaning of section 897(c)(2) of the Code during the
applicable period specified in section 897(c)(1)(A)(ii) of the Code.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->79<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;No shares in the New Alkermes Group Entities have at any time during the Reorganization
derived the greater part of their value from any of the assets specified in Section&nbsp;29 of the Taxes
Consolidation Act 1997 of Ireland (the &#147;<U>TCA</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;None of New Alkermes or the New Alkermes Group Entities is or has been a party to any
&#147;reportable transaction,&#148; as defined in section 6707A(c)(1) of the Code and Treasury Regulation
section 1.6011-4(b) that is or was required to be reported to the relevant Taxing Authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;None of New Alkermes or the New Alkermes Group Entities has any liability for any material
Tax (i)&nbsp;of any Person other than New Alkermes and the New Alkermes Group Entities, including under
Treasury Regulations section 1.1502-6 (or any similar provision of any Similar Law), as transferee
or successor or by contract, (ii)&nbsp;as a result of any change in method of accounting for a taxable
period ending on or prior to the Closing Date, (iii)&nbsp;as a result of any &#147;closing agreement&#148; as
described in section 7121 of the Code (or any corresponding or similar provision of state, local or
non-U.S. Tax law) executed on or prior to the Closing Date, or (iv)&nbsp;as a result of any installment
sale or open transaction disposition made on or prior to the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;The documents listed in <U>Section&nbsp;7.1(i)</U> of the Elan Disclosure Schedule are true,
accurate, and complete in all material respects, and include all material information that is
responsive to the information request on &#147;Substantial Business Activities&#148; provided by Alkermes to
Elan on March&nbsp;1, 2011.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;Each of New Alkermes and the New Alkermes Group Entities has disclosed on their federal
income Tax Returns all positions taken therein that could give rise to a substantial understatement
of federal income Tax within the meaning of Code section 6662(d). Except as disclosed in
<U>Section&nbsp;7.1(j)</U> of the Elan Disclosure Schedule, none of New Alkermes or the New Alkermes
Group Entities has requested or received a ruling from any Taxing Authority or signed a closing or
other agreement with any Taxing Authority relating to Taxes which would have an effect with respect
to any taxable period ending on or after the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;Since acquiring the intellectual property which is transferred as part of the
Reorganization Transfers described in Step 6 of <U>Schedule&nbsp;1</U>, EPIL and Interco have been
carrying on a trade of dealing in intellectual property, including the buying and selling of
intellectual property and all income and gains earned from this trade have qualified for the rate
of corporation tax in Ireland specified in Section&nbsp;21(1) of the Taxes Consolidation Act 1997.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;Each New Alkermes Group Entity (other than Merger Sub, Eagle Holdings, U.S. Holdco and the
U.S. Acquired Entities) is resident for tax purposes only in Ireland and no such entity has any
liability for tax in any other jurisdiction.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;At the Closing, no part of the Business will be subject to taxation in any jurisdiction
other than the United States or Ireland.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(n)&nbsp;The tax basis (for the purposes of Schedule&nbsp;D Case I) in the intellectual property
transferred to it as part of the Reorganization Transfers described in Step 6 of <U>Schedule</U>
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->80<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><U>1</U>, is $299&nbsp;million. There has been no appropriation from trading stock of any of such
intellectual property.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(o)&nbsp;Prior to the issue of shares by Interco as part of the Reorganization Transfers, Interco
has never been a member of the same group for the purposes of Section&nbsp;616 of the Taxes
Consolidation Act 1997 as EPIL or ES5. Prior to the issue of shares by New Alkermes as part of the
transactions contemplated by this Agreement, New Alkermes has never been a member of the same group
for the purposes of Section&nbsp;616 of the Taxes Consolidation Act 1997 as ES3.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.2. <U>Tax Indemnification</U>. (a)&nbsp;From and after the Closing Date, the Elan Tax
Indemnitors shall pay or cause to be paid, and jointly and severally shall indemnify each Alkermes
Tax Indemnitee and protect, save and hold each Alkermes Tax Indemnitee harmless from and against
the following Taxes:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) any Tax imposed upon or relating to Elan or any of the Continuing
Affiliates for any period, including any such Tax for which any of the Alkermes Tax
Indemnitees (or any Subsidiary thereof) may be liable (w)&nbsp;under Section&nbsp;1.1502-6 of
the Treasury Regulations (or any similar provision of any Similar Law), (x)&nbsp;as a
transferee or successor, (y)&nbsp;by contract or (z)&nbsp;otherwise, on a secondary or joint
and several basis;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) any Tax imposed upon any of New Alkermes, the New Alkermes Group Entities
or the Business Assets with respect to any Pre-Closing Period, including any
interest, penalties, additions to tax or other additional amounts imposed with
respect thereto, other than (w)&nbsp;any such Taxes that are accounted for in the Closing
Modified Working Capital (x)&nbsp;Taxes imposed solely and directly as a result of the
merger of Alkermes and Merger Sub, which Taxes are not associated with a transaction
prior to the Closing Date of any of New Alkermes or its direct and indirect
Subsidiaries, and for the avoidance of doubt, any Tax arising as a result of the
ceasing of any of New Alkermes or its direct and indirect Subsidiaries on prior to
the Closing Date to be a member of any group (including any consolidated group,
affiliated group, or otherwise) for any Tax purpose is not excluded from
indemnification by this <U>Section&nbsp;7.2(a)(ii)(x)</U>, (y)&nbsp;Taxes imposed on Alkermes
or Interco in connection with Step 12A of <U>Schedule&nbsp;1</U> and (z)&nbsp;Taxes imposed
as a result of the borrowing by Merger Sub and the payment of $500&nbsp;million to New
Alkermes in Step 12B/C of <U>Schedule&nbsp;1</U>;
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) any Covered Losses or Taxes incurred or sustained by any Alkermes Tax
Indemnitee arising out of a breach of representations contained in <U>Section
7.1</U>; and
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iv) any Taxes (including Transfer Taxes) imposed in connection with the
transactions described in <U>Schedule&nbsp;1</U> other than (x)&nbsp;Taxes imposed solely and
directly as a result of the merger of Alkermes and Merger Sub, which Taxes are not
associated with a prior transaction prior to the Closing Date of any of New Alkermes
or its direct and indirect Subsidiaries, and for the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->81<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="left" style="font-size: 10pt; margin-top: 6pt; margin-left: 4%">avoidance of doubt, any Tax arising as a result of the ceasing of any of New
Alkermes or its direct and indirect Subsidiaries on prior to the Closing Date to be
a member of any group (including any consolidated group, affiliated group, or
otherwise) for any Tax purpose is not excluded from indemnification by this
<U>Section&nbsp;7.2(a)(iv)(x)</U>, (y)&nbsp;Taxes imposed on Alkermes or Interco in
connection with Step 12A of <U>Schedule&nbsp;1</U> and (z)&nbsp;Taxes imposed as a result of
the borrowing by Merger Sub and the payment of $500&nbsp;million to New Alkermes in Step
12B/C of <U>Schedule&nbsp;1</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except as otherwise provided in <U>Section&nbsp;7.5</U>, payment in full of any amount due to
the Alkermes Tax Indemnitees under this <U>Section&nbsp;7.2</U> shall be made to the affected Alkermes
Tax Indemnitee in immediately available funds at least two (2)&nbsp;Business Days before the date
payment of the Taxes to which such payment relates is due.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Alkermes Tax Indemnitees shall not be entitled to assert any indemnification pursuant
to this <U>Section&nbsp;7.2</U> after the end of the applicable survival period as specified in
<U>Section&nbsp;7.12</U>; <U>provided</U>, that, if on or prior to the last date of such survival
period, Alkermes shall have provided Elan with written notice of a claim for indemnification under
this <U>Section&nbsp;7.2</U>, then the Alkermes Tax Indemnitees shall continue to have the right to be
indemnified with respect to such indemnification claim until such claim has been satisfied or
otherwise resolved as provided in this <U>Article&nbsp;VII</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.3. <U>Allocation of Certain Taxes</U>. For purposes of this <U>Article&nbsp;VII</U>,
in order to apportion appropriately any Taxes relating to a Straddle Period, the Parties hereto
shall, to the extent permitted or required under applicable Law, treat the Closing Date as the last
day of the taxable year or period for all purposes of New Alkermes and the New Alkermes Group
Entities. In the case of Taxes arising in a taxable period of any of New Alkermes or the New
Alkermes Group Entities, or with respect to a Business Asset, that includes but does not end on the
Closing Date, except as otherwise provided in this <U>Section&nbsp;7.3</U>, the portion of such Taxes
that are allocable to the Pre-Closing Period shall be (x)&nbsp;in the case of Taxes that are imposed on
a periodic basis, franchise Taxes based on capitalization, debt or shares of stock authorized,
issued or outstanding and ad valorem Taxes, the amount of such Taxes for the entire taxable period,
multiplied by a fraction the numerator of which is the number of calendar days in such taxable
period ending on and including the Closing Date and the denominator of which is the entire number
of calendar days in such taxable period, and the balance of such Taxes shall be attributable to the
Post-Closing Period; <U>provided</U>, that if any property, asset or other right of any of New
Alkermes or the New Alkermes Group Entities, or any Business Asset, is sold, disposed of or deemed
disposed of or otherwise transferred or realized for any Tax purpose on or prior to the Closing
Date, then ad valorem, capital gains, transfer or other Taxes pertaining to such property, asset or
other right shall be attributed entirely to the Pre-Closing Period; and (y)&nbsp;in the case of Taxes
not described in (x)&nbsp;the amount that would be payable on the basis of an interim closing of the
books as of the end of the Closing Date. For purposes of this <U>Section&nbsp;7.3</U>, (i)&nbsp;any Tax on
gain or income resulting from the triggering into income of deferred intercompany transactions
under Section&nbsp;1.1502-13 of the Treasury Regulations or excess loss accounts under Section&nbsp;1.1502-19
of the Treasury Regulations or under Part&nbsp;20 of the TCA that occurs as a result of the
Reorganization or the Merger shall be considered to be attributable to the Pre-Closing Period and
(ii)&nbsp;each partnership or &#147;flowthrough&#148; entity in which any of New Alkermes
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->82<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or the New Alkermes Group Entities holds an interest shall be treated as if its taxable year
ended at the close of business on the Closing Date and Taxes attributable to the income and gain of
such entities through the close of business on the Closing Date (as determined in a reasonably
practicable manner) shall be considered to be attributable to the Pre-Closing Period.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.4. <U>Carryovers, Refunds and Related Matters</U>. (a)&nbsp;Any refund or credit of
Taxes (including any interest thereon) received by New Alkermes or any of the New Alkermes Group
Entities and that is a refund or credit of Taxes with respect to a Pre-Closing Period, other than
any such refunds or credits that are accounted for in the Closing Modified Working Capital, shall
be for the account of Elan and shall be promptly reimbursed to Elan or its designee by New Alkermes
or the New Alkermes Group Entity.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Any refund or credit of Taxes (including any interest thereon) that relates to any of
Alkermes, New Alkermes, the New Alkermes Group Entities or their respective Subsidiaries and that
is a refund or credit of Taxes with respect to a Post-Closing Period that is received by Elan or
any of its Subsidiaries or Affiliates shall be the property of Alkermes, New Alkermes, the New
Alkermes Group Entity or their relevant Subsidiary and shall be promptly paid by Elan to such
Person.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;In applying <U>Sections&nbsp;7.4(a)</U> and <U>7.4(b)</U>, any refund or credit of Taxes
(including any interest thereon) for a Straddle Period shall be allocated between the Pre-Closing
Period and the Post-Closing Period in accordance with <U>Section&nbsp;7.3</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.5. <U>Preparation and Filing of Tax Returns</U>. (a)&nbsp;Elan shall file or cause to
be filed (i)&nbsp;any combined, consolidated or unitary Return that includes Elan, any direct or
indirect Subsidiary of Elan that directly or indirectly holds an equity interest in New Alkermes or
any Continuing Affiliate and (ii)&nbsp;any other Return of any of New Alkermes or the New Alkermes Group
Entities for any taxable period that ends on or before the Closing Date. All such Returns shall be
true, correct and complete in all material respects and accurately set forth all items to the
extent required to be reflected or included in such Tax Returns by applicable Law. All such
Returns shall be timely filed in a manner consistent with past practice, shall not include any
change in any method of accounting (unless required by Law) and shall not include any Tax election
that is inconsistent with past practice. Elan shall, reasonably promptly after the filing of a
Return described in clause <U>(i)</U> or <U>(ii)</U> above, provide New Alkermes a copy of such
Return (or a copy of a pro forma separate Return in the case of a Return described in clause
<U>(i)</U>). Elan shall remit to the relevant Taxing Authority all Taxes shown by such Returns to
be due. New Alkermes shall cause the New Alkermes Group Entities to furnish information to Elan in
connection with any such Return, at Elan&#146;s expense, in accordance with the past procedures, customs
and practices of Elan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except to the extent set forth in <U>Section&nbsp;7.5(a)</U>, New Alkermes shall file or cause
to be filed all Returns of, or that include, New Alkermes and any of the New Alkermes Group
Entities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;With respect to any Return of any of New Alkermes or the New Alkermes Group Entities for a
Straddle Period (such a Return, a &#147;<U>Straddle Period Return</U>&#148;), New Alkermes shall deliver a
copy of such Return to Elan at least forty (40)&nbsp;Business Days prior to the due date
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->83<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(giving effect to any extension thereof), accompanied by an allocation between the Pre-Closing
Period and the Post-Closing Period of the Taxes shown to be due on such Return. Such Return and
allocation shall not be filed or become final without prior written consent of Elan (not to be
unreasonably withheld, conditioned or delayed). Within fifteen (15)&nbsp;Business Days after the date
of receipt by Elan of such Return and allocation, Elan may deliver to New Alkermes a written
request for changes to such Return or allocation. If Elan does not deliver such a request within
such period, the Return and allocation shall be final and binding. If Elan delivers such a
request, then New Alkermes and Elan shall undertake in good faith to resolve the issues raised in
such request prior to the due date (including any extension thereof) for filing such Return. If
New Alkermes and Elan are unable to resolve any issue within (10)&nbsp;Business Days from the date of
receipt by new Alkermes of the request for changes, then Elan and New Alkermes jointly shall engage
the Neutral Auditors to determine the correct treatment of the item or items in dispute. Each of
Elan and New Alkermes shall bear and pay one half of the fees and other costs charged by the
Neutral Auditors. The determination of the Neutral Auditors shall be final and binding on the
Parties hereto.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;In the case of each Straddle Period Return, not later than two (2)&nbsp;Business Days before
the due date (including any extension thereof) for payment of Taxes with respect to such Return,
Elan shall pay to New Alkermes or the relevant New Alkermes Group Entity the portion of the Taxes
in connection with such Return for which Elan is responsible pursuant to <U>Sections&nbsp;7.2</U> and
<U>7.3</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.6. <U>Tax Contests</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Notices</U>. If any Taxing Authority asserts a Tax Claim, then the Party hereto first
receiving notice of such Tax Claim promptly shall provide written notice thereof to the other Party
or Parties; <U>provided,</U> that the failure of such Party to give such prompt notice shall not
relieve the other Party of any of its obligations under this <U>Section&nbsp;7.6</U>, except to the
extent that the other Party is actually prejudiced thereby. Such notice shall specify in
reasonable detail the basis for such Tax Claim and shall include a copy of the relevant portion of
any correspondence received from the Taxing Authority.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Interco hereby agrees that it shall not, without having first obtained the consent of
Elan, initiate any correspondence or discussions with the Irish Revenue Commissioners (&#147;<U>Irish
Revenue</U>&#148;) asserting to Irish Revenue that the intellectual property, transferred to it as part
of the Reorganization Transfers described in Step 6 of <U>Schedule&nbsp;1</U>, should be treated
otherwise than as trading stock for any Pre-Closing Period. If Irish Revenue initiates contact
with Interco asserting that such intellectual property should be treated otherwise than as trading
stock for any Pre-Closing Period, Interco agrees that it shall promptly inform Elan that such
contact has been made.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Interco shall not claim a tax basis (for the purposes of Schedule&nbsp;D Case I) in the
intellectual property transferred to it as part of the Reorganization Transfers described in Step 6
of <U>Schedule&nbsp;1</U>, of more than the amount specified in <U>Section&nbsp;7.1(n)</U>, unless
otherwise agreed with Irish Revenue as a result of correspondence or discussions initiated by Irish
Revenue and conducted in accordance with the provisions of this <U>Section&nbsp;7.6</U>. If, as a
result of such correspondence or discussions with Irish Revenue, Interco obtains a tax basis in the
intellectual
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->84<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">property of more than the amount specified in <U>Section&nbsp;7.1(n)</U>, Interco agrees to repay
to Elan (as an adjustment to the purchase price paid in Step 6 of <U>Schedule&nbsp;1</U>) any Tax
benefit, actually realized solely as a result of claiming the increased tax basis, less any costs
or additional Tax incurred.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;New Alkermes agrees that it shall not, for the duration of the time period specified in
section 80(8)(b) of the Stamp Duties Consolidation Act 1999 (&#147;<U>SDCA</U>&#148;) dispose of the shares
in Holdco that it acquired in Step 10 of <U>Schedule&nbsp;1</U> if such disposition would cause a
clawback pursuant to Section&nbsp;80(8)(b) of the SDCA of relief from stamp duty granted pursuant to
section 80(2) of the SDCA in respect of the transfer of shares described in Step 10 of <U>Schedule
1</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Elan shall have the right to control, at its own expense, any audit, examination, contest,
litigation or other proceeding by or against any Taxing Authority (a &#147;<U>Tax Proceeding</U>&#148;) in
respect of New Alkermes or a New Alkermes Group Entity for any taxable period that ends on or
before the Closing Date, or for a Straddle Period and relates to any matter that is indemnifiable
pursuant to <U>Section&nbsp;7.2(a)</U>, and in the case of a Tax Proceeding involving the matters
referred to in <U>Sections&nbsp;7.1(k)</U> and <U>7.2(a)(iv)</U>; <U>provided</U>, that Elan shall
provide New Alkermes with a timely and reasonably detailed account of each stage of such Tax
Proceeding; <U>provided</U>, <U>further</U>, that Elan shall consult with New Alkermes regarding
any such Tax Proceeding which relate solely to matters indemnifiable pursuant to <U>Section
7.2(a)</U> and shall allow New Alkermes to participate in any such proceeding (at its own cost and
expense and that Elan conduct such Tax Proceedings in a reasonable manner and shall indemnify New
Alkermes and its Subsidiaries, including the New Alkermes Group Entities, from and against any
interest, penalties, surcharges or additional Taxes arising as a result of such Tax Proceeding, to
the extent such interest, penalties, surcharges and additional Taxes are not already paid pursuant
to the indemnities contained in <U>Section&nbsp;7.2(a)</U>); <U>provided</U>, <U>further</U>, that
with respect to a Tax Proceeding that includes matters that are not indemnifiable pursuant to
<U>Section&nbsp;7.2(a)</U>, Elan shall have the right to control only those aspects of the Tax
Proceeding related to such matters that are indemnifiable pursuant to <U>Section&nbsp;7.2(a)</U>;
<U>provided</U>, <U>further</U>, that none of New Alkermes or the New Alkermes Group Entities and
any of their respective Subsidiaries or any director or officer of any of the foregoing shall be
required to sign any document or make any assertion or representation that is not true and correct
and in accordance with applicable Law; <U>provided</U>, <U>further</U>, that no settlement or
other disposition of any claim for Tax which would adversely and materially affect New Alkermes,
the New Alkermes Group Entities or any of their Subsidiaries in any Post-Closing Period shall be
agreed to without New Alkermes&#146; prior written consent, which consent shall not be unreasonably
withheld or delayed.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;Subject to <U>Section&nbsp;7.6(g)</U>, New Alkermes shall have the right to control the
conduct of any other Tax Proceeding in its sole discretion with respect to any other Tax matter not
covered in <U>Section&nbsp;7.6(e)</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;<U>Straddle Periods</U>. In the case of a Tax Proceeding for a Straddle Period (and to
the extent the conduct of such Tax Proceeding does not relate to the matter described in
<U>Section&nbsp;7.6(d)</U> or does not fall within <U>Section&nbsp;7.6(e)</U>) of New Alkermes or any New
Alkermes Group Entity, New Alkermes and Elan shall jointly represent their interests in any such
Tax Proceeding, shall employ counsel of their mutual choice and shall cooperate with the other and
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->85<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">the other&#146;s Representatives in a prompt and timely manner in connection with any such Tax
Proceeding. Elan and New Alkermes shall mutually agree on any settlement or other disposition of
the Tax Proceeding. In the event Elan and New Alkermes are unable to agree regarding any aspect of
the conduct of any such Tax Proceeding, the decision shall be made by the counsel employed to
pursue such Tax Proceeding on the basis of counsel&#146;s good faith judgment regarding the course of
action that would produce the overall lowest present value of Tax and litigation cost to Elan and
New Alkermes. Any such Tax Proceeding expenses shall be borne by Elan and New Alkermes in the same
proportion as such related Taxes are borne by Elan and New Alkermes in accordance with <U>Section
7.3</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.7. <U>Cooperation</U>. Each Party hereto shall, and shall cause its Subsidiaries
and Affiliates to, provide to each of the other Parties hereto such cooperation, documentation and
information as any of them reasonably may request in (i)&nbsp;filing any Return, amended Return or claim
for refund, (ii)&nbsp;determining a Liability for Taxes or an indemnity obligation under this
<U>Article&nbsp;VII</U> or a right to refund of Taxes, (iii)&nbsp;conducting any Tax Proceeding or (iv)
determining an allocation of Taxes between a Pre-Closing Period and Post-Closing Period. Such
cooperation and information shall include providing copies of all relevant portions of relevant
Returns, together with all relevant portions of relevant accompanying schedules and relevant work
papers, relevant documents relating to rulings or other determinations by Taxing Authorities and
relevant records concerning the ownership and Tax basis of property and other information, which
any such Party may possess. Each Party will retain all Returns, schedules and work papers, and all
material records and other documents relating to Tax matters, of New Alkermes and the New Alkermes
Group Entities for their respective Tax periods ending on or prior to the Closing Date until the
later of (x)&nbsp;the expiration of the statute of limitations for the Tax periods to which the Returns
and other documents relate or (y)&nbsp;eight (8)&nbsp;years following the due date (without extension) for
such Returns. Thereafter, the Party holding such Returns or other documents may dispose of them,
provided that such Party shall give to the other Parties written notice prior to doing so. Each
Party shall make its employees reasonably available on a mutually convenient basis at its cost to
provide explanation of any documents or information so provided. Each Party required to file
Returns pursuant to this <U>Article&nbsp;VII</U> shall bear all costs of filing such Returns.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.8. <U>Termination of Tax Sharing Agreements</U>. Any and all Tax allocation or
sharing agreements or other agreements or arrangements relating to Tax matters between any of New
Alkermes or the New Alkermes Group Entities on the one hand and Elan, or any Continuing Affiliate
on the other hand shall be terminated with respect to each of New Alkermes and the New Alkermes
Group Entities (and the Subsidiaries thereof) as of the day before the Closing Date and, from and
after the Closing Date, New Alkermes and the New Alkermes Group Entities shall not have any rights
or obligations thereunder for any past or future period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.9. <U>Tax Election</U>. New Alkermes agrees that, except (i)&nbsp;as provided elsewhere
in this Agreement, (ii)&nbsp;with the consent of Elan (such consent not to be unreasonably withheld or
delayed), (iii)&nbsp;as required by applicable Law, or (iv)&nbsp;to correct an error in a Tax Return, New
Alkermes shall not, and shall not cause or permit any of the New Alkermes Group Entities to make or
change any Tax election or amend any Tax Return or take any Tax position filed pursuant to
<U>Sections&nbsp;7.5(a)</U> and <U>7.5(c)</U> in respect of a Pre-Closing Period or Straddle Period,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->86<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">except that New Alkermes shall be permitted to take such actions with respect to any Tax
election or Tax Return for a Pre-Closing Period or Straddle Period to the extent such action would
not give rise to a claim for indemnification pursuant to <U>Section&nbsp;7.2(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.10. <U>Certain Disputes</U>. Disputes arising under this <U>Article&nbsp;VII</U> and
not resolved by mutual agreement within thirty (30)&nbsp;days shall be resolved by the Tax Accounting
Referee, chosen and mutually acceptable to both Elan and New Alkermes within five (5)&nbsp;days of the
date on which the need to choose the Tax Accounting Referee arises, and if no person is mutually
acceptable, the President of the Irish Taxation Institute shall choose the Tax Accounting Referee.
The Tax Accounting Referee shall resolve any disputed items within thirty (30)&nbsp;days of having the
item referred to it pursuant to such procedures as it may require. The determination of the Tax
Accounting Referee shall be final and binding on the Parties hereto. The costs, fees and expenses
of the Tax Accounting Referee shall be borne equally by Elan and New Alkermes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.11. <U>Definitions</U>. The following terms shall have the meanings set forth as
follows:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;&#147;<U>Alkermes Tax Indemnitees</U>&#148; means New Alkermes, Alkermes and each of their
respective Subsidiaries and Affiliates, including the New Alkermes Group Entities.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;&#147;<U>Elan Tax Indemnitors</U>&#148; means Elan and each of the Transferring Subsidiaries.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;&#147;<U>Post-Closing Period</U>&#148; means any taxable period or portion thereof of New Alkermes
or the New Alkermes Group Entities or with respect to the Business Assets beginning after the
Closing Date, including the Post-Closing Straddle Period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;&#147;<U>Pre-Closing Period</U>&#148; means any taxable period or portion thereof of New Alkermes
or the New Alkermes Group Entities or with respect to the Business Assets ending on or before the
Closing Date, including the Pre-Closing Straddle Period.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;&#147;<U>Pre-Closing Straddle Period</U>&#148; means the portion of the Straddle Period ending on
the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;&#147;<U>Returns</U>&#148; or &#147;<U>Tax Returns</U>&#148; means any returns, reports or statements
(including any amended returns or information returns) required to be filed for purposes of a
particular Tax.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;&#147;<U>Straddle Period</U>&#148; means a taxable period that begins on or before and ends after
the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;&#147;<U>Post-Closing Straddle Period</U>&#148; means the portion of the Straddle Period beginning
on the date after the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)&nbsp;&#147;<U>Tax</U>&#148; or &#147;<U>Taxes</U>&#148; means any federal, state, local or non-U.S. net or gross
income, gross receipts, capital gains, corporation, license, payroll, employment, excise,
severance, stamp, occupation, premium, windfall profits, environmental, customs duties, capital
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->87<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">stock, franchise, profits, withholding, social security (or similar), unemployment,
disability, real property, personal property, sales, use, transfer, registration, value added,
alternative, or add-on minimum, estimated or other tax of any kind whatsoever, whether computed on
a separate or consolidated, unitary or combined basis or in any other manner, including any
interest, penalty or addition thereto, whether disputed or not and including any obligation to
indemnify or otherwise assume or succeed to the Tax liability of any other Person.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)&nbsp;&#147;<U>Tax Accounting Referee</U>&#148; means any internationally recognized accounting firm
chosen and mutually acceptable to both Elan and New Alkermes excluding any firm that audits either
Elan or Alkermes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)&nbsp;&#147;<U>Tax Claim</U>&#148; means any claim with respect to Taxes made by any Taxing Authority
that, if pursued successfully, would reasonably be expected to serve as the basis for a claim for
indemnification of the Alkermes Tax Indemnitee under this <U>Article&nbsp;VII</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)&nbsp;&#147;<U>Taxing Authority</U>&#148; means any governmental agency, board, bureau, body, department
or authority of any United States federal, state or local jurisdiction or any foreign jurisdiction,
having or purporting to exercise jurisdiction with respect to any Tax.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)&nbsp;&#147;<U>Transfer Tax</U>&#148; means all goods and services, excise, sales, use, value added,
transfer (including real property transfer), withholding tax pursuant to Section&nbsp;980 Taxes
Consolidation Act 1997 of Ireland (as amended), stamp, stamp duty reserve, documentary, filing,
recordation, registration and other similar Taxes (including conveyance and notarial fees),
together with any interest, penalties and additional amounts imposed with respect thereto.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.12. <U>Survival</U>. The representations and warranties set forth in <U>Section
7.1</U> shall survive the Effective Time until sixty (60)&nbsp;days after the expiration of the
applicable statute of limitations.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.13. <U>Treatment for U.S. Federal Income Tax Purposes</U>. For U.S. Federal income
tax purposes, the Parties agree to treat the Merger as a taxable sale of Alkermes stock under
section 1001 of the Code.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;7.14. <U>Adjustments</U>. (a)&nbsp;Any indemnification payment under <U>Article
VII</U> or <U>Article&nbsp;IX</U> (the &#147;<U>Relevant Indemnity Payments</U>&#148;) shall be treated for U.S.
federal income Tax purposes and Irish tax purposes as an adjustment to the consideration. All sums
payable under <U>Article&nbsp;VII</U> or <U>Article&nbsp;IX</U> and any payment made pursuant to
<U>Sections&nbsp;2.14</U> or <U>2.15</U> shall be paid on an after-tax basis, and free and clear of
all deductions or withholdings except as may be required by Law. If any such deductions or
withholdings are required by Law, the payer shall be obliged to pay to the recipient such sum as
will, after such deduction or withholding has been made, leave the recipient with the same amount
as it would have been entitled to receive, in the absence of any such requirement to make a
deduction or withholding. The Parties agree to cooperate in a commercially reasonable manner to
ensure that any Relevant Indemnity Payment is made to the appropriate Alkermes Tax Indemnitee,
Alkermes Indemnified Party, or Elan Indemnified Party, as applicable, (each, an &#147;<U>Indemnity
Recipient</U>&#148;) to avoid the imposition of any Tax or withholding Tax on the Relevant Indemnity
Payments to the extent possible, provided that the Indemnity Recipient shall not be required to
take any action that would cause it to incur
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->88<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">any additional costs, expenses, Taxes or Covered Losses that it is not indemnified for
pursuant to <U>Section&nbsp;7.2(a)</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Except with respect to matters covered in <U>Section&nbsp;7.6(c)</U>, in the event that an
Alkermes Tax Indemnitee actually realizes any Tax refunds or credits to Taxes (collectively,
&#147;<U>Tax Benefits</U>&#148;) (determined on a with-or-without basis) attributable to amounts for which
it was indemnified or is entitled to indemnification in accordance with <U>Article&nbsp;VII</U> or
<U>Article&nbsp;IX</U> hereof, such party will (i)&nbsp;in the case of Tax Benefits actually realized and
attributable to amounts for which it was indemnified, promptly pay the Elan Tax Indemnitor the
amount of the Tax Benefits so realized, and (ii)&nbsp;in the case of all other Tax Benefits actually
realized, offset such amounts against any indemnification payment then due from the Elan Tax
Indemnitors.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE VIII</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Conditions Precedent</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.1. <U>Conditions to Each Party&#146;s Obligation</U>. The obligations of the Parties to
consummate the Merger shall be subject to the satisfaction on or prior to the Closing Date of all
of the following conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Receipt of Shareholder Approvals</U>. Alkermes shall have obtained the Alkermes
Shareholder Approval.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>No Injunctions or Restraints, Illegality</U>. No Laws shall have been adopted or
promulgated, and no temporary restraining order, preliminary or permanent injunction or other order
issued by a court or other Governmental Authority of competent jurisdiction shall be in effect
having the effect of making the Merger or the other transactions contemplated hereby illegal or
otherwise prohibiting consummation of the Merger or the other transactions contemplated hereby.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Antitrust Approval</U>. The waiting period (and any extension thereof) applicable to
the Merger under the HSR Act shall have been terminated or shall have expired and all other
antitrust approvals, shall have been received (or, where appropriate, notification submitted), if
required.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Governmental and Regulatory Approvals</U>. Other than the filings pursuant to the HSR
Act and any other required antitrust Laws identified after the date hereof, all consents, approvals
and actions of, filings with and notices to any Governmental Authority required of Alkermes, Elan
or any of their Subsidiaries to consummate the Merger, the Transactions and the other transactions
contemplated hereby, the failure of which to be obtained or made would have or would reasonably be
expected to have a Business Material Adverse Effect shall have been obtained or made.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>NASDAQ Listing</U>. The New Alkermes Ordinary Shares to be issued in the Merger shall
have been approved for listing on NASDAQ, subject to official notice of issuance.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->89<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;<U>Registration Statement</U>. The Registration Statement shall have been declared
effective under the Securities Act and shall not be the subject of any stop order or proceedings
seeking a stop order.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;<U>Financial Assistance</U>. All Irish financial assistance issues arising in respect of
the Reorganization shall have been validated in accordance with Section&nbsp;60 of the Irish Companies
Act 1963 and filed with the Irish Companies Registration Office.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;<U>Re-registration of New Alkermes</U>. New Alkermes shall have been re-registered as a
public limited company in accordance with the provisions of the Irish Companies (Amendment) Act
1983 and a certificate of incorporation on re-registration to this effect from the Irish Companies
Registration Office shall have been provided to Alkermes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.2. <U>Additional Conditions to Alkermes&#146; Obligations</U>. The obligations of
Alkermes to consummate the Merger shall be subject to the satisfaction on or prior to the Closing
Date of all of the following additional conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Representations, Warranties and Covenants of the Elan Parties</U>. Each of the
representations and warranties of Elan set forth in this Agreement (other than the representation
and warranty set forth in <U>Section&nbsp;7.1(i)</U>) shall be true and correct, in each case as of the
date of this Agreement and as of the Closing Date as though made on and as of the Closing Date
(except to the extent in either case that such representations and warranties speak as of another
date, in which case they shall be true as of such date), interpreted without regard to any
materiality, material adverse effect, or &#147;Business Material Adverse Effect&#148; (or other similar
materiality qualifiers) contained therein, except where the failure of such representations and
warranties of Elan to be true and correct as so made, would not, individually or in the aggregate,
have or reasonably be expected to have a Business Material Adverse Effect. The representation and
warranty set forth in <U>Section&nbsp;7.1(i)</U> shall be true and correct as of the date of this
Agreement and as of the Closing as though made on and as of the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Performance of Obligations of the Elan Parties</U>. Each of the Elan Parties shall
have performed or complied in all material respects with all agreements and covenants required to
be performed by it under this Agreement at or prior to the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Reorganization</U>. The Reorganization shall have been effected pursuant to the
Reorganization Transfer Agreements. Elan shall have provided evidence of the completion of the
Reorganization reasonably satisfactory to Alkermes, including evidence of any necessary actions of
the boards of directors or stockholders of the Elan Entities, any Transferring Subsidiary, New
Alkermes and the New Alkermes Group Entities in respect of the Reorganization.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Indebtedness</U>. New Alkermes and the New Alkermes Group Entities shall have no
Indebtedness as of the Closing Date (other than Elan Reorganization Indebtedness and Indebtedness
in respect of the IP Transfer Loan Note).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;<U>Financial Statements</U>. The Audited Financial Statements, when delivered, shall not
have differed in any material respect from the Historical Financial Statements, other
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->90<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">than in respect of the different accounting standards under which they were prepared and any
applicable Agreed Adjustments.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;<U>Certificate</U>. Alkermes shall have received at the Closing a certificate dated the
Closing Date and validly executed by the chief executive officer or the chief financial officer of
Elan to the effect that the conditions specified in paragraphs <U>(a)</U>, <U>(b)</U>,
<U>(c)</U>, and <U>(d)</U> of this <U>Section&nbsp;8.2</U> have been satisfied.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;<U>Deliveries</U>. The Elan Parties (or the applicable Continuing Affiliate) shall have
delivered all the certificates, instruments, agreements and other documents to be delivered
pursuant to <U>Section&nbsp;2.13</U> (except to the extent expressly provided otherwise in <U>Section
2.13(vi)</U>).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;<U>No Code Change</U>. There shall have been no change in Law with respect to Code
Section&nbsp;7874, or official interpretation thereof, that, in the opinion of Cleary Gottlieb Steen &#038;
Hamilton LLP (or other nationally recognized tax counsel), would materially increase the risk that
New Alkermes would be treated as a United States domestic corporation for United States federal tax
purposes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;8.3. <U>Additional Conditions to Obligations of the Elan Parties</U>. The obligation
of the Elan Parties to consummate the Merger shall be subject to the satisfaction on or prior to
the Closing Date of all of the following additional conditions:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;<U>Representations, Warranties and Covenants of Alkermes</U>. Each of the
representations and warranties of Alkermes set forth in this Agreement shall be true and correct,
in each case as of the date of this Agreement and as of the Closing Date as though made on and as
of the Closing Date (except to the extent in either case that such representations and warranties
speak as of another date, in which case they shall be true as of such date), interpreted without
regard to any materiality, material adverse effect or &#147;Alkermes Material Adverse Effect&#148; (or other
similar materiality qualifiers) contained therein, except where the failure of such representations
and warranties of Alkermes to be true and correct as so made, would not, individually or in the
aggregate, have or reasonably be expected to have an Alkermes Material Adverse Effect.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;<U>Performance of Obligations of Alkermes</U>. Alkermes shall have performed or complied
in all material respects with all agreements and covenants required to be performed by it under
this Agreement at or prior to the Closing Date.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;<U>Certificate</U>. Elan shall have received at the Closing a certificate dated the
Closing Date and validly executed by the chief executive officer or the chief financial officer of
Alkermes to the effect that the conditions specified in paragraphs (a)&nbsp;and (b)&nbsp;of this <U>Section
8.3</U> have been satisfied.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;<U>Deliveries</U>. Alkermes shall have delivered to Elan all the certificates,
instruments, agreements and other documents to be delivered pursuant to <U>Section&nbsp;2.14</U>
(except to the extent expressly provided otherwise in <U>Section&nbsp;2.14(iv)</U>).
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->91<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE IX</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Survival; Indemnification</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.1. <U>Survival</U>. The covenants and other agreements of the Parties contained in
this Agreement which by their terms apply or are to be performed in whole or in part after the
Effective Time shall survive the Closing and the consummation of the transactions contemplated
hereby until so performed or terminated. The representations and warranties contained in this
Agreement shall survive the Effective Time until the second (2<SUP style="FONT-size: 85%; vertical-align: text-top">nd</SUP>) anniversary of the
Effective Time, except that (a)&nbsp;the representations and warranties set forth in <U>Sections
3.9</U> and <U>3.10</U> shall survive the Effective Time until the third (3<SUP style="FONT-size: 85%; vertical-align: text-top">rd</SUP>)
anniversary of the Effective Time, and (b)&nbsp;the representations and warranties set forth in
<U>Article&nbsp;VII</U> shall survive as set forth in <U>Article&nbsp;VII</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.2. <U>Indemnification by Elan</U>. (a)&nbsp;Subject to <U>Section&nbsp;9.5(a)</U>, from
and after the Closing Date, Elan shall indemnify and hold harmless New Alkermes, the Surviving
Corporation and the New Alkermes Group Entities and their respective officers, directors and
Affiliates (collectively, the (&#147;<U>Alkermes Indemnified Parties</U>&#148;) from and against any and all
Covered Losses suffered by such Alkermes Indemnified Parties resulting from or arising out of (i)
any inaccuracy in or breach of any of the representations or warranties of Elan in this Agreement
(other than those set forth in <U>Article&nbsp;VII</U> hereof, indemnity for which is addressed in
<U>Article&nbsp;VII</U>) and the Ancillary Agreements (other than the IP Transfer Loan Note), in each
case when made, and, except for representations and warranties that speak of a specific date or
time (which need only be true and correct as of such date and time), on and as of the Closing Date,
(ii)&nbsp;any breach or nonfulfillment of any covenants or agreements made by the Elan Parties herein or
by Elan or any Continuing Affiliate in the Ancillary Agreements, (iii)&nbsp;any Liability or obligation
of any of New Alkermes, the Surviving Corporation or the New Alkermes Group Entities arising from
or relating to Excluded Assets or any business or conduct of such entity prior to the Closing other
than the Business, (iv)&nbsp;except as specifically set forth in this Agreement, (A)&nbsp;the employment of
any employee or consultant by Elan or its Subsidiaries in respect of the Business prior to the
Effective Time, (B)&nbsp;otherwise in respect of employee matters as a result of the transactions
contemplated by this Agreement, including (X)&nbsp;any benefit in the nature of severance pay arising
from the consummation of the transactions contemplated by this Agreement, (Y)&nbsp;with respect to any
employee or consultant whose employment or consulting service is transferred (or who claims that
his or her employment or consulting service is transferred) pursuant to the Transfer Regulations,
arising out of any failure by Elan or any of its Subsidiaries to comply with obligations under the
Transfer Regulations, or (Z)&nbsp;arising from any claim by or on behalf of any person other than an
Ireland Employee who asserts that he or she is entitled to transfer to the employment of Interco or
New Alkermes whether pursuant to the Transfer Regulations or otherwise, including all costs, to
include remuneration costs, incurred as a result of Interco or New Alkermes being compelled to
employ such person as a result of any such claim, (C)&nbsp;other than a claim for pension or death
benefit entitlements in respect of service after the Effective Time, any matter or thing related to
the Ireland DB Plans and any action or omission of Elan or any of its Subsidiaries with respect to
employees, or related to any Employee Plan other than the Ireland DB Plans or (D)&nbsp;any Controlled
Group Liability, (v)&nbsp;any Pre-Closing Environmental Matters and (vi)&nbsp;any of the Specified Matters.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->92<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Alkermes Indemnified Parties shall not be entitled to assert any indemnification
pursuant to clause <U>(i)</U> of <U>Section&nbsp;9.2(a)</U> after the date on which such
representation and warranty ceases to survive; <U>provided</U>, that if on or prior to the date
such representation ceases to survive, a Notice of Claim shall have been given to Elan pursuant to
<U>Section&nbsp;9.4</U> for such indemnification, the Alkermes Indemnified Parties shall continue to
have the right to be indemnified with respect to such indemnification claim until such claim for
indemnification has been satisfied or otherwise resolved as provided in this <U>Article&nbsp;IX</U>.
The Alkermes Indemnified Parties shall not be entitled to assert any indemnification pursuant to
clauses <U>(ii)</U> or <U>(v)</U> of <U>Section&nbsp;9.2(a)</U> after the seventh (7<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>)
anniversary of the Closing Date; <U>provided</U>, that if on or prior to the seventh
(7<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>) anniversary of the Closing Date, a Notice of Claim shall have been given to Elan
pursuant to <U>Section&nbsp;9.4</U> for such indemnification, the Alkermes Indemnified Parties shall
continue to have the right to be indemnified with respect to such indemnification claim until such
claim for indemnification has been satisfied or otherwise resolved as provided in this <U>Article
IX</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.3. <U>Indemnification by Alkermes</U>. (a)&nbsp;Subject to <U>Section&nbsp;9.5(b)</U>
hereof, from and after the Closing Date, Alkermes shall indemnify and hold harmless Elan and the
Continuing Affiliates and their respective officers, directors and Affiliates (collectively, the
&#147;<U>Elan Indemnified Parties</U>&#148;) from and against any and all Covered Losses suffered by such
Elan Indemnified Parties resulting from or arising out of (i)&nbsp;any inaccuracy in or breach of any of
the representations or warranties of Alkermes in this Agreement and the Ancillary Agreements, in
each case, when made, and, except for representations and warranties that speak of a specific date
or time (which need only be true and correct as of such date and time), on and as of the Closing
Date, (ii)&nbsp;any breach or nonfulfillment of any covenants or agreements made by Alkermes herein or,
solely in respect of covenants or agreements to be performed after the Closing, by New Alkermes,
the Surviving Corporation, the New Alkermes Group Entities or Alkermes in this Agreement or in the
Ancillary Agreements, (iii)&nbsp;any Liability of any of New Alkermes, the Surviving Corporation or the
New Alkermes Group Entities or arising from or related to the Business Assets, other than any
Liability for which the Elan Indemnified Parties have indemnified the Alkermes Indemnified Parties
pursuant to <U>Section&nbsp;9.2</U>, or Intellectual Property Rights transferred to a New Alkermes
Group Entity pursuant to the IP Transfer Agreement; (iv)&nbsp;any action taken by Elan or its
Subsidiaries pursuant to <U>Section&nbsp;5.3(h)</U> and (v) (A)&nbsp;the employment of any employee or
consultant by New Alkermes or its Subsidiaries in respect of the Business after the Effective Time,
including (x)&nbsp;any benefit in the nature of severance pay arising after the consummation of the
transactions contemplated by this Agreement, (y)&nbsp;with respect to any employee or consultant whose
employment or consulting service is transferred (or who claims that his or her employment or
consulting services is transferred) pursuant to the Transfer Regulations, arising out of any
failure by Alkermes or any of its Subsidiaries to comply with obligations under the Transfer
Regulations from and after the Effective Time, including all costs, to include remuneration costs,
incurred as a result of Elan being compelled to provide severance or to re-employ any such person
or (z)&nbsp;any claim to pension or death benefits in respect of services after the Effective Time, or
(B)&nbsp;any action or omission of Alkermes or any of its Subsidiaries with respect to employees, or
related to any Post-Closing Employee Plan.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;The Elan Indemnified Parties shall not be entitled to assert any indemnification pursuant
to clause <U>(i)</U> of <U>Section&nbsp;9.3(a)</U> after the date on which such
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->93<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">representation and warranty ceases to survive; <U>provided</U>, that if on or prior to the
date such representation ceases to survive, a Notice of Claim shall have been given to Alkermes
pursuant to <U>Section&nbsp;9.4</U> hereof for such indemnification, the Elan Indemnified Parties shall
continue to have the right to be indemnified with respect to such indemnification claim until such
claim for indemnification has been satisfied or otherwise resolved as provided in this <U>Article
IX</U>. The Elan Indemnified Parties shall not be entitled to assert any indemnification pursuant
to clause <U>(ii)</U> of <U>Section&nbsp;9.3(a)</U> after the seventh (7<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>) anniversary of
the Closing Date; <U>provided</U>, that if on or prior to the seventh (7<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP>) anniversary
of the Closing Date, a Notice of Claim shall have been given to Alkermes pursuant to <U>Section
9.4</U> hereof for such indemnification, the Elan Indemnified Parties shall continue to have the
right to be indemnified with respect to such indemnification claim until such claim for
indemnification has been satisfied or otherwise resolved as provided in this <U>Article&nbsp;IX</U>.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.4. <U>Indemnification Procedures</U>. (a)&nbsp;Upon obtaining knowledge of any claim
or demand which has given rise to, or is expected to give rise to, a claim for indemnification
hereunder, New Alkermes or Elan, as the case may be, shall promptly (and in any event within thirty
(30)&nbsp;days) give written notice (&#147;<U>Notice of Claim</U>&#148;) of such claim or demand to the other.
The party giving such Notice of Claim shall furnish to the other party in reasonable detail such
information as the Alkermes Indemnified Parties or the Elan Indemnified Parties, as the case may
be, may have with respect to such indemnification claim (including copies of any summons, complaint
or other pleading which may have been served on it and any written claim, demand, invoice, billing
or other document evidencing or asserting the same). Subject to the limitations set forth in
<U>Sections&nbsp;9.2(b)</U> and <U>9.3(b)</U>, no failure or delay by New Alkermes or Elan in the
performance of the foregoing shall reduce or otherwise affect the obligation of Elan or Alkermes,
respectively, to indemnify and hold the Alkermes Indemnified Parties or the Elan Indemnified
Parties, respectively, harmless, except to the extent that such failure or delay shall have
actually adversely affected the ability of Alkermes or Elan, as the case may be, to defend against
or satisfy any Covered Losses for which the party seeking indemnification is entitled to
indemnification hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;If the claim or demand set forth in the Notice of Claim given pursuant to <U>Section
9.4(a)</U> hereof is a claim or demand asserted by a third party, the party receiving such Notice
of Claim shall have fifteen (15)&nbsp;days after the date on which Notice of Claim is given to notify
the party giving such Notice of Claim in writing of its election to defend such third party claim
or demand on behalf of the party seeking indemnification. If the party receiving such Notice of
Claim elects, on behalf of Alkermes or Elan, as the case may be, to defend such third party claim
or demand, the party seeking indemnification shall make available to the indemnifying party and its
agents and representatives all records and other materials which are reasonably required in the
defense of such third party claim or demand and shall otherwise cooperate with, and assist the
indemnifying party in the defense of, such third party claim or demand, and so long as Elan or
Alkermes, as the case may be, is defending such third party claim in good faith, the Alkermes
Indemnified Parties or Elan Indemnified Parties, as applicable, shall not pay, settle or compromise
such third party claim or demand. In such case, Alkermes or Elan, as the case may be, may pay,
settle or compromise such third party claim or demand (i)&nbsp;with the written consent of Elan or
Alkermes, on behalf of the Elan Indemnified Parties or the Alkermes Indemnified Parties, as the
case may be, or (ii)&nbsp;without such consent, so long as such settlement includes (A)&nbsp;an unconditional
release of the Elan Indemnified Parties or the Alkermes
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->94<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Indemnified Parties, as the case may be, from all Liability in respect of such claim or
litigation, (B)&nbsp;does not subject the indemnified parties to any injunctive relief or other
equitable remedy, and (C)&nbsp;does not include a statement or admission of fault, culpability or
failure to act by or on behalf of any indemnified party. If the party receiving such Notice of
Claim elects to defend such third party claim or demand, (i)&nbsp;such assumption will conclusively
establish for purposes of this Agreement that the claims described in such Notice of Claim are
within the scope of and subject to indemnification hereunder and (ii)&nbsp;the Alkermes Indemnified
Party or the Elan Indemnified Party, as the case may be, shall have the right to participate in the
defense of such third party claim or demand, at such indemnified party&#146;s own expense. In the
event, however, that such indemnified party reasonably determines that representation by counsel to
the indemnifying parties of both such indemnifying parties and the indemnified party could
reasonably be expected to present such counsel with a conflict of interest, then the indemnified
party may employ separate counsel to represent or defend it in any such action or proceeding and
the indemnifying parties will pay the fees and expenses of such counsel; <U>provided</U>, that
Elan or Alkermes, as the case may be, shall not, in connection with any proceeding or related
proceedings in the same jurisdiction, be liable for the fees and expenses of more than one separate
firm of attorneys (in addition to reasonably necessary local counsel) at any time for all Alkermes
Indemnified Parties or Elan Indemnified Parties, as the case may be. If the party receiving such
Notice of Claim does not elect to defend such third party claim or demand or does not defend such
third party claim or demand in good faith, the Alkermes Indemnified Parties or Elan Indemnified
Parties, as the case may be, shall have the right, in addition to any other right or remedy they
may have hereunder, at the expense of Elan or Alkermes, as the case may be, to defend such third
party claim or demand; <U>provided</U>, that (i)&nbsp;such Alkermes Indemnified Parties or Elan
Indemnified Parties, as the case may be, shall not have any obligation to participate in the
defense of, or defend, any such third party claim or demand; (ii)&nbsp;such Alkermes Indemnified
Parties&#146; or Elan Indemnified Parties&#146;, as the case may be, defense of or participation in the
defense of any such third party claim or demand shall not in any way diminish or lessen the
obligations of Elan or Alkermes, as applicable, under the agreements of indemnification set forth
in this <U>Article&nbsp;IX</U>; and (iii)&nbsp;such Alkermes Indemnified Parties or Elan Indemnified
Parties, as the case may be, may not settle any claim without the consent of Elan or Alkermes,
respectively (which consent shall not be unreasonably withheld, conditioned or delayed).
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;With respect to any third party claim subject to indemnification under this <U>Article
IX</U>: (i)&nbsp;both the party receiving such Notice of Claim and the Elan Indemnified Parties or
Alkermes Indemnified Parties, as the case may be, shall keep the other Persons reasonably informed
of the status of such third party claim and any related Actions at all stages thereof where such
Person is not represented by its own counsel, and (ii)&nbsp;the Parties agree to render to each other
such assistance as they may reasonably require of each other and to cooperate in good faith with
each other in order to ensure the proper and adequate defense of any third party claim;
<U>provided</U>, that the party receiving such Notice of Claim shall pay the reasonable
out-of-pocket expenses incurred in providing such cooperation (including reasonable legal fees and
disbursements) by the Party providing such cooperation but shall not be required to compensate such
Party for time spent by its officers, directors, employees or agents in such cooperation.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;Except for third party claims being defended in good faith, (i)&nbsp;Elan shall satisfy its
obligations under this <U>Article&nbsp;IX</U> in respect of a valid claim for indemnification hereunder
which is not contested by Elan in good faith in cash within 30&nbsp;days after the date on
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->95<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">which Notice of Claim is given and (ii)&nbsp;Alkermes shall satisfy its obligations under this
<U>Article&nbsp;IX</U> in respect of a valid claim for indemnification hereunder which is not contested
by Alkermes in good faith in cash within 30&nbsp;days after the date on which Notice of Claim is given.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.5. <U>Limitations; Additional Procedures</U>. (a)&nbsp;Elan shall have no liability for
indemnification pursuant to clause <U>(i)</U> of <U>Section&nbsp;9.2(a)</U> with respect to Covered
Losses for which indemnification is provided thereunder, (i)&nbsp;that are De Minimis Damages, (ii)
unless the aggregate of all Covered Losses (other than De Minimis Damages) exceeds $5,000,000 (the
&#147;<U>Threshold</U>&#148;), in which case Elan shall be liable for all such Covered Losses (other than De
Minimis Damages), including the amount of the Threshold or (iii)&nbsp;in excess of $500&nbsp;million in the
aggregate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Alkermes shall have no liability for indemnification pursuant to clause <U>(i)</U> of
<U>Section&nbsp;9.3(a)</U> with respect to Covered Losses for which indemnification is provided
thereunder, (i)&nbsp;that are De Minimis Damages, (ii)&nbsp;unless the aggregate of all Covered Losses (other
than De Minimis Damages) exceeds the Threshold, in which case Alkermes shall be liable for all such
Covered Losses (other than De Minimis Damages), including the amount of the Threshold or (iii)&nbsp;in
excess of $500&nbsp;million in the aggregate.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;For purposes of any indemnity obligation under this <U>Article&nbsp;IX</U> with respect to any
breach of any covenant or obligation, or any representation or warranty contained in this
Agreement, any express qualifications or limitations set forth in such covenant or obligation, or
representation or warranty, as to materiality, material adverse effect, &#147;Business Material Adverse
Effect&#148; or &#147;Alkermes Material Adverse Effect&#148; (or other similar materiality qualifiers) contained
therein, shall be disregarded.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;The right to indemnification, reimbursement or other remedy based upon the
representations, warranties, covenants and agreements contained in this Agreement shall not be
affected by any investigation conducted with respect to, or any knowledge actually acquired at any
time, whether before or after the execution and delivery of this Agreement or the Closing Date,
with respect to the accuracy or inaccuracy of or compliance with any such representation, warranty,
covenant or agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;Notwithstanding anything herein to the contrary, no Elan Indemnified Person or Alkermes
Indemnified Person shall be entitled to any indemnification or reimbursement under any provisions
of this Agreement for any amount to the extent such Person or its Affiliates has been indemnified
or reimbursed for such amount under any other provision of this Agreement or any Ancillary
Agreement or under any insurance policy.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;In no event shall Covered Losses be subject to indemnification under <U>Sections&nbsp;9.2
</U>or <U>9.3</U> to the extent such Covered Losses were included or taken into account in the
calculation of the Final Modified Working Capital or Final Net Cash Amount.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;Except in the case of fraud, from and after the Closing, the exclusive remedy for any Elan
Indemnified Person or Alkermes Indemnified Person for Covered Losses or other monetary damages
arising from a breach of this Agreement or otherwise relating to the transactions contemplated by
this Agreement (except as otherwise provided in any Ancillary
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->96<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Agreement) shall be the indemnification provided under this <U>Article&nbsp;IX</U> or <U>Article
VII</U>. There shall be no remedy at law or otherwise for De Minimis Damages arising out of the
events or circumstances described in clause <U>(i)</U> of <U>Sections&nbsp;9.2(a)</U> or
<U>9.3(a)</U>. Nothing in this Agreement shall interfere with or impede a party&#146;s right to seek
equitable remedies (including specific performance or injunctive relief) to enforce any covenant in
this Agreement or any Ancillary Agreement.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)&nbsp;NOTWITHSTANDING ANYTHING TO THE CONTRARY IN THIS AGREEMENT, IN NO EVENT SHALL ANY PARTY BE
LIABLE FOR (A)&nbsp;ANY PUNITIVE DAMAGES OR (B)&nbsp;ANY LOST PROFITS OR CONSEQUENTIAL, SPECIAL OR INDIRECT
DAMAGES; <U>provided, however</U>, that if an Elan Indemnified Person or Alkermes Indemnified
Person is held liable to a third party based on any final judgment of a court of competent
jurisdiction for any such Covered Losses and the applicable indemnifying party is obligated to
indemnify such Person for the matter that gave rise to such Covered Losses, then such indemnifying
party shall be liable for, and obligated to reimburse such Elan Indemnified Person or Alkermes
Indemnified Person, as the case may be, for such Covered Losses.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;9.6. <U>Exclusive Tax Indemnification</U>. Notwithstanding anything to the contrary
in this <U>Article&nbsp;IX</U>, the above provisions of this <U>Article&nbsp;IX</U> shall not apply to Tax
indemnification matters, which matters shall instead be governed by <U>Article&nbsp;VII</U>.
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE X</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Termination</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.1. <U>Termination</U>. This Agreement may be terminated at any time prior to the
Closing by:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)&nbsp;Alkermes and Elan by mutual written consent;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;either Alkermes or Elan if the Effective Time shall not have occurred by the close of
business on 180<SUP style="FONT-size: 85%; vertical-align: text-top">th</SUP> day following the date of this Agreement (the &#147;<U>Termination
Date</U>&#148;); <U>provided</U>, that the right to terminate this Agreement pursuant to this
<U>Section&nbsp;10.1(b)</U> shall not be available to (i)&nbsp;Alkermes if its failure to fulfill any
obligation under this Agreement has been the cause of, or resulted in, the failure of the Effective
Time to occur on or before the Termination Date or (ii)&nbsp;Elan, if Elan&#146;s or one or more of its
Subsidiaries&#146; failure to fulfill any obligation under this Agreement has been the cause of, or
resulted in, the failure of the Effective Time to occur on or before the Termination Date;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;either Alkermes or Elan if any Governmental Authority shall have issued an order, decree
or ruling or taken any other action (which such Party shall have used its reasonable best efforts
to resist, resolve or lift, as applicable, in accordance with <U>Section&nbsp;5.2</U>) permanently
restraining, enjoining or otherwise prohibiting the Merger or the Reorganization, and such order,
decree, ruling or other action shall have become final and nonappealable;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;by either Alkermes or Elan if the Alkermes Shareholders Approval shall not have been
obtained by reason of the failure to obtain the Required Alkermes Vote upon the
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->97<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">taking of such vote(s) at a duly held meeting of shareholders of Alkermes, or at any
adjournment thereof; or
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)&nbsp;by Elan, prior to the Alkermes Shareholders Meeting, if the board of directors of Alkermes
shall have withdrawn or modified in any manner adverse to Elan its recommendation that the
shareholders of Alkermes approve the Merger or shall have resolved to take any such action (an
&#147;<U>Alkermes Change in Recommendation</U>&#148;).
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)&nbsp;By Alkermes, if Elan shall have breached or failed to perform in any material respect any
of its representations, warranties, covenants or other agreements contained in this Agreement,
which breach or failure (A)&nbsp;would render the condition in <U>Section&nbsp;8.2(a)</U> or <U>Section
8.2(b)</U> incapable of being satisfied, and (B)&nbsp;is incapable of being cured or has not been cured
by Elan within 20 calendar days after written notice has been given by Alkermes to Elan of such
breach or failure to perform; or
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)&nbsp;By Elan, if Alkermes shall have breached or failed to perform in any material respect any
of its representations, warranties, covenants or other agreements contained in this Agreement,
which breach or failure (A)&nbsp;would render the condition in <U>Section&nbsp;8.3(a)</U> or <U>Section
8.3(b)</U> incapable of being satisfied, and (B)&nbsp;is incapable of being cured or has not been cured
by Alkermes within 20 calendar days after written notice has been given by Elan to Alkermes of such
breach or failure to perform
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.2. <U>Procedure and Effect of Termination</U>. In the event of termination of
this Agreement by either or both of Elan and Alkermes pursuant to <U>Section&nbsp;10.1</U>, written
notice thereof shall forthwith be given by the terminating Party to the other, and this Agreement
shall thereupon terminate and become void and have no effect, and the transactions contemplated
hereby shall be abandoned without further action by the Parties, except that <U>Sections&nbsp;5.1</U>,
<U>5.5</U>, and <U>9.5(h)</U>, and <U>Articles I</U>, <U>X</U> and <U>XI</U> shall survive
the termination of this Agreement; <U>provided</U>, that, except as set forth in <U>Section
10.3</U>, such termination shall not relieve any Party hereto of any liability for any breach of
this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;10.3. <U>Termination Payments.</U> (a)&nbsp;Elan shall pay to Alkermes the Alkermes
Termination Fee by wire transfer to an account of Alkermes in immediately available funds within
two (2)&nbsp;Business Days of termination in the event that this Agreement is terminated in accordance
with <U>Section&nbsp;10.1(f)</U> or, by Elan, in accordance with <U>Section&nbsp;10.1(b)</U>, and, in the
case of this clause <U>(ii)</U>, at any time on or after the date of this Agreement and prior to
such termination any EDT Acquisition Proposal shall have been made and not withdrawn or formally
(and, if such EDT Acquisition Proposal was publicly made, publicly) rejected by Elan, in each case,
prior to such termination.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Alkermes shall pay to Elan the Elan Termination Fee by wire transfer to an account of
Alkermes in immediately available funds within two (2)&nbsp;Business Days of termination in the event
that this Agreement is terminated: (i)&nbsp;by Elan due to an Alkermes Change in Recommendation pursuant
to <U>Section&nbsp;10.1(e)</U>; or (ii)&nbsp;in accordance with <U>Section&nbsp;10.1(d)</U> or <U>Section
10.1(g)</U> or, by Alkermes, in accordance with <U>Section&nbsp;10.1(b)</U>, and, in the case of this
clause <U>(ii)</U>, at any time on or after the date of this Agreement and prior to such
termination any Alkermes Acquisition Proposal shall have been made and not withdrawn or formally
(and, if
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->98<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">such Alkermes Acquisition Proposal was publicly made, publicly) rejected by Alkermes, in each
case, prior to such termination.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;The Parties acknowledge that the agreements contained in this <U>Section&nbsp;10.3</U> are an
integral part of the transactions contemplated by this Agreement and that without such provisions
the Parties would not have entered into this Agreement. If either Alkermes or Elan, as the case
may be, fails to pay the Elan Termination Fee or the Alkermes Termination Fee, as the case may be,
or any portion thereof and the other Party commences a suit which results in a judgment against the
Party that failed to pay for the respective Termination Fee or any portion thereof, the losing
Party shall also pay the prevailing Party&#146;s costs and expenses (including reasonable attorney&#146;s
fees and disbursements) in connection with such suit, together with interest on the respective
Termination Fee (or any portion thereof that has not been paid timely in accordance with this
Agreement) and on the amount of such costs and expenses at the prime interest rate of Citibank,
N.A. in effect on the date such payment was required to be made through the date of payment.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;In the circumstances in which a Termination Fee is payable in accordance with this
<U>Section&nbsp;10.3</U>, (i)&nbsp;each of the Parties acknowledges and agrees that a Party&#146;s receipt of the
requisite Termination Fee from the other Party pursuant to this <U>Section&nbsp;10.3</U> is not a
penalty, but rather is liquidated damages, in a reasonable amount that is intended to compensate
the other Parties, solely in the circumstances in which such Termination Fee is payable, for
efforts and resources expended and on the expectation of the consummation of the Transactions
contemplated hereby, which amount would otherwise be impossible to calculate without precision,
(ii)&nbsp;a Party&#146;s receipt of the requisite Termination Fee from the other Party pursuant to this
<U>Section&nbsp;10.3</U> shall be the sole and exclusive remedy of such recipient Party against the
other Party, its Subsidiaries, the Financing Parties and each of their respective former, current
and future Affiliates, Representatives, general and limited partners, members, managers and
assignees for any loss or damage suffered as a result of the failure of the Transactions to be
consummated or for a breach or failure to perform hereunder, and (iii)&nbsp;in the event a Termination
Fee is paid in accordance with this <U>Section&nbsp;10.3</U>, none of Elan, its Subsidiaries or any of
their respective former, current and future Affiliates, Representatives, general and limited
partners, members, managers or assignees, on the one hand, or Alkermes, its Subsidiaries, the
Financing Parties or any of their respective former, current and future Affiliates,
Representatives, general and limited partners, members, managers and assignees, on the other hand,
shall have any further liability or obligation to Alkermes, its Subsidiaries or the Financing
Parties, on the one hand, or to Elan or its Subsidiaries, on the other hand, relating to or arising
out of this Agreement, the transactions contemplated hereby, the Commitment Letter or in respect of
any other document or theory of law or equity or in respect of oral representations made or alleged
to be made in connection herewith or therewith; <U>provided</U>, that in no event shall a Party&#146;s
liability for the willful or intentional material beach or failure to perform any of its covenants
or agreements in this Agreement be limited (it being understood and agreed that the failure to
consummate the transactions contemplated by this Agreement in the event that all of the conditions
to Closing have been satisfied or waived in accordance with this Agreement shall be deemed a
willful or intentional material breach of this Agreement); <U>provided</U>, <U>further</U>, that
this <U>Section&nbsp;10.3(d)</U> shall not limit the right of any Party to seek specific performance of
this Agreement pursuant to <U>Section&nbsp;11.10</U> and the remedies related thereto prior to the
termination of this Agreement in accordance with its terms.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->99<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>ARTICLE XI</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B>Miscellaneous</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.1. <U>Counterparts</U>. This Agreement may be executed in one or more
counterparts, all of which shall be considered one and the same agreement, and shall become
effective when one or more counterparts have been signed by each of the Parties and delivered to
the other Parties.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.2. <U>Governing Law; Jurisdiction and Forum; Waiver of Jury Trial</U>. (a)&nbsp;This
Agreement shall be governed by and construed in accordance with the laws of the State of New York
applicable to contracts to be performed entirely within that State, except to the extent the laws
of the Commonwealth of Pennsylvania perforce apply to the Merger.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)&nbsp;Each of the Parties irrevocably (a)&nbsp;consents to submit itself to the personal jurisdiction
of any state or federal court located in the City of New York, Borough of Manhattan, in the event
any dispute arises out of this Agreement or any Ancillary Agreement or any of the transactions
contemplated hereby or thereby, (b)&nbsp;agrees that it will not attempt to deny or defeat such personal
jurisdiction by motion or other request for leave from any such court, and (c)&nbsp;agrees that it will
not bring any action relating to this Agreement or any Ancillary Agreement or any of the
transactions contemplated hereby or thereby in any court other than a state or federal court
sitting in the City of New York, Borough of Manhattan. Each Party further irrevocably consents to
the service of process out of any of the aforementioned courts in any Action by the mailing of
copies thereof by mail to such Party at its address set forth in this Agreement by registered mail,
such service of process to be effective upon acknowledgment of receipt of such registered mail;
<U>provided</U>, that nothing in this <U>Section&nbsp;11.2(b)</U> shall affect the right of any Party
to serve legal process in any other manner permitted by Law. The consent to jurisdiction set forth
in this <U>Section&nbsp;11.2(b)</U> shall not constitute a general consent to service of process in the
State of New York and shall have no effect for any purpose except as provided in this <U>Section
11.2(b)</U>. The Parties agree that a final judgment in any such Action shall be conclusive and
may be enforced in other jurisdictions by suit on the judgment or in any other manner provided by
Law.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)&nbsp;Notwithstanding the foregoing, each of the Parties hereto agrees that it will not bring or
support any action, cause of action, claim, cross-claim or third-party claim of any kind or
description, whether in law or in equity, whether in contract or in tort or otherwise, against any
of the Financing Parties, their Subsidiaries, and each of their respective former, current and
future Affiliates, Representatives, general and limited partners, members, managers and assignees
in any way relating to this Agreement or any of the transactions contemplated hereby, including any
dispute arising out of or relating in any way to the Commitment Letter or the performance thereof,
in any forum other than the Supreme Court of the State of New York, County of New York, or, if
under applicable Law exclusive jurisdiction is vested in the federal courts, the United States
District Court for the Southern District of New York (and appellate courts thereof). The Parties
hereby further agree that New York State or United States Federal courts sitting in the borough of
Manhattan, City of New York shall have exclusive jurisdiction over any action brought against any
Financing Party, its Subsidiaries, and any of their respective former, current and future
Affiliates, Representatives, general and limited partners, members,
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->100<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">managers and assignees under the Commitment Letter in connection with the transactions
contemplated by this Agreement and the Commitment Letter.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)&nbsp;EACH PARTY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY
HAVE TO A TRIAL BY JURY IN RESPECT OF ANY ACTION ARISING OUT OF OR RELATING TO THIS AGREEMENT OR
ANY ANCILLARY AGREEMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY, INCLUDING ANY LEGAL
PROCEEDING AGAINST ANY FINANCING PARTY, ITS SUBSIDIARIES, OR ANY OF THEIR RESPECTIVE FORMER,
CURRENT AND FUTURE AFFILIATES, REPRESENTATIVES, GENERAL AND LIMITED PARTNERS, MEMBERS, MANAGERS AND
ASSIGNEES ARISING OUT OF THE COMMITMENT LETTER, OR THE ACTIONS OF ANY PARTY IN THE NEGOTIATION,
ADMINISTRATION, PERFORMANCE AND ENFORCEMENT OF THIS AGREEMENT. EACH PARTY CERTIFIES THAT IT HAS
BEEN INDUCED TO ENTER INTO THIS AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND
CERTIFICATIONS SET FORTH ABOVE IN THIS <U>SECTION 11.2</U>.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.3. <U>Entire Agreement; Third Party Beneficiaries</U>. This Agreement and the
Ancillary Agreements, the Schedules and Exhibits hereto and thereto, and the Confidentiality
Agreement contain the entire agreement between the Parties with respect to the subject matter
hereof and there are no agreements, understandings, representations or warranties between the
Parties other than those set forth or referred to herein. Except for <U>Section&nbsp;7.2</U>, which is
intended to benefit, and to be enforceable by, the Alkermes Tax Indemnitees, <U>Section&nbsp;9.2</U>
which is intended to benefit, and be enforceable by, the Alkermes Indemnified Parties, <U>Section
9.3</U> which is intended to benefit, and be enforceable by, the Elan Indemnified Parties,
<U>Sections&nbsp;11.2(c)</U> and <U>(d)</U> which are intended to benefit, and be enforceable by, the
Financing Parties and each of their Affiliates, equityholders, directors, employees, agents and
advisors, this Agreement is not intended to confer upon any Person not a Party hereto (and their
successors and assigns permitted by <U>Section&nbsp;11.6</U>) any rights or remedies hereunder.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.4. <U>Expenses</U>. Except as set forth in this Agreement, including <U>Section
10.3</U> hereof, and the Ancillary Agreements, whether the Merger is or is not consummated, all
legal, investment banking and other costs and expenses incurred in connection with this Agreement
and the transactions contemplated hereby shall be paid by the party incurring such costs and
expenses. For the avoidance of doubt, any costs incurred in connection with the Agreement and the
transactions contemplated hereby by Elan and its Subsidiaries, (including New Alkermes or the New
Alkermes Group Entities) prior to the Closing, including any arrangements referred to in
<U>Section&nbsp;3.15</U> with respect to the Elan Financial Advisors (including any indemnity
obligations to the Elan Financial Advisors), shall be deemed incurred by Elan or one or more of the
Continuing Affiliates, and not by any of Alkermes, New Alkermes or the New Alkermes Group Entities.
Notwithstanding the foregoing, (i)&nbsp;all filing fees paid in respect of the Alkermes Proxy Statement
and the Registration Statement, (ii)&nbsp;printing and mailing costs related to the preparation,
printing and dissemination of the Alkermes Proxy Statement, the prospectus contained in the
Registration Statement, and (iii)&nbsp;all filing fees paid in connection with the antitrust filings
made pursuant to <U>Section&nbsp;5.2(c)</U>, shall be borne equally by Elan and Alkermes.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->101<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.5. <U>Notices</U>. All notices hereunder shall be sufficiently given for all
purposes hereunder if in writing and delivered personally, sent by documented
internationally-recognized overnight delivery service or, to the extent receipt is confirmed,
telecopy, facsimile or other electronic transmission service to the appropriate address or number
as set forth below.
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notices to Elan shall be addressed to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 4%; margin-top: 6pt">Elan Corporation, plc<BR>
Treasury Building<BR>
Lower Grand Canal Street<BR>
Dublin 2<BR>
Ireland<BR>
Attn.: Company Secretary<BR>
Fax No.: &#043; 353 1709 4713
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 4%; margin-top: 6pt">with a copy (which shall not constitute notice) to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 4%; margin-top: 6pt">Cahill Gordon &#038; Reindel LLP<BR>
80 Pine Street<BR>
New York, NY 10005<BR>
Attn.: Christopher T. Cox, Esq.<BR>
Fax No.: &#043;1 212 269-5420
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 4%; margin-top: 6pt">and to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 4%; margin-top: 6pt">A&#038;L Goodbody Solicitors<BR>
25/28 International Financial Services Centre<BR>
North Wall Quay<BR>
Dublin 1<BR>
Ireland<BR>
Attn.: John Given<BR>
Fax No.: &#043; 353 1 649 2649
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or at such other address and to the attention of such other person as Elan may designate by written
notice to Alkermes.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Notices to Alkermes or New Alkermes (after the Closing) shall be addressed to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 4%; margin-top: 6pt">Alkermes, Inc.<BR>
852 Winter Street<BR>
Waltham, MA 02451<BR>
Attn.: General Counsel<BR>
Fax No.: &#043;1 781 609-6255<BR><BR>

with a copy (which shall not constitute notice) to:
</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->102<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">



<DIV align="left" style="font-size: 10pt; margin-left: 4%; margin-top: 6pt">Cleary Gottlieb Steen &#038; Hamilton LLP<BR>
One Liberty Plaza<BR>
New York, New York 10006<BR>
Attn.: Daniel S. Sternberg, Esq.<BR>
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;William A. Groll, Esq.<BR>
Fax No.: &#043;1 212 225-3999
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 4%; margin-top: 6pt">and to:
</DIV>

<DIV align="left" style="font-size: 10pt; margin-left: 4%; margin-top: 6pt">Arthur Cox<BR>
Earlsfort Centre<BR>
Earlsfort Terrace<BR>
Dublin 2, Ireland<BR>
Attn.: Christopher P.J. McLaughlin<BR>
Fax No.: &#043; 353 1 616 3901
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">or at such other address and to the attention of such other person as Alkermes may designate by
written notice to Elan.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.6. <U>Successors and Assigns</U>. This Agreement shall be binding upon and inure
to the benefit of the Parties hereto and their respective successors and assigns; <U>provided</U>,
that no Party may assign its rights or delegate any or all of its obligations under this Agreement,
by operation of law or otherwise, without the express prior written consent of each other Party.
Any assignment in violation of the proviso in the preceding sentence shall be null and void.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.7. <U>Headings; Definitions</U>. The section and article headings contained in
this Agreement are inserted for convenience of reference only and will not affect the meaning or
interpretation of this Agreement.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.8. <U>Amendments and Waivers</U>. This Agreement may not be modified or amended
except by an instrument or instruments in writing signed by the Party against whom enforcement of
any such modification or amendment is sought. Any Party may, only by an instrument in writing,
waive compliance by another Party with any term or provision of this Agreement on the part of such
other Party to be performed or complied with. The waiver by any Party of a breach of any term or
provision of this Agreement shall not be construed as a waiver of any subsequent breach.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.9. <U>Severability</U>. If any term or other provision of this Agreement is
invalid, illegal or incapable of being enforced by any rule of law or public policy, all other
conditions and provisions of this Agreement shall nevertheless remain in full force and effect,
insofar as the foregoing can be accomplished without preventing the Parties from realizing the
major portion of the economic benefits of the Merger that they currently anticipate obtaining
therefrom. Upon such determination that any term or other provision is invalid, illegal or
incapable of being enforced, the Parties shall negotiate in good faith to modify this Agreement so
as to effect the original intent of the Parties as closely as possible to the fullest extent
permitted
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->103<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">by applicable Law in an acceptable manner to the end that the transactions contemplated hereby
are fulfilled to the extent possible.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Section&nbsp;11.10. <U>Specific Performance</U>. The Parties agree that irreparable damage would
occur in the event that any Party fails to consummate the transactions contemplated by this
Agreement in accordance with the terms of this Agreement and that the Parties shall be entitled to
specific performance in such event, in addition to any other remedy at law or in equity.
</DIV>

<P align="center" style="font-size: 10pt"><!-- Folio -->104<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;IN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed and delivered
as of the date first written above.
</DIV>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ELAN CORPORATION, PLC<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ William F. Daniel</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">William F. Daniel</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">EVP &#38; Company Secretary</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ANTLER SCIENCE TWO LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ William F. Daniel</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">William F. Daniel</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Director</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ELAN SCIENCE FOUR LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ William F. Daniel</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">William F. Daniel</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Director</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">EDT PHARMA HOLDINGS LIMITED<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ William F. Daniel</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">William F. Daniel</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Director</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">EDT US HOLDCO INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ John L. Donahue</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">John L. Donahue</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Vice President &#38; Secretary</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;Merger Agreement Signature Page&#093;</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>


<DIV style="font-family: 'Times New Roman',Times,serif">


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ANTLER ACQUISITION CORP.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ John L. Donahue</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">John L. Donahue</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Vice President &#38; Secretary </TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">ALKERMES, INC.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Gordon G. Pugh</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">Gordon G. Pugh</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Senior Vice President, Chief Operating Officer </TD>
    <TD>&nbsp;</TD>
</TR>
</TABLE>

<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD align="left">&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ James M. Frates</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Name:&nbsp;&nbsp;</TD>
    <TD align="left">James M. Frates</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD valign="top">Title:&nbsp;&nbsp;</TD>
    <TD align="left">Senior Vice President, Chief Financial Officer and Treasurer</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>&#091;Merger Agreement Signature Page&#093;</B>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
